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The niortality and morbidity of human population as a resuh of infections 
ha\e a long histon' of battle between human intellect and parasite capability to 
o\ ercome therap\'. No wonder strategies of chemotherapy have changed from time 
to time for achieving better therapeutic advantages. Discovery of natural products to 
combat the infection has been followed by discoveries of chemical agents which are 
capable of selective interference of parasite and when these have failed because of 
the emergence of dnig resistant parasites, search for new molecular stnictures have 
been initiated to combat the situation. Even today dmg resistance continues to be a 
problem despite the preliminary success achieved in selected cases. The battle of 
human interact and parasite survival in host, therefore, continues to fascinate 
Biochemists. 
Leishmaniasis is a major global public health problem, ranging in severity 
from cutaneous (CL), post kala-azar dennal (PKDL), and diffuse cutaneous (DCL) 
to mucocutaneous (MCL) and visceral (VL) infections that are endemic in 88 
tropical and subtropical countries around the world, accounting for 75,000 deaths 
per year. Different fonns of leishmaniases are generally cuased by different distinct 
sptcies of Lcishmcmia having a digenetic life cycle alternating between an 
atlagellated amastigote fonri replicative within the macrophages of the host and a 
tlagellated promastigote fonn that multiplies within the gut of sandily. Many times 
the drugs active on one strain, have variable or no effect on other strains. Thus, 
identification of a Lcishmania isolate is important to detennine prognosis and 
collect chemotherapeutic regimes and also for epidemiological and basic biological 
.studies. Sui-vival of parasite within the host is dependent on its successful entry into 
macrophages and transfonnation into amastigote form. Given the role of 
macrophages in the eradication of invading microbes, coupled with their ability to 
kill Lcishmania if provided with the correct stimulus, the parasite must have evolved 
under strong selective pressure strategies to ensure survival. One of the critical 
antileishmanial actions of phagocytic cells is the generation of toxic oxidative 
metabolites. Phagocytosis perturbs the plasma membrane of the macrophage leading 
to a rapid increase in the rate of oxygen consumption. This process, tenned as 
lespiraton,' burst, results in the production of reactive oxygen metabolites such as 
superoxide anion and hydrogen peroxide {H2O2). Thus, the oxygen generating 
s>steni of the host macrophages and antioxidant system of parasite plays an 
important role m survival of parasite and establishment of infection. 
The pentavalent antimonials (Sb'), sodium stibogluconate and N-
methylglucamme antimonate are the preferred drugs for the treatment of most fonns 
of leishmaniasis, while amphotericin B and pentamidine are secondary 
chemotherapeutic agents. Treatment with these agents is not consistently effective 
(particularly for the most vimlent Leishmama disease forms), are expensive and all 
have serious toxic side effects, including cardiac and/or renal failure. Many of these 
drugs also cause hepatic damage and are immunosuppressants. The parasite also 
survives in macrophages by causing immunosuppression. Suppression of the 
symptoms of the disease with the parasite reappeanng in immunosuppressed 
subjects is often achieved in most chemotherapy of leishmaniasis. In Indian 
traditional system of medicine, there is a long list of plants having immunostimulant 
and hepatoprotective activity. A standardized or cnide fraction of such plant may be 
used in the fomi of a combination therapy alongwith known antileishmanial dnigs. 
Although there are several compounds under various stages of development, 
no dmg has yet been discovered which is definitively effective m achieving a 
complete (or radical) cure of the infections. Several clinical reports have noted the 
persistence of the parasite after treatment, and clinical cure has been demonstrated 
in both experimental anaimals and humans. Experimental drugs such as the 
pyrazolopyrimidines, allopurinol ribonucleotide, the 8-aminoquinoline WR6026, and 
the steroid synthetase inhibitor intraconazole, show promise and are currently being 
evaluated for the treatment of various fonns of leishmaniasis. StiW, there is a 
constant need of evaluation of newer prototypes and analogues of active compounds 
which may be orally active, non-toxic and may give complete erradication of 
parasite. Further, the development of a new drug for the treatment of leishmaniasis 
has been impeded by the lack of a simple, rapid m vitro drug screening system 
through which a large number of compounds may be evaluated for their 
antileishmanial activity. Current approaches for design and development of 
antileishmanial agents involve identification and characterization of potential 
biochemical and molecular targets. 
1 Analysis of Restriction Fragment Length Polymorphism in the 
Kinetoplast DNA of Leishmania donovani 
In the present study we have attempted to identify RFLP in Indian strains of 
/.. donovani. Kinetoplast DNA (kDNA) was isolated from 4 different strains viz: 
IJR6, Dd8, RMRI and AG83 of L. donovani prevalent in India. Strain UR6 is a 
nonpathogenic strain while Dd8, RMRI68 and AG83 are highly vimlent and 
responsible for much of the havoc in the eastern region of India. 
Samples of kDNA from each strain were isolated and digested with EcoRI, 
which produced only a single fragment (a linearised minicircle of 875 bp) in all the 
strains. Hind III (6 bp recognition sequence) cleaved Dd8 kDNA at a single site of 
0,89 kb while in AG83, a band of 0.98 kb was obtained. AG83 kDNA digested with 
Mspl (4 bp recognition sequence) showed 4 bands in the region of 0.83 kb-0.12 kb, 
whereas in case of Dd8, a linearised minicircle fragment of 0.83 kb was observed. 
Taq I (4 bp recognition sequence) released most of the kDNA minicircle from its 
highly concatenated form and produced 5 bands in the region of 0.98 kb-0.12 kb in 
Dd8 kDNA, TaqI produced 2 bands (0.83 kb and 0.12 kb) in UR6 kDNA. Hae III 
produced 2 bands (between 0.56-0.12 kb) in Dd8 and 4 bands migrating between 
mol. wt. region of 0.83 kb-0.12 kb in RMRI kDNA. Hind III produced a single 
linearised minicircle band of 0.89 kb in Dd8 kDNA while 2 bands between 0.83-
0.58 kb region m UR6 kDNA. 
In Southern blot analysis, ''^ P kDNA of UR6 was used as probe. It hybridised 
strongly with UR6 kDNA digested by EcoRI, Hae III and Hind III. In case of 
RMRI, kDNA digested with EcoRI and Hind HI showed 2 bands (0.98-0,83 kb) and 
in case of Hae III, 5 bands below 0.83 kb were observed. AG83 kDNA and Dd8 
kDNA, when digested with EcoRI, Hind III and Mspl respectively, on hybridisation 
with nick translated ^^ P kDNA of UR6 showed almost similar pattern. 
Confining our measure of homology to minicircle component only of 
mitochondrial kDNA, we found that three highly virulent strains viz: RMRI, Dd8 
and AG83 have homology to each other and have certain kDNA sequences common 
with UR6. DNA sequences which diverge at different rates among virulent strains, 
represent potentially valuable tools in diagnostics, epidemiological and ecological 
studies of Lcishniania. 
No maxicircle derived bands could be seen in any of the restriction digests of 
kDNAs, This could be due, either, to low content of maxicircle in the purified 
network or the removal of the maxicircles during isolation procedure. 
II In vitro and In vivo Screening of Newly Synthesized and known 
Antileishmanial Drugs/Compounds Against Leishmania donovani 
Total 136 compounds belonging to different chemical stnictures were 
synthesized in Medicinal Chemistry Division of CD.R.I. and screened for in vitro 
and /;? vivo antileishmanial activity. These included diamidines, fused pyrimidines, 
nitroalkanes, phenyl aceto nitriles, malonitriles, aplysinopsin, imidazoles, indoles, 
chalcones, quinolines, bisquinolines, isoquinolines and poly amines. The effect of 
standard antileishmanials viz: sodium stibogluconate (SSG), pentamidine 
isethionate, allopurinol and nystatin on superoxide dismutase (SOD), catalase 
(CAT), glutathione reductase (OR), glutathione peroxidase (GPx), xanthine oxidase 
(XO) and NADPH oxidase was observed. XO and NADPH oxidase could not be 
detected in parasite. Stibanate and pentamidine inhibited all the four antioxidant 
enzymes namely SOD, CAT, OR and GPx to a significant extent while allopurinol 
and nystatin inhibited only SOD and had no inhibitory effect on other three 
enzymes. Since, standard antileishmanials showed consistency with parasite SOD 
inhibition hence this was selected as a model for developing enzyme based in vitro 
screen. 
An integrated approach is being followed for screening of novel molecules 
designed and synthesized for leishmanicidal activity. The molecules are first tested 
for their effect on growth and proliferation of L. donovani promastigotes using in 
viiro culture system as evaluated by incorporation of [''H]-thymidine. It is a non-
specific general screening system depending on the parasite survival and 
multiplication. Inhibition of parasite SOD enzyme has been established by us as an 
enzyme based in vitro screen system. The enzyme plays a predominant role in 
establishment of Leishmania parasite within the hostile environment of macrophages 
b\' constant detoxification of reactive oxygen intennediates. Advantage has been 
taken of the fact that the major SOD of host is Cu/Zn and/or Mn dependent whereas 
the parasite SOD has Fe as prosthetic group. Some of these compounds were also 
tested in t'.v-\7\Y> screen system of ainastigote-macrophage and also in vivo against 
/.. clonovani infection in golden hamsters, the use of the two in vilro screens helped 
in screening a large number of compounds and reducing the labour of using ex-vivo 
amastigote-macrophage system which is tedious and time consuming and also 
weading out the compounds for in vivo testmg in animals, thereby, reducing the use 
of a large number of animals for testing. 
In principle, a compound causing specific inhibition of leishmanial SOD with 
no significant effect on the host enzyme may be a potential leishmanicidal agent. All 
the standard antileishmanial drugs showed good correlation with parasite SOD 
inhibition together with boostmg up host SOD. The results of the present 
dissertation show a positive correlation between parasite SOD inhibitory activity 
with the ni vivo antileishmanial activity as far as compounds of diamidines, 
polyamines, nitroalkanes, malonitriles, imidazoles, indoles, polyamines, quinolines, 
bisquinolines, and isoquinoline series are concerned. In series pyrazolopyrimidines 
and phenyl aceto nitriles, there were some false negative results (stimulation of 
parasite SOD) when compared with leishmanicidal activity against L. donovani in 
golden hamsters (reduction in amastigote number in infected spleen). In these two 
series the ['H]-thymidine uptake test could be very well used for quick screening. 
Through these tests we have found few active compounds of certain series (vrz: 
nitroalkane, pyrazolopyrimidine, diamidine and imidazole) showing 75% to 85% 
activity which can be further evaluated for their efficacy. 
Ill Status of Oxidative Stress and Antioxidant Defence System During L 
donovani Infection and the Effect of Sodium Stibogluconate Treatment 
in Mesocricetiis auratus 
Leishmanial infection is a pathological disturbance which affects the host 
biosystem. The principal organs which undergo deleterious changes are the liver, 
spleen, thymus, lymphnodes and bone-marrow. Survival of/>. donovani amastigotes 
in these tissues and the defence mechanism(s) evolved by the host to cope up with 
the infection are poorly understood. During L. donovani infection there was 
formation of activated oxygen species such as superoxide anion, which in turn 
increased the levels of lipid peroxides in infected tissues. The activity of xanthine 
oxidase which is said to be an index of superoxide fomiation increased significantly. 
It was observed that the significant changes of varying degrees took place in 
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reactive o\\gen species (ROS) generating and scavenging system in lymphoid 
tissues, the overall impact of these changes was the maintenance of lower 
concentraion of ROS in situ, that could be scavenged by the parasite antioxidant 
defence system and hence provided a favourable atmosphere to the parasite to 
survive. 
In infected spleen although superoxide anions were produced at a rate greater 
to that produced in normal spleen due to stimulated xanthine oxidase, these were 
quickl> removed by elevated glutathione (GSH) levels. It is known that glutathione 
is a potent scavenger of ROS. Increased GSH levels are associated with decreased 
glutathione-S-transferase (GST) activity, Increased levels of lipid peroxides (LPO) 
in infected thymus indicated increased production of ROS which may be taken care 
by increased activity of catalase, while the GSH levels were decreased due to 
increased GST activity. Interestingly in lymphnodes, peritoneal exduate cells and 
bone marrow cells, no elevated levels of lipid peroxides were observed. However, 
increased le\els of GSH were present in all the three tissues. 
Sodium stibogluconate (SSG; 10 mg/kg/day x 5, ip) caused reduction in 
parasite burden by 88.3% in liver and 84.4% in spleen. SSG appears to disnipt the 
balance between ROS generating and scavenging system, which is evident fi^om 
significantly increased LPO levels in all the lymphoid tissues after its treatment. This 
IS accompanied by normalization/lowering of increased antioxidant parameters 
resulting in increased ROS concentration in situ. The altered conditions appear to be 
injurious to parasite and as a result parasite does not survive. The inhibition of 
antioxidant enzymes of both host and parasites by sodium stibogluconate may 
represent one of its mode of action for the chemotherapeutic activity and also its 
toxicity. This is probably the reason that inspite of clearance of parasite by 
stibanate, the survival period of infected animals was comparatively larger than that 
of infected animals treated with stibanate. 
IV Protective Effect of Picroliv from Picrorhiza kiirroa Against Leishmania 
donovani Infection in Mesocricetiis aiiratus 
In /.. donovani infection, liver is the primary site of infection with marked 
biochemical alterations in it. SSG remains the first line dnig for treatment of VL. At 
10 mg/kg/day x 5, ip on 7th day post treatment (FT) it caused significant increase in 
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the levels of hepatospecific enzymes viz: glutamate oxaloacetate transaminase 
(GOT), glutamate pynivate transaminase (GPT), y-glutamyl transpeptidase (y-GT), 
succinate dehydrogenase (SDH), glucose-6-phosphatase (G-6-P04ase), acid 
phosphatase (AP04ase), acid ribonuclease (ARNase), lipid peroxides (LPO) and 
bilimbm. However, on 21 day PT the magnitude of change in all the above 
described parameters was less marked with GOT and SDH reverting back to their 
nornial values. 
L. donovanl infection caused severe liver damage which showed an 
increasing trend as the infection progressed in spleen. SSG administered to L. 
donovani infected golden hamsters could not restore the altered parameters to 
nonnal levels but further aggravated the magnitude of percent change by 10% to 
20% in various parameters. However, on 21st day PT the magnitude or change in 
the aforementioned parameters was less as compared to 7th day PT. 
Picroliv, a standardized mixture of iridoid glycosides prepared from the 
alcoholic extract of root and rhizome of PIcrorhiza kiirroa has shown strong 
hepatoprotective activity against several models of hepatotoxicity. Therefore, the 
present study was undertaken with an objective to study its hepatoprotective effect 
(12.5 mg/kg/day x 7, oral) alone and in combination with SSG on parasitemia, lipid 
peroxidation and hepatic marker enzymes of golden hamsters dunng L. donovani 
infection. The results indicated an increase in leishmanicidal activity of SSG along 
with a marked hepatoprotective effect by Picroliv in ternis of biochemical markers. 
The survival of the animals infected with L. donovani, normal animals treated with 
SSG, and infected animals treated with SSG also increased substantially by 
treatment with Picroliv. Thus it can be said that Picroliv can be used as an adjunct to 
chemotherapy of leishmaniasis with SSG by enhancing its efficacy, decrease in 
toxicit). reduction in parasitemia and restoration of immune status of host. 
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PREFACE 
Leishmaniasis is a major public health problem in many parts of the world. 
Recent estimates show that of 88 countries affected, there may be 15 million 
people infected globally and 350 million at risk of whose some 1.5 to 2 million 
will be infected each year. Leishmaniasis spread by the bite of many different 
species of sandfly; which in turn pass on Leishmania parasite of many different 
species producing at least five distinct diseases with differing symptoms: 
cutaneous, diffvise cutaneous, mucocutaneous, visceral and post kala azar dermal 
leishmaniasis. Of these visceral leishmaniasis (VL; kala-azar) caused by 
protozoan parasite of Leishmania donovani complex is most severe and fatal if 
left untreated. About 90% of VL cases are reported from two regions - a wide 
zone in North East India, Bangladesh and Southern Nepal and Sudan. In India, 
during 1977-79 epidemic, there were an estimated 20,000 deaths as a result of 
kala-azar, 
The parasite leads a digenetic life cycle, an extracellular proiiiastigote in 
the gut of sandfly and an intracellular amastigote which resides and multiplies in 
macrophage and other phagocytic cells of reticuloendothelial system Survival of 
the parasite within macrophages appears to be assisted by factors that neutralize 
their microbicidal machinery by impairing the oxygen dependent mechanisms. 
The drug of choice even today are the pentavalent antimonials m the form of 
sodium stibogluconate (pentostam) or N-methyl glucammc antimonate 
(Cllucantime) administered mtraperitoneally. The drugs are expensive, potentially 
toxic and 10-25% cases relapse. Moreover, reports of large number of drug 
resistant cases are also pouring in. Thus, there is a dire need to develop more 
effective antileishmanial agents which are orally administerable, effective after a 
modest number of administration and nontoxic. 
Since experimental agents are evaluated in in vitro and in vivo models, it is 
desirable to have a technically simple test which may screen large number of 
compounds for selecting a few to be put in in vivo testing which is time taking, 
cumbersome and requires a large number of animals. 
Another major problem in leishmaniasis is a large number of strains of the 
parasite causing different diseases and the different response of a particular drug 
to different parasite species/strain e.g. oral azoles are more effective than 
antimonials against cutaneous leishmaniasis caused by L. mexicana but were not 
effective against L. hrazilicnsis; thus highlighting the importance of identifying 
the parasite. Further, for identification of virulence detenninants and their 
manipulation by molecular attenuation by gene depletion or replacement, thereby, 
providing invasive but non-pathogenic mutants for vaccination, the analysis of 
genetic heterogeneity of Leishmania isolates is called for. 
The intracellular parasitism of this organism also leads to immune 
suppression. Association of Leishmania as opportunistic infection in AIDS has 
worsened the situation. It has been demonstrated that sodium stibogluconate 
though removes the parasite by killing but adds further to immune suppression 
during infection. Thus an immunostimulant which may also decrease the toxicity 
of the antimonials or pentamidine (being used as second line of drugs) would be 
welcome. 
The present work has been carried out with a view to address some of the 
problems mentioned above. The dissertation has been divided into six sections. 
1. This section deals with the Introduction and Review of Literature gixing a 
brief but comprehensive account of the historical aspects of the disease, 
biology of the parasite, pathology, diagnosis, pathogenicity, drug 
development and chemotherapy. 
2. This deals with the materials and methods which include general protocols 
for maintenance of culture of L. donovani promastigotes m vitro, infection 
in VIVO, isolation of mitochondrial kDNA and its analysis, chcnucal and 
biochemical estimations in parasite and host. 
3. In this section, restriction fragment length polymorphism has been done 
with a view to use it as a technique for studying the genetic heterogeneity 
in various strains. 
4. This section deals with the development of in vitro screening models for 
rapid screening of large number of compounds of various prototypes and 
thereby preventing the unethical waste of animals. 
5. This section describes the status of oxidative stress and antioxidant s\stem 
of host during L. donovani infection and the effect of sodium 
stibogluconate on it, with a view to understand the role of reactive oxygen 
species and the antioxidant enzymes in parasite survival/killing inside the 
macrophages. 
6. It illustrates the effect of standard antileishmanial drug sodium 
stibogluconate on various hepatic parameters, leading to hepatotoxicity of 
the dmg and use of Picroliv, a standardized preparation of alcoholic 
extracts of roots and rhizome of Picrorhiza kurroa (an iridoid glycoside) 
as an adjunct therapy to SSG for improving the immune status of host, 
protection of hepatotoxicity and potentiation of antileishmanial activity of 
SSG. 
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SECTION 1.0 
INTRODUCTION 
AND 
REVIEW OF LITERATURE 
Parasitic infections are a major health problem world wide This is 
particularly true, in under developed and developing countries, where thcv cause 
a substantial socio-economic burden. The global prevalence of human parasitic 
infections has already exceeded 50% and is on an increasing trend. Diverse factors 
are responsible, including population crowding, poor sanitation and health 
education, inadequate control of parasite vectors and reservoirs of infection, 
population migration and military operations, and lastly, development of 
resistance towards agents used for chemotherapy. Parasites live in or on other 
living organisms (hosts), obtaining from them, part or all of their nutriment, 
commonly exhibiting some adaptive stnictural modifications and (often) causing 
some degree of damage to their hosts. There are seven major infectious diseases 
malaria, schistosomiasis, trypanosomiasis (including African sleeping sickness and 
the American fonn called Chagas' disease), leishmaniasis, leprosy, fllariasis and 
amoebiasis. Of the various parasitic infections, malarial, leishmanial and 
tiypanosomal infections have attracted more attention because of their high 
morbidity and mortality. 
Parasitic diseases are classified in two groups: Protozoal infections: these 
are caused by unicellular organisms which multiply within the host cells resulting in 
a large antigenic stimulus, as in the case of malaria, trypanosomiasis, leishma niasis 
and toxoplasmosis; and the Metazoal infections: which include helminthic 
mfections like schistosomiasis and fllariasis, caused by multicellular organisms 
which do not multiply in the host and hence the antigenic stimulus is related to the 
wonn burden in the body. 
Resistance to parasitic infections resembles to that of bacterial and viral 
infections, though environmental factors such as climate, habit and habitat Q( 
host, diet and occupation play an important role. Parasites have evolved 
extraordinary mechanisms for surviving in their hosts. A selection of 
mechanisms serves to illustrate the challenges involved in developing the 
strategies for immunization against parasites (Bloom, 1979), Tiie challenge to 
engender resistance or immunity against these parasites is to improve the natural 
host's immune system. The problem of not achieving immunity to parasite 
infections is complicated by the ability of the parasite to evade the host's 
immune mechanisms, such as, ability to live in macrophages (Leishmania) and 
display antigenic variation. Leishmania parasites do not display much antigenic 
variations as promastigote and amastigote have apparently many common surface 
molecules (Chang e/o/.. 1985). 
The leishmaniases form a group of parasitic tropical diseases spread by the 
bites of many different species of sandfly, which is turn pass on Leishmania 
parasites of many different species, producing atleast five distinct diseases with 
different symptoms: 
Cutaneous leishmaniasis (CL) (better known as 'oriental sore' 'Delhi boil' 
etc) is a comparatively harmless disease with specific ulcerating granuloma of skin 
starting from an initial papulae and later transforming into an ulcer. The causative 
organism is Leishmania tropica or Leishmania major. This disease is common 
along the shores of the Mediterranean, Syria, Arabia, Mesopotamia, Persia to 
Central Asia, the drier parts of central and western India and many parts of Central 
Africa. Simple CL usually heals without treament, leaving the person immune to 
further infection with that species of Leishmania. Thus, in many parts of south-west 
Asia, infections are deliberately encouraged on the buttocks of babies (or given by 
the injection of live vimlent organisms in the arm called leishmanization) in order to 
immunize them against fiirther infection, and thus avoid multiple lesions and 
disfiguring scars on the face. For the simple CL of the Old World, if the lesion is not 
near vital organs, no treatment is recommended by WHO, due to the cost and 
possible side effects of available chemotherapy. Although lesions tend to heal after 
few months, they leave unsightly scars. 
Diffuse cutaneous leishmaniasis (DCL) is rare, but more serious, the 
complication occurs when the immune system fails to react effectively to infection. 
Lesions cover a large part of the body, never heal without treatment, and the 
majority of cases relapse even if treated. 
Mucocutaneous leishmaniasis (MCL) or Espundia affects the mucous 
membranes of nose, ear, mouth, palate and lips, causing irrepairable destniction and 
unsightly deformities. The organism responsible for this disease is Leishmania 
hraziliensis, confined to Central and South America. 
Visceral leishmaniasis (VL), the most dreaded fonn amongst various 
diseases caused by Leishmania donovani complex occurs in Asia, southern Europe 
and Middle East, Africa and Central Southern America and has in recent years 
assumed epidemic proportions in certain parts of India. It is a disease of great 
public health importance in the eastern parts of India, specially Bihar, where out of 
42 districts, 38 are declared endemic for kala-azar. Between 250,000-300,000 cases 
were estimated in 1992 (Ashford, 1992). Due to chronic fever, hepatosplenomegaly, 
lymphoadenopathy and anaemia, thousands of patients have become emacited and 
incapable to work. 
Post kala-azar dermal leishmaniasis (PKDL) takes the fonn of cutaneous 
nodules, some times lasting several years, and develops in some treated visceral 
leislmianiasis patients one or two years after infection. 
The disease is still diagnosed by clinical symptoms and microscopic 
examination for the presence of parasite in the tissues of suspected patients and 
also culturing the samples. The infected bite of sandflies {Phlehofomus or 
Lutzomyia spp.) is responsible for the transmission of the disease to humans 
(Killick-Kendrick & Peters, 1987). The spread of leishmaniases follows the distri-
bution of these vectors in the temperate, tropical and subtropical regions of the 
world (Chang & Bray, 1985). Epidemiologically, leishmaniases are mostly a 
zoonosis (Blackwell, 1992). The reservoir animals are canines, rodents or 
edentates in all the endemic regions, except India where man-to-man transmi-
ssion seems to be the case. The disease persists in most endemic areas and 
periodically becomes epidemic. Recently among millions of patients tens of 
thousands have lost their lives during the outbreaks of visceral leishmaniasis in 
India and Africa. 
The Indian and Sudanese epidemics of visceral leishmanisis, parasite 
resistance to antimonials and the emergence of AIDS-related leishmaniasis have 
all increased the urgency for new dmgs, and the reappraisals of the old ones for 
the disease. The need for improved therapy and control measures was recognized 
by the TDR/WHO programme where leishmaniasis was selected as one of the 
seven most important tropical diseases requiring increased research resources. 
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Figure : Digram of the levels of discrimination of the Leishmania species and 
subspecies. 
1 1 HISTORY OF THE DISEASE 
Kala-azar or visceral leishmaniasis (VL) has existed as a disease entity in 
India since long, though there is no special mention about it in early literature. It 
is quite expected, because in earUer times the causative organisms were not 
known and unlike malaria, no special features of clinical manifestations could be 
noticed. All such cases were grouped under fevers and treated accordingly 
with antipyretics and febrifiigins. It was in early nineteenth century that some of 
its special features, like darkening of skin and enlargement of spleen and liver 
could be detected and appreciated. It was then named as kala-azar' or Black-
fever' and was thought to be a special type of malarial fever and treated 
accordingly. The human leishmaniasis was first reported in 1885 by Cunningham 
in histological sections of oriental sore. At the beginning of the present century 
the causative organism was discovered by Leishman and Donovan independently 
in 1903 and the parasite was named as Leishmania donovani, by Ross, in the 
same year incorporating the names of both the discoverers. Since tliat time, started 
the real history of chemotherapy of kala-azar with attempts for drug development. 
The chnical sign-symptom complex could then be attributed to the disease for its 
identification. 
Once the causative organism became known, attempts started at various 
centres to find a chemical compound, which could kill the parasite without being 
much toxic to the host. The history of the drug development against VL can be 
divided into two periods: the earlier one, the period of emperical testing of dnigs 
which were already in existence for other diseases, using directly man or naturally 
infected animals and the later one, the period of critical testing. During the 
former period, no new drug specifically against kala-azar could be developed, as 
trials of new compounds in human patients were considered dangerous, proving 
toxic to the host. As for the later, the first prerequisite was to have target 
parasite in a small laboratory animal model wherein detailed studies could be 
taken up for assessing the drug dose relationship, safety of the drug as denoted 
by chemotherapeutic index and any long term adverse effects. 
1 2 BIOLOGY OF LEISHMANIA DONOVANI 
The different species of L donovani have their own species of sandfly 
vectors, and reservoir hosts. Mainly sandfly of the genus Phlehoiomus is the 
vector. In Central and South America however, the vector belongs to the genus 
Lutzomiya {Kahyar et al., 1991). 
Life Cycle 
Leishmania species are intracellular protozoan parasites that lead a digenetic 
life cycle. These parasites depend upon unactivated mononuclear phagocytes 
(Alexander & Rusell, 1992) of their vertebrate hosts for their survival and 
multiplication. The parasite exists in two forms, as extracellular flagellated 
promastigote form in the alimentary tract of the vector sandfly and as an 
obligatory aflagellated, non motile, intracellular amastigote fonn within the 
phagolysosome vacuoles of mammalian macrophages of reticuloendothelial system 
(Chang & Dwyer, 1976; Chang et a/., 1985). Upon proliferation, promas tigotes in 
the sandfly midgut differentiate fi^om a noninfective procyclic fomi into a vimlent 
metacyclic fonn and migrate to the anterior part of the intestinal tract of the fly 
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FIG. 1 : Life Cycle of Leishmania donovani, 
Fig. 1: Flourescent micrograph of promastigotes of L. donovam cultured at 26°C 
using acridine orange. Magnification X 400. 
Fig. 2 : Giemsa stained preparation of amastigotes present in spleen of golden 
hamster infected with L. donovam as detected by spleen biopsy. Magnification X 
1000. 
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(Sacks & Perkins, 1984; Sacks, 1989; Pimenta e/a/.. 1992). The life cycle of 
L donovani has been worked out by Laveran and Ross (1903) and Ross (1903). 
When an infected sandfly {Phlehotomus argentipus) bites a healthy human being, it 
introduces promastigotes in the skin. The macrophages of the skin engulf 
the promastigotes where they change into an amastigote form and instead of being 
killed (which normally occurs in the case of other foreign organsims), multiply by 
binary fission. When sufficiently large number of amastigotes are produced and 
accumulated within the parasitised macrophages, they nipture, liberating the 
amastigotes. The amastigotes are then taken in by fresh macro phages and 
disseminated in other tissues. When a female sandfly takes in a blood meal 
containing an infected macrophage, amastigotes are liberated within the insect gut, 
where they change into promastigotes, and start multiplying by binary fission. In a 
tew days the whole gut, upto the pharynx becomes fiall of promas-tigotes. When 
such an infected female sandfly bites a normal human host, it introduces the 
promastigotes which in turn are taken up by macrophages of the host. Thus, the 
transmission cycle is completed (Fig. 1). 
1 3 CLINICAL FEATURES AND PATHOLOGY 
The symptomology of L donovani infection is characteristic. The 
incubation period is usually fi"om 6 weeks to 6 months but can be as short as 2 
weeks or as long as 9 years (Faust & Russel, 1964). The initial symptoms consist 
of malaise, headache and fever, occurring at irregular intervals and later 
becoming of daily occurrence often accompanied by chills and sweating. Other 
symptoms include cough, diarrhoea, dizziness, vomitting, bleeding of gums, pain 
in the limbs and weight loss. Later, the clinical picture is transformed to 
enlargement of spleen and liver, anaemia with leuckopenia and lympho-
adenopathy. The skin becomes dark grey, corresponding to the name of the disease 
"Kala-azar" (black sickness). In the most acute infections death may occur within 
few weeks, in subacute cases within a year and in chronic cases from 2 to 4 years. 
Since the macrophages are involved in defence mechanism, the kala-azar 
patients are invariably immuno-depressed and promote speedy multiplication of 
parasites.The patients thus, easily fall prey to secondary invaders. 
Patients who have recovered from VL become hfe-long immune to 
reinfection (preimmunition) but occassionally relapse may also occur. In cases 
where there is incomplete treatment the patient may develop a condition which is 
usually referred to as Post Kala-azar Dermal Leishmaniasis (PKDL). This 
condition has been very often witnessed in India and occassionally in East 
Africa. About 20% of patients in India, develop PKDL (Cheesbrough, 1988). 
1.4 DIAGNOSIS OF KALA-AZAR 
Diagnosis is an essential element in the management of disease at the 
individual pateint level. Because if untreated, overt disease is usually fatal. 
Detection is also important in epidemiological studies of vectors and reservoir 
hosts, understanding of which is necessary for the control and eradication of the 
disease. The aim of clinical diagnosis is to develop a simple, rapid, economical, 
specific and highly sensitive test suitable for field application. It is also impor-
tant to identify the causative organism which would provide an additional 
information to help in choosing and assessing a chemotherapeutic regimen. 
Routine diagnosis of VL is generally based on the clinical presentations 
which include irregular fever, progressive splenomegaly, hyperglobinemia, anae-
mia and immune suppression. On the basis of clinical signs and symptoms, it is 
impossible to differentiate VL from other cases of febrile splenomegaly. 
Confirmed diagnosis of active leishmaniasis is based primarily on the 
demonstration of parasite {Leishman donovan bodies) in biopsy smears and 
culture isolated from bone marrow/spleen/liver/lymphnode and skin (Marsden & 
Jones, 1985). Bone marrow or splenic aspiration from patients is a painftil 
invasive technique whereas culture is time consuming and the possibility of 
contamination, relatively high costs make them inappropriate for epidemio-
logical studies (Arias et al., 1985). Inoculation of the clinical material (bone-
marrow, spleenic/skin aspirates) leading to the establishment of patent infection in 
the inoculated animal (hamster), also confirm the initial diagnosis (Chang & 
Hendericks; 1985). However, in cases having low parasite burden culturing or 
repeated microscopic examination may be unsuccessftil in the demonstration of 
parasite (Kirsten et al., 1987; Nilsen & Mishana, 1987; Mebrahtu e( cr/..1993), 
although immunostaining procedures having increased sensitivity have been 
described for the detection of amastigotes in cases of CL (Lynch c/a/., 1986; 
Anthony c/«/.. 1987). 
1.4.1 Immunological Tests 
The most widely applied immunological test in leishmaniasis has been 
the Leishmanin or Montenegro's skin test (WHO, 1984). The test is usually 
positive in CL and MCL. It is negative in active VL and most cases of PKDL 
but becomes positive after recovery. The positive rates of leishmanin skin test 
in KA hyper endemic areas ranges from 2-20% and in CL hyperendemic areas it is 
over 80% (Caliill et al., 1965). False positive rates are as high as 90%, in areas 
where clinical leislimaniasis has never been reported (Southgate & Oriendo, 
1967). 
Reed et al (1987) reported the use of soluble antigens for the determination 
of specific delayed hypersensitivity (DH). It was found convenient, specific and 
sensitive for determination of DH response in American VL. This antigen can be 
stored at 2-8"C until used and is reported to be active even after 5 years of storage 
(Badaro et al., 1990). Antigenic cross-reactivity between different species of 
Leishmania (Southgate & Manson-Bahr, 1967) and also some other 
heterologous organisms such as Trypanosoma cruzi (Shaw & Lainson, 1975), 
Lcptosomonas pessoai, Mycobacterium hovis (Smrkovski & Lainson, 1977) have 
also been reported. Hence the Leishmanin reaction is not species specific. 
Some other immunological in vitro tests, such as, blast transformation test 
and macrophage migration inhibition tests (Zeledon et al., 1976; Aikat et al., 1979) 
have been applied for the assessment of the cellular immunity response to 
I.eishmania. Zijlstra & El-Hassan (1993) applied Leishmania and tuberculin skin 
tests in patients with leishmaniasis in Sudan. 
1.4.2 Serological Tests 
L donovani infection induces certain physiological changes which could 
be taken as an indication of active infection and thereby its presence in the host. 
Leucopenia, a prominent feature of VL is revealed by examining the leukocyte 
count. VL cases are marked by hypergamma globulinemia resulting in the 
reversal of albumin-globulin ratio. The increase is more marked in the IgG than the 
IgM component, and the IgG levels are correlated well with the Fonnol Gel Test 
(aldehyde test) and Urea Stibamine Test (antimony test) (Ghose cl ai, 1980). 
However, tliese tests are only positive in the late VL cases and lack an appropriate 
degree of specificity, as these become positive in other liypergammaglobulinemic 
conditions as well. Several serodiagnostic test systems employing a "labelled" 
reagent dominate the field at present. These sero-immunodiagnostic tests can be 
categorised into two groups: 
1.4.2.1 Antibody based tests : These recognize antibody in the serum and are as 
follows: 
(i) Complement fixation test (CFT) : The complement fixation test has been 
used for the diagnosis of KA since late sixties with considerable success 
(Hockmeyer et al., 1984; Pappas et al, 1985a,b) . The antigens used in the 
majority of these studies have been extracted either from mycobacteria and/or 
other acid fast bacilli in addition to leishmanial antigens. However, the anti-
complementary nature of the sera of some of the VL patients (Bray, 1985) and false 
positivity of the test in Chagas' disease and other unrelated diseases, particularly 
in tuberculosis, leprosy, actinomycosis etc., have limited the utility of this test 
(Ghose e/o/.. 1994). 
ii) Indirect Itaemagglutination test (IHA): IHA using sheep erythrocytes 
coated with soluble promastigote antigens is sensitive and has long been used for 
detecting KA cases (Mukherjee et ai, 1968). The test is positive at a reasonably 
high level in KA and at a low level in PKDL (Haldar et al., 1981), but has not been 
used under field conditions. 
iii) Immunoflotirescent test (IFT):l¥T has been used exten sively in 
the serology of leishmaniasis including KA (Badaro et al., 1983; Pappas et al., 
1983a; Latif e/ al., 1979). The test (Bray, 1985), is simple and easy to perform, 
although occassional cross reactivity with sera firom Chagas' disease, malaria, 
toxoplasmosis, amoebiasis, etc. may limit its usefialness in areas where these 
diseases are prevalent (Badaro e/a/., 1983; Pappas £i? a/.. 1983b). 
iv) Agar gel diffusion test. KA semm has been shown to give precipitin 
lines against leishmanial antigens in agar gel diffusion (Bray & Lainson, 1967). 
The sensitivity and rapidity of the precipitin test are increased considerably by the 
introduction of counter-immunoelectrophoresis (ClEP) technique. The test is 
marked by a high degree of positivity for KA cases despite the problem of 
occassional cross-reactivity with sera from unrelated diseases (Haldar; 1982). A 
portable apparatus has also been developed for conducting ClEP tests in the field 
(Monjour etal., 1988). 
v) Enzyme-linked immunosorbent assay (ELISA): ELISA, initially 
developed by VoUer (VoUer et al., 1974), has been extensively used in the sero-
diagnosis of VL (Decock et al., 1985; Mukherjee et al.. 1991) and PKDL (Nandy 
cl a!., 1987). Soluble antigens derived from L donovani promastigotes are usually 
used for the test and the results can be read either visually (Jahn cl a!., 1983) or 
spectrophotometrically, using an ELISA reader. It is preferable to use local L 
donovani isolates for the antigen preparation so as to increase the sensitivity of 
the test (Badaro et al., 1986). The micro-plate ELISA method has been simplified 
by dot-ELISA for the rapid diagnosis of Leishmania cases (Pappas el al., 1985; 
Brodier & Ryter, 1986; Srivastava & Singh, 1988; Walton et al., 1986). 
Sensitivity of the test can be increased by using protein A or protein G 
conjugates . The test, however, has the problem of occassional cross-reactivity 
with sera from unrelated diseases, such as African trypanosomiasis and 
Chagas' disease (Guimareas e/a/., 1986), schistosomiasis (Morsy et a/., 1989), 
leprosy and tuberculosis (Xu el a/., 1982). A recombinant product rK39ofthe39 
amino acid repeats encoded by a kinesin-like gene, specific for all members of L 
donovani complex has recently been used in serodiagnosis by ELISA of both 
human and canine VL (Singh et al, 1995). However, the cloned antigen rK39 has 
been used as an indicator of only active disease and has been found to be 
nonreactive with the sera from early and self healing infected subjects (Badaro et 
al, 1996). 
vi) Direct agglutination test (DAT): A simple yet reliable test for the 
detection of KA cases based on direct agglutination of promastigotes by serum 
antibodies has been developed. To be useftil in mass screening programmes, the 
specificity and sensitivity of. the test are further improved by the addition of citrate 
and 2-mercaptoethanol (Harith etal, 1988). This test, shows a very high degree 
of specificity and sensitivity towards KA and has been used with great advantage 
in areas free from trypanosomiasis (Addy et a/., 1989). Cummins el al (1994) 
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developed a latex agglutination test (LAT) with comparable sensitivity to that of 
DAT. It has an added advantage of being rapid and extremely simple to perfomi. 
LAT showed a sensitivity of 88% and a specificity of 96%, Moody & El-Safi 
(1996) concluded that the LAT is a simple and practical serological technique for 
the diagnosis of VL, particularly at dispensai^ level. 
Direct Agglumination Test (DAT, Leishma Test) is being routinely used at 
Central Drug Research Institute, for diagnosis of kala-azar and has been given to 
Span Diagnostics (Surat) for marketing. It is a simple and cheap method in which 
clumping of cells due to the antibody present in the blood can be monitored 
visibly. Only a drop of blood collected on filter paper is sufficient. Leishma 
Test has been perfonned on more than 4000 cases of different categories. The test 
possesses sensitivity to the tune of around 99% and shows no cross reactivity 
w ith the patients of tuberculosis, leprosy, giardiasis, amoebiasis, malaria and 
filariasis. Recently, a seroepidemiological survey was conducted in Varanasi 
district of Uttar Pradesh using Leishma Test. A total of 1360 blood samples 
collected from 6 villages of Varanasi, including cases with chronic fever and allied 
symptoms, post treated cases of KA as well as asymptomatic individuals. 417 out 
o\' 1163 cases with no symptoms of KA tested posifive by DAT indicating towards 
the possibility of eruption of a KA epidemic in region. Several asymptomatic 
individuals who tested positive by Leishma test later developed the full blown 
disease when followed up to 3-4 months establishing the usefiilness of Lieshma test 
m early diagnosis of the disease. 
Immunodiagnosis of parasite disease by detecting specific antibodies against 
the parasite has been used since long. The method is usually very sensitive, but 
its specificity is sometimes unsatisfactow due to commonly encountered cross 
reactions. This limits its application. Another serious limitation of this diagnostic 
test,is the persistence of antibodies even after successful chemo-therapy which 
gives false positive reaction in cured patients. 
L4.2.2 Antigen based tests 
Antigen detection for diagnostic puiposes is more important compared to 
antibody based tests as it detects circulafing parasite and hence indicates the active 
stage of the disease. The test becomes negative following successful therapy and 
thus may also have apphcation in monitoring response of tlie patients to 
chemotlierapy. Several test systems liave been developed foi detection of 
I.L'ishniama cuculating antigens. 
i) Use of monoclonal antibodies: Development of monoclonal antibodies 
against Lcishmauia sp. has helped not only in identification of leishmanial orga-
nisms but also in diagnosis of the disease (Jaffe and McMahon-Pratt, 1987; Om 
& Bao, 1987. Shaw et al., 1989). These monoclonal antibodies have been used in 
the affinity purification of L cionovani protein antigens of 70 kD and 72 kD sizes. 
Both these proteins are recognized specifically by human visceral leishmaniasis 
serum (90%) but not by sera from cutaneous leishmaniasis or Cliagas' disease in 
dot-ELlSA test (JafTe & Zalis., 1988). A highly immunogenic 80 kD membrane 
protein from L. cionovani has been purified and shown to be useful as an antigen 
for serodiagnosis of KA (White & Mc-Mahon Pratt, 1988). Identification of L 
(lonovani antigens recognized by VL sera has been carried out by immuno-
blot experiments. Available data (Jaffe & Zalis, 1988; White & Mc-Mahon Pratt, 
1988; Ralland-Burger cl al., 1991) show considerable variations, as multiple 
bands ranging between 120 kD and 14 kD are recognized by infected sera of 
different geographic origins. Recently, a 94 kD L. cionovani antigen has been 
shown to react 100% with sera collected from clinically and parasitologically 
confirmed VL patients and with 76% of suspected VL cases, but not with control 
sera (Rolland-Burger et al., 1991). 
The major surface glycoprotein of Leishmania (gp63) has drawn considerable 
attention in recent years (Tzinia & Soteriadou, 1991; Yang cl al., 1991). 
Purified 63 kD glycoproteins from different Leishmania spp. have been found to 
be structurally and immunologically related (Tzinia & Soteriadou, 1991) and are 
recognized by sera from patients with different forms of leishma niasis, including 
KA (Ghose cl al., 1994). Genes encoding gp63 have been cloned and 
expressed and the recombinant 60-63 kD proteins shown to be precipitated by sera 
from VL patients (Heath cl al., 1987). 
Apart from protein and glycoprotein antigens, I.ci.slimania parasites have 
been shown to contain unique glycoconjugates known as lipo-phosphoglycan (LPG) 
on their surface (Turco & Sacks, 1991). LPG and the related glycolipids are 
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highly immunogenic and have been shown to be recognized by immune human 
sera (Karp cl al.. 1991). These molecules appear to be related to excretory factors 
(l:F), that have been used for serotyping of Leishmania sp. (Sclinur, 1982). 
A polysaccharide- rich antigen (PRA) prepared from L ihnovani promas-tigotes 
has been shown to react with KA sera both by ELISA and CIEP (Ray & Ghose, 
1986). 
//) Antigen spot test (AST): It is based on reaction between the antigen 
present in patients' urine (spotted on nitrocellulose strip) and a Lcishmania specific 
monoclonal antibody which may be visualised by ELISA. In our Institute the test 
has been validated through more than 700 urine samples collected from the 
individuals with active kala-azar, endemic normals, non endemic normals and 
people suffering from other related diseases. AST is sensitive in about 80% cases 
and 99% specific. 
1.4.3 Protein-Based Approaches 
i) Protein sequencing. Comparison of protein sequences is, historically, 
an important method for characterising and taxonomically placing organisms 
(Goodman, 1981). However, sequencing of proteins is expensive and technically 
more difficult than nucleic acid sequencing. Instead, protein sequences can be 
infetTed from the corresponding nucleic acid sequence, allowing newly-acquired 
data to be compared with old. 
ii) Protein electrophoresis : The electrophoretic profile of enzymes and 
other proteins can be considered characteristic of a particular individual (Harris, 
1966). Charged amino acid side-chains contribute to an overall molecular charge 
which determines the extent of movement of the protein molecule through a gel 
nratrix. Only those changes that affect the net charge of proteins can be detected 
using this method. To some extent the shape and size of molecules also 
affect electrophoretic mobility. To maximise the variation detectable, a range 
of conditions, including alterations in pH and gel concentration, must be applied 
(Coyne, 1982). These methods are inexpensive and large number of isolates can 
be examined (Murphy et al.. 1990). 
Protein electrophoretic methods widely used in the investigation of 
genetic variation include isoenzyme and allozyme analysis (Swofford & 
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Berlocher, 1987). There have been numerous studies on parasite groups using 
these approaches (Walhker, 1983; Godfrey ct al.,, 1990; Bryant & Flockhart, 
1986). In isoenzyme analysis, all functionally similar enzymatic proteins are 
detected using histochemical stains containing specific substrates. Allozymes are a 
subset of isozymes, and include only those proteins confimied by pedigree studies 
to be produced by allelic alternatives at a single genetic locus. Individual 
differences in allozymes provide infonnation regarding the level of variation within 
a population. 
1.4.4 Molecular Approaches to DNA-Diagnosis 
From the ongoing discussion it has become apparent that biochemical and 
serological techniques used for diagnosis have encountered difficulties due to 
cross-reacti\'ity in a variety of diseases and there is an urgent need to develop 
rapid and accurate means of identification of parasites to aid both clinicians 
and epidenuologists. Further, leishmaniasis is currently being treated using toxic 
dnigs (antimonials) having long dose regimens. Thus, a correct species diagnosis 
fiom the initial lesion would help in altering treatment protocols and in using 
these drugs more effectively. 
The DNA of a parasite is the ultimate blueprint of that parasite, which 
characteristically remains unchanged during every stage of the life-cycle. The 
advent of recombinant DNA technology has provided a battery of new tools and 
approaches that have been or could be used to complement and extend the 
knowledge of the epidemiology of many parasites. Basically, two levels of 
distinction can be made: an absolute distinction between two clearly defined 
species or groups of parasites, or a finer distinction that examines differences 
between individuals within a group by examining DNA sequences which show 
variations. DNA based approaches focus on genes rather than gene products 
and so avoid problems of life-cycle stage variations, environmentally and host-
induced modifications, as well as posttranslation modifications. Since DNA is 
relatively stable, particularly in comparison to enzymes, collection and storage of 
material can be less stringent than that required for many other identification 
methods. DNA-based procedures can be extremely sensitive in detecting variation, 
and even silent nucleotide positions can be compared. 
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A salient feature of kinetoplastid flagellates is their lack of detectable 
cliromosoiiial condensation during the cell cycle, a condition that has imposed a 
long-standing limitation to the cytogenetic analysis of /.c/.v/?/;;<////(:/(Lighthall & 
Giannini, 1992). Except for kDNA, which could be isolated from kmetoplasts and 
purified by ultracentrifugation, the bulk of the genome does not resolve until the 
pulsed field gradient gel electrophoresis is developed. 
1.4.4.1 Kinetoplast DNA (kDNA) 
The mitochondrial DNA of trypanosomatid protozoa, temied kinetoplast 
DNA (kDNA) is unique in its structure, function and mode of replication. kDNA is 
a massive network composed of thousands of topologically interlocked DNA 
circles. The network contains two types of DNA molecules : maxicircles present 
in a few dozen copies and minicircles present in several thousand copies. 
The first indications of the existence of kinetoplast DNA came nearly 100 
years ago. It was in 1898 that Zieman reported that the kinetoplast (like the 
nucleus) stained a brilliant red with the newly discovered Romanovsky coun-
terstrains (Ziemann, 1898). The basophillic character of kinetoplast is attributed to 
the high local concentration of DNA, a finding confimied by measurements of 
['H] thymidine incorporation and DNase sensitivity (Steinert ct al., 1958). The 
remarkable molecular configuration was finally revealed by electron microscopy 
(Simpson & Da Silva, 1971). 
The molecular components of kDNA 
i) Maxicircles : Maxicircles are the functional homologues of mitochondrial 
DNA ranging from 20 to nearly 40 kb in size. They encode ribosomal RNAs and 
several proteins, most of which are involved in mito-chondrial energy 
transduction (e.g. cytochrome b, subunits of cytochrome oxidase, and subunits of 
NADH dehydrogenase). They apparently do not encode tRNAs. A remarkable 
feature of maxicircles is that most of their transcripts undergo RNA editing to 
fonn a fiinctional mRNA (Benne et ol., 1986). Editing involves addition or 
deletion of uridine residues at specific sites in the transcript, and in some mRNAs 
more than half of the nucleotides in the coding sequence are introduced by editing 
(Feagin el al., 1988; Benne, 1994). Within each maxicircle resides a non-
coding variable region of about 8 kb in Trypanosoma bnicei (Myler, e/a/., 1993) 
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and dbowX \2kh \r\ Lcishmania farenloloc (Muhich ef a/., 1983), which contains 
many repetitive sequences and is said to be associated with the minicircle 
repHcation origin (Shapiro & Englund, 1995). Maxicircles encode some guide 
RNAs (Blum cl ol., 1990). Recently Lee e( al (1995) have identified 
Leishmania species by a specific DNA probe that is conserved only in the 
maxicircle DNA of human-infective Leishmania parasites. 
ii) Minicircles. Minicircles make up over 90% of the mass of the network 
and in different species they range in size from about 0.5 to 2.9 kb. In most of the 
species, all the minicircles in a network are of about the same size. A cmcial 
genetic fimction of minicircles is to encode small guide RNAs that govern the 
specificity of RNA editing (Sturni & Simpson, 1990). The minicircles in a 
network are heterogenous in sequence, and the degree of heterogeneity appears to 
reflect the number of guide RNAs needed for editing. A laboratory strain of L 
(arentolac, in which editing occurs at modest level, has 17 different minicircle 
classes (Maslov & Simpson, 1992). Aside from the region encoding guide RNAs, 
minicircles also have a conserved region (usually 100-180 nucleotides and 
virtually identical in all minicircles in a network) that contains the origin of 
replication origin. Some minicircles such as those in L tarcniolac (Kidane e/o/., 
1984) contain a single conserved region. This characteristic has allov/ed their 
use as diagnostic probes (Smith e/a/., 1989). Cloned minicircle fragments have 
been used as probes to distinguish organisms at the species, subspecies and strain 
levels (RodgerscV a/., 1990), 
1.4,4.2 Basic principles of DNA diagnostic methods 
The principle behind all the DNA diagnostic methods is of creating 
conditions necessary for a labelled single stranded DNA of specific sequence 
characteristic of one species, subspecies, strain or isolate, to find and hybridize 
with its complementary strand in the DNA of the parasite, under test. If there 
are no strands in the unknown DNA complementary to probe sequence, no signal 
will be detected but if, positive hybridization has taken place, it will be detected 
due to the presence of label. 
i) Pulse-field gradient gel electrophoresis (PFGE): It was first used by 
Schwartz and Cantor (1984) to separate intact yeast chromosomes. High voltages 
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are applied in alternating pulses across (at least) 2 different fields of the gel, 
allowing the resolution of the DNA molecules in an approximate range of 10 to 104 
kb pairs. Molecular karyotypes of I.cishmonia and Plasmodium have been pro-
duced using PFGE (Kemp c/o/.. l990;Lighthall & Gianni, 1992). PFGE separa-
ted chromosomes or chromosome fragments can be probed and then isolated or 
cloned for further analysis. The molecular karyotype of isolates, can be com-
pared and variable bands may be shown to correspond to biological variants, such 
as, vinilent and avirulent strains (Cox, 1985); or even individual clones within a 
strain (Bishop & Miles, 1987). It has been demonstrated that mole-cular 
karyotypes of I.eishmania strains differ in number, size and staining intensity of 
bands, but chromosomes from closely related strains were found to be more 
similar, suggesting that it is possible to recognise unidentified isolates of a 
particular strain or species group (Lighthall & Giannini, 1992). 
li) DNA-DNA hybridisation The degree of homology between 
genomes of organisms can be assessed using the technique of DNA-DNA 
hybridisation (Werman e/ al., 1990). In this technique the extent of base pair 
mismatch is determined by the subsequent melting temperature of the hybrids. A 
change of 1"C in melting temperature denotes approximately 1% sequence 
difference. A melting curve when plotted is used to estimate the extent of overall 
genetic divergence of two groups. A disadvantage of this technique is that, 
although the DNA sequence is examined directly, individual characters are not 
identified and therefore, can not be traced through a phylogeny. The method is 
expensive and more so quite large amounts (milligrams) of DNA is required. 
iii) Dot-blot analysis. An absolute distinction between groups of parasites 
can be made using the technique, based on the isolation of a DNA sequence which 
is unique to one of the parasite groups, being compared. DNA samples from 
unknown' parasites are immobilised on nitrocellulose or nylon filters and 
hybridised with the radiolabeled group specific probe. The technical advantages 
of this system is that, parasites belonging to a particular species, subspecies or 
group can be identified specifically with high sensitivity, and also, that large 
number of samples can be processed simultaneously. Such technique could 
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surely fomi the basis of a diagnostic test, as quantities of DNA as low as 10-100 
picogT;Mii can be detected. 
iv) In situ hybridisation: The technique is similar to that of dot-blot 
technique, except for the fact, that here individual parasites can be immo-
bilised and the probe hybridised to the parasite is/« AV/I/(Hide & Tait, 1991). 
Thus, individual parasites within a mixture can be assayed for the ability to 
hybridise to a specific probe. However, this technique remains as second choice as 
it is less sensitive and difficult to use. 
v) Restriction fragment length polymorphism (RFLP): Restriction 
endonucleases are enzymes of bacterial origin which recognise and cleave specific 
(usually 4-6 bp) DNA sequences. RFLP analysis identifies point DNA polymor-
phisms that disnipt these recognition sites, as well as larger mutations, that alter 
the length of the DNA fragment, between recognition sites. Here the DNA is 
digested by restriction enzymes and the fragments produced are separated by 
electrophoresis on the basis of size, through a gel matrix. To visualise, the RFLP 
pattern, the separated DNA fragments are usually transferred from the gel to a 
solid support (nitrocellulose paper) and hybridised with a labelled probe. 
Organisms can be characterised and compared by the number and pattern of bands 
produced (Despres et a/., 1991; McManus & Bowles, 1996). 
RFLP profiles of kDNA have been found to be useful in the characterization 
oi' Lcishmania species and strains (Barker c( ai, 1986; Jackson cl al., 1986; Wirth 
ci (7/..1986; Gomez-Eichelmann et al., 1988; Smith ef al., 1989; Angelici e( al., 
1989; Guizani el al., 1994), and have been successflilly used to distinguish species, 
belonging to the Old Wodd and New Worid leishmaniasis (Kennedy, 1984). 
However, intraspecific variations were found during the analysis of strains 
belonging to different areas in some cases (Spithill & Gnimont, 1984). 
Although the comparison of restriction fragments and restriction sites is an 
indirect measure of sequence variation, it is independent of external influence. Since 
RFLP analysis is relatively easy, it is possible to examine variation in a large 
number of individuals and/or at a large number of loci. One drawback of the method 
is that, unless the restriction endonuclease sites are laboriously mapped, it can only 
be assumed that 2 co-migrating bands are homologous. 
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vi) PCR-based approaches. Tlie advent of the polymerase chain reaction 
(PCR) (Saiki ct ai, 1985; Mulhs & Faloona, 1987; Saiki ct al.„ 1988) has 
revolutionised molecular genetic studies. It allows the rapid selection, isolation, 
amplification and sequencing of DNA ft^om small amounts of tissue. Double 
stranded genomic DNA is denatured by heating and then the temperature is lowered 
to allow 2 specific primers to anneal to their complementary sequences on opposite 
strands of the DNA. Template directed DNA synthesis proceeds fi^om the primed 
sites in both directions when catalysed by a polymerase. Double stranded products 
result and the procedure is repeated approximately 30 times. In each cycle, the 
target DNA is replicated by a factor of 2 so that, after many cycles, millions of 
copies of the original fragment are available for subsequent manipulation. A 
limitation of this method is that some sequence infomiation must be available to 
enable synthesis of the specific primers which delimit the ends of the PCR fragment. 
However, since asolute homology of primers and binding sites is not required, the 
primer sequence may be designed based on sequence infomiation available from 
related organisms, or on sequences known to be conserved for a range of organisms. 
PCR based techniques require only small amounts of template DNA 
(theoretically a single molecule) of relatively inferior quality and therefore, the 
amount of material required for analysis is greatly reduced in comparison to all other 
methods. This is a particular advantage in the study of protozoa since culturing of 
isolates is not required, thus avoiding the risk of subpopulation and minor variant 
selection (Deane c( ai. 1984). For methods involving the PCR, the major potential 
drawback is the risk of contamination of the sample with material from another 
source, especially previously amplified DNA. 
a) PC 'R-linked RFLP (PCR-RFPP). In a modified version of the conventional 
RFLP procedure, PCR amplified fragments are digested with restriction 
endonucleases, electrophoretically separated and their characteristic patterns 
visualized directly after ethidium bromide staining (Saperstein & Nickerson, 1991). 
The quality and amount of DNA required is greatly reduced, no DNA probe is 
necessary (although PCR primers must be available) and the time consuming 
blotting and hybridisation steps are avoided. The conventional RFLP method 
requires microgram quantities of reasonably high quality DNA but, if linked to PCR, 
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nanogram quantities of DNA are adequate. PCR-ainplified small subunit rRNA 
genes of a number of protozoan species have been analysed in this manner, 
producing characteristic ''riboprints" suitable for identification purposes and 
reflecting genetic diversity (Brindley el ai, 1993). 
b) Random amplified polymorphic DNA (IMPD): A variation on the standard 
PCR method involves the random, rather than specific, amplication of fragments of 
the genome (Williams el al., 1990; Welsh & McClelland, 1990). Instead of 2 
primers each designed to anneal to specific sequences only a single short randomly 
selected primer is used in the PCR. The primer anneals at positions of highest 
homology under the given PCR conditions. If 2 of these binding positions are 
sufficiently close together and the primers have annealed on opposite strands with 
the 3' ends directed inwards, a double-stranded fragment of DNA will be amplified. 
Any number of such fragments might be produced depending upon the primer, the 
DNA template and the PCR conditions. Wlien these fragments are separated by gel 
electrophoresis, a complete fingerprint pattern results. Species or strain-specific 
fraginents may be detectable as unique band: when a range of organisms are 
compared in the same PCR. Subsequently, these distinctive bands may prove useftil 
as probes. This approach is now being applied in molecular characterisation studies 
of a range of parasites (Neto e/fl/.. 1993; Morgan e/a/., 1995) 
The practical usefulness of the RAPD method is limited for several reasons: 
1. Primers used in RAPD analysis are non-specific, any contaminating DNA will 
also produce a fingerprint, greatly conftising the analysis. 
2. The method is prone to problems of reproducibility, since slight differences in 
the concentration or quality of template DNA or any one of many different 
PCR components and conditions are likely to alter the final fingerprint 
obtained. 
3. Totally uncharacterized pieces of DNA are being compared, any unique 
bands between closely related organisms are most likely to represent very 
rapidly changing "junk" DNA, and individual isolates may vary precluding 
correlation of fingerprint patterns with biologically important features. 
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1.4.4.3 Recent advances in molecular characterization of leishmaniasis 
The use of kinetoplastid DNA probes to distingush between isolates of 
Ix'islimonia has been under investigation for a inuch longer period (Wirth & 
McMahon-Pratt, 1982; Barker & Burcher 1983; Kennedy, 1984) because of the 
iiigh copy number of kDNA sequences which provided multiple targets for DNA 
probes. A DNA probe that could differentiate between two Lcishmania species 
when a lesion sample was applied directly to nitrocellulose (Wirth at al., 1986; 
Rogers et al., 1988) was used successfully to diagnose both visceral and cutaneous 
Lcishnicinicms (Lopes & Wirth, 1986; Wirth et al., 1986; Smith cl a!., 1989). DNA 
probes have also been used for hybridisation in situ, when lesion material 
applied to a microscope sUde is probed with the kDNA probe, allowing 
visualisation of the parasite's presence (Van el a!., 1987). Development of kDNA 
diagnostics for the Old World species has required selective cloning of species-
specific kDNA ft-aginents (Smith et al., 1989, Gramiccia et al., 1992). Such probes 
have been used to identify parasites in clinical biopsy material (Ben Ismail et al., 
1991) as well as in experimentally infected and wild caught sandflies (Ready et al., 
1988). Howard era/(1991) made a breakthrough by isolating a cDN A clone 
named Lmet2. It comprised of 4 copies of an imperfect 60 bp repeat motif. On 
southern blot the Lmet2 sequence was found to be entirely specific to members 
of the L. cloiiovani complex. The probe could detect fewer than 100 parasites on 
dot/slot blots and has been used successflilly to identify parasites in field 
prepared squash blots of sandflies and skin-snip smears from naturally infected 
canine resei-voir hosts (Wilson e/a/., 1992). Barker and co-workers (de-Bruijn & 
Barker, 1992; Smyth et al., 1992; deBniijn et al., 1993) foccussed their attentions 
on the development and field application of PCR-based diagnostics for 
Leishmaniasis. Following extensive sequence analysis of kDNA minicircles of 
different species, synthetic oligonucleotide primers have been developed which 
combine species-specific and'universal' kinetoplastid specific sequences allowing 
the entire ininicircle to be amplified during PCR reaction. Applying this overall 
strategy, primers specific for the L. braziliensis complex (de Bruijn & Barker 
1992) have been thoroughly evaluated under field conditions. The L. braziliensis 
kinetoplastid primer pair has been used to amplify parasite DNA from patient 
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and reservoir host biopsy material as well as from dry sandflies. Eresh et al 
(1994) were successflil in designing oligonucleotide primers which were highly 
specific for L. mcxicana complex isolates and could be used to distinguish 
between I..(L.) mexicana and L(L.) amazonensis isolates. The more recent 
minicircle variable region amplification technique using amplified minicircle 
variable regions as molecular probles was able to characterise 3 distinct groups of 
Old World' Leishmania spp: viscerotropic species (L. donnvani, L. infantum) and 
the closely related 'New World'.v/^ ec/c.v L. chagasi, L major and L. tropica and 
tlie Leishmania sp. causing post kala azar dermal Leishmaniasis (PKDL) 
(Bozza et al., 1995). To facilitate the use of PCR for the analysis of a large number 
of samples in the field Qiao et al {\995) replaced agarose gel electrophoresis 
and hybridisation detection of PCR product with a more simple and inexpensive 
colorimetric method. Anderson and co-workers (1996) described PCR as a 
more sensitive method than direct microscopy in the diagnosis of cutaneous Leish-
maniasis due to L. major. In the recent years the development of the random 
amplified polymorphic deoxyribonucleic acid (RAPD) method is considered to be a 
more convenient tool with which to study genetic polymorphism and aid in the 
identification and determination of the relationships of species and strains within 
the genus Leishmania (Anderson et al., 1996; Schonian et al., 1996; Noyes et al., 
1996). 
The sequence heterogeneity of kinetoplast DNA minicircles of L. 
donovani strain UR6 has been described by Dasgupta & Majumdar, 1989. They 
have generated a highly specific minicircle fraginent of the Leishmania species 
{L. donovani UR6) causing post-kala-azar dernial Leishmaniasis, which showed 
no cross hybridisation with other viscerotropic species and hence represented a 
potentially valuable tool in the taxanomic identification of Leishmania strains 
(Dasgupta e/fl/., 1991). Two oligonucleotide primers Lsmcl and Lsmvl derived 
from the conserved and variable region of a major class kDNA minicircle 
(pLURkE3) of Leishmania strain UR6 have been shown by Bhattacharya et al 
(1993). These primers were highly specific and when used for the polymerase 
chain reaction (PCR) could amplify a 461 bp fragment from the kDNAs of 
cutaneous species only (Smgh e/a/., 1994). Hassan et al 1993 applied PCR to 
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amplify the imilticopy mini exon derived RNA (Med RNA) intergenic spacer 
region of/., donovani, which is shown to be conserved among hidian isolates of L. 
donovani and hence useftil as a specific discriminatory probe, it has been 
successftilly tested on clinical samples from kala-azar and PKDL patients and can 
discriminate between L donovani and L amazonensis, L major and L infantum 
(Adhyaetai, 1995). 
1.5 PARASITE KILLING 
The host offers resistance to invading parasite by a series of mechanisms. 
The production of lactic acid and fatty acids by the skin and the secretion of the 
mucous tissue represent the first type of defence mechanisms. The second type 
of host defense relates to the secretion of lysozymes, phospholipases and IgA class 
of immunoglobulins. In tissues and blood, the antibodies of IgM and IgG class 
along with the components of the complement system offer yet another mecha-
nism of defence. Finally, the most effective resistance to the invading parasite is 
offered by phagocytic cells.Phagocytosis of the parasites by macrophages perturbs 
the plasma membrane of the macrophages, increases the rate of oxygen consump-
tion and results in the production of reactive oxygen intennediates (Roos & 
Weening, 1978; 1979). This process is called as oxidative burst. The reactive 
oxygen intennediates are superoxide (O2*), hydrogen peroxide (H2O2) hydroxyl 
radical (OH') and singlet oxygen (O') (Stjemholm & Manak, 1970; Kellogg & 
Fridovich, 1975). The generation of (02") from oxygen requires a reducing 
equivalent (Allen et al.,, 1972; Marietta et al.,, 1988). This is derived from 
glucose. An increased level of NADPH reduces oxygen either directly by 
utilizing NADPH oxidase or indirectly by reducing other substrates with the help 
of NADH oxidase. Once the superoxide is generated, it can undergo spontaneous 
dismutation to hydrogen peroxide (H2O2) and singlet oxygen (Albina & Henry, 
1991). Hydrogen peroxide can flirther react with superoxide to fiimish OH* and 
singlet oxygen (Green el al., 1990). These reactive oxygen intermediates are 
the cytotoxic substances capable of killing Leishmania parasites. 
The reactive nitrogen intemiediate like NO owes its origin to the guanidine 
nitrogen atom of L-Arginine (Liew cl al, 1990; Stuehr & Marietta, 1985, 1987). It 
is reported that immunostimulation of macrophages either by exogenous 
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stimulation such as lypopolysacchardies from H. coli or by endogenous 
lymphokines leads to the generation of nitric oxide (NO). This reacts flirther to 
yield NO2' and NO_r (Murray, 1981). 
1.6 PARASITE SURVIVAL 
Amidst all these strategies of the host defence, Leishmania parasite 
establishes, survives and replicates. It is, therefore, essential to understand the 
parasite defence mechanism for identifying biochemical target sites for new drug 
design. Survival of the parasite occurs by manipulating host defence mechanism at 
three distinct stages: 
1. Entry of the parasite in the host cell is mediated by the receptors present on 
its cell surface which do not elicit any microbicidal response; 
2. Intracellular survival is managed by neutralizing the lethal effect of 
reactive oxygen and nitrogen intermediates generated by the host cell; 
3. Establishment and multiplication of intracellular parasite occur by suppress-
ing the cell mediated immunity response of the host 
1.6.1 Strategies for Survival within Macrophages: 
i) Inhibition of the oxidative burst. It is well established that the extent of 
the oxidative burst of macrophages elicited by Leishmania depends on the growth 
phase of the parasite. Wliereas log phase fornis induce a strong increase in the 
oxygen consumption of macrophages, neither metacyclics nor amastigotes lead to a 
significant generation of oxidative metabolites (da Silva, 1989; Bogdan e( al, 1990). 
Once Leishmania are located intracellularly, they down regulate the oxygen-
dependent killing mechanisms of activated macrophages. This is independent of the 
receptor used for entry into the host. Glew et al, (1988) showed that the acid 
phosphatase on the surface of L. donovani is capable of blocking the production of 
superoxide and H2O2 by phagocytes. Interestingly, the total cellular and membrane 
activity of acid phosphatase correlates well with parasite vinilence; the enzyme 
activity of vinilent L. donovani clones is twice that of avimlent clones (Katakura & 
Kobayashi. 1988). Another potent inhibitor of the oxidative burst is the LPG that 
acts by inhibiting protein kinase C, one of the key enzymes involved in the 
generation of oxidative metabolites (McNeely et ai, 1989). 
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ii) Scavenging of oxidative metabolites: Leishmania are provided with a 
number of substances that serve to neutrahze or eliminate oxidative metabohes. 
Amastigotes, but not promastigotes, show a high activity of enzymes (glutathione 
peroxidase, superoxide dismutase, catalase) that are known to degrade these toxic 
macrophage products. This may account for the enhanced intracellular survival of 
amastigotes as compared to promastigotes (Pearson, 1983). Chan et al (1989) have 
illuminated a second important parasite-protective mechanism: the LPG of 
Leishmania, which consists of repetitive saccharide units, scavenges oxygen 
radicals and prevents the killing of the parasite by hydroxyl radicals. 
iii) Inactivation of lysosomal enzymes and maintenance of a pH 
homeostasis within the phagolysosome. Apart from oxygen-dependent antiparasite 
processes, a number of phagolysosomal, oxygen-independent factors such as acid 
pH, osmotic stress or lytic enzymes contribute to the antiparasitic activity of 
macrophages. Leishmania have developed a variety of escape mechanisms against 
these. LPG is capable of inhibiting the lysosomal p-galactosidase and erythrocytes 
coated with LPG are protected from lysis by macrophages (Eilam et al, 1985; 
Handman t'/a/.. 1986). 
The gp63 molecule may also have parasite protective functions in the 
phagolysosome. Its protease activity, with an optimum at pH 4, inactivates 
proteolytic host enzymes and thus protects parasite proteins from phagolysosomal 
degradation (Chaudhuri ct al, 1989). 
Leishmania amastigotes are highly adapted to the acidic medium inside the 
phagolysosome, and do not block its acidification. The uptake of essential 
metabolites (eg. glucose, proline, pyrimidine bases) is dependent on the cotransport 
of protons (H"^ ) and is therefore optimal at pH 4.0-5.5. At the same time Leishmania 
are able to maintain a neutral intracellular pH despite the acidic environment inside 
the phagolysosome. These biochemical processes may frirther explain the amazing 
capacity of amastigotes to survive and multiply within macrophages (Mukkada et 
al, 1985; Zilberstein & Dwyer, 1985). 
iv) Infection of macrophage populations with reduced leishmanicidal 
capacity. The primary infection site of all fonns of leishmaniases is the skin. This is 
CRicial for the initial replication of the parasite in two respects. First the 
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leishnianicidal capacity of macrophages is significantly lower at 30-35"C (i.e. the 
temperature that predominates in the skin) than at 37"C. Second, promastigotes 
apparently fail to trigger an oxidative burst in dennal macrophages, thereby 
facilitating their survival and replication (Bogdan et al., 1990). 
Thus, the total cure of leishmaniasis may require chemotherapeutic and 
immunotherapeutic agents. The objective of a chemotherapeutic agent is to undo 
the survival mechanism of the parasite while the immunotherapeutic agent helps 
the host to regain its lost immune defence mechanisms. Since a chemotherapeutic 
agent is expected to knock-off the survival mechanism of the parasite, it is 
essential to understand the status and mechanism of the host defence. Any 
chemotherapeutic agent which may interfere at one locus and/or at many loci in 
the total cascade of parasite enzymatic activities would not only make the 
parasite weak but would also lead to enhanced availability of reactive oxygen 
and nitrogen intemiediates generated by the host. Since the parasite superoxide 
dismutase (SOD) and the free radical scavangers like glutathione peroxidase and 
catalase are responsible for the protection of parasites from the oxidative burst 
of macrophages, a chemotherapeutic agent capable of specifically knocking off 
any of these enzymes of parasite could also be of value for the treatment of 
leishmaniasis (Arias & Jakoby, 1976). 
1.7 DRUG DEVELOPMENT AND DISCOVERY 
Throughout the history of modem therapeutics, dmgs were equated with 
small organic molecules. Pharmaceutical chemists, both in industry and academia, 
synthesized compounds, usually building upon past successes and biologists then 
screened these compounds for therapeutic potential. Problems of synthesis, scale-
up, analytical methodology, formulation and possible pharmacokinetic and 
pharmacodynamic behaviour were all reasonably well understood. Over the past 
few years, two distinct, but interrelated, trends in drug discovery have emerged that 
have drastically altered this situation. The advent of the combinatorial library 
approach to drug synthesis (Gold et al, 1995) has dramatically expanded the types 
and numbers of compounds available for testing, thus requiring an equally dramatic 
increase in the speed and precision required in initial screens (Kleinberg and 
Wanke, 1995; Bevan et al., 1995). However, combinatorial chemistry, like 
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traditional drug discovery, relies heavily on dnig screening. A second emerging 
trend makes use of our increasingly sophisticated knowledge about the molecular 
pathogenesis of disease processes, and involves designing or identifying molecules 
that interact precisely with required targets for therapeutic intervention. 
The classic paradigm of dmg discovery has been to synthesize a number of 
organic compounds, test them in a complex, disease-based, screen, identify a lead 
compound, undertake further synthesis and then re-initiate the cycle. Promising 
compounds would then be introduced into extensive preclinical toxicological testing, 
and suitable compounds would eventually be clinically tested. Recent innovations 
have dramatically altered the traditional paradigin. First, drug screening is 
increasingly target based (Rosenfield cl ai, 1995; Caporale, 1995; West & Fairlie, 
1995). Rather than initially testing a dmg in a complex animal model, rapid, high-
throughput screens against defined targets (cloned receptors, enzymes, transcription 
factors) are used to identity promising candidates. Because of the large number of 
compounds that can be tested this way, data handling and analysis become much 
more complex, so sophisticated infonnation-handling systems are essential (Cho & 
.luliano, 1996). 
Developing a new antileishmanial is a critical research priority, as no truely 
effective therapy is available. Dnigs currently in use were developed decades ago, 
and have limitations in both efficacy and toxicity. Resistance to previous dnigs is 
now widespread. To overcome some of these difficulties in a timely and cost-
etTective way,a combination of new technology in molecular biology, X-ray 
crystallography and biochemistry has been used to screen analogue chemo-
therapeutic leads directed against enzymes of a number of parasites of humans. 
In leishmaniasis, a peculiar situation occurs where macrophages (the cells 
which nonnally have the function to distroy invaders) are affected. This adaptation 
not only deranges host's defence system but even defeats man's ingenuity in 
directing and delivering dmgs at the appropriate site. There are certain limitations 
associated with the in vivo screening systems viz: manual labour, time, biological 
variations, need for large quantity of compound and ethical use of laboratory 
animals. 
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The situation unquestionably demands the use of proper screening system, 
rationale chemical synthesis and targetted drug dehvery, Cunent approaches for 
design and development of antiparasitic agents involve identification and 
characterization of potential biochemical and molecular targets (Fairlamb, 1996). An 
ideal target should have following properties. 
1. It should be essential for the survival of the parasite in the mammalian host 
and absent from the host or non-essential for the host. 
2. The target should be sufficiently different between host and parasite to permit 
selective inhibition. 
3. The target should be amenable to detailed study at the molecular level (e.g. an 
enzyme or a metabolite). 
1.8 SCREENING SYSTEMS 
The first prerequisite of a reliable test system is that it should have a good 
correlation with clinical situation. Fortunately in antileishmanial screening L. 
donovani parasite has been employed, right from the begining of the history of 
antileislimanial chemotherapy. Yet, not a single acceptable drug could emerge. The 
main reason being that the parasite is protected by macrophages and the compounds 
which are toxic to parasite within the macrophage are often toxic to host also. These 
hurdles have instigated chemists to redesign their strategies for molecular synthesis. 
Models for drug testing 
Two test systems are in vogue; in vitro and in vivo. Preference obviously 
goes in favour of/>? vitro system since this: 
a) yields quick turnover of results, b) requires parasites only from few animals, and 
c) needs very small quantity of test compounds. But all these plus points would be 
negated if the degree of extrapolation of results to the target host is not within 
acceptable range. 
For want of quick feedback of screening results, a suitable in vitro system is 
desirable. Both promastigotes and amastigotes have been used as test parasites. 
1.8.1 In vitro test systems 
Two types of in vitro test systems are in vogue: 
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1.8.1.1 General screens 
Effect of the compound is evaluated on growth, proliferation and metabolic 
activity of the intact parasite in an in vitro culture system. 
i) Promastigotes: It is the simplest model to be used in which the parasite multiplies 
in cell free media (Berman, 1985). They are diluted to a concentration of 0.1-2.0 x 
10^ ' per ml of cultivation medium. A dnig is added to the experimental culture and 
inhibition of promastigote multiplication is assessed after approximately 3 days 
during which the control organisms multiply 3-6 times. The leishmanicidal activity 
of the test compound can be assessed by following methods: 
a) Microscopic assay: The test is based on the killing of Leishmania promastigotes 
in vitro. Initial concentration of the drug/compound test is 100 f.ig/ml with 10^  
promastigotes in I ml culture. Incubation temperature is 25+l"C for 5 days and the 
viable/motile promastigotes are counted under microscope. The compounds showing 
>90% inhibition in promastigote counts are considered as positive for leishmanicidal 
activity. 
b) [•'Hl-Thymidine incorporation assay It is based upon the uptake of a 
radiolabled nucleic acid precursor as an index of parasite growth. Suppression of the 
uptake of thymidine indicates parasite response to drug. A 96 well niicrotiter culture 
plate is seeded with 1-2 x lO'' cells per well. The cultures are grown normally or in 
presence of the test compounds (initial cone. 100 jiM) for 72 hrs. The cultures are 
pulsed with ^H-thymidine (0.2 fiCi/well) and allowed to grow further for at least 18 
hrs. The cultures are harvested on the cell harvester and incorporation of ^H-
thymidine is measured. Percentage inibition of thymidine incorporation as compared 
to control (no dmg/compound) is computed. The compounds showing >90% 
inhibition at 100 \.[M may be evaluated further for detemiination of IC-50 values 
(Grogl era/., 1989). 
c) MTT reduction assay 
This assay is based on the reduction of a tetrazolium salt MTT [3-(4,5-
diethylthiazole-2-yl)]-2,5-diphenyl tetrazolium bromide to tlie purple colour 
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fonnazon salt in the presence of metabolically active/proliferating /.. donovani 
promastigotes in an in vitro culture system. 
The /-, donovani promastigotes harvested in the log phase of culture are 
seeded in 96 well microliter culture plates at the density of approximately 2x10^ 
promastigotes per well. The compounds are dissolved in the appropriate solvent and 
added to the culture at the final concentration of 100 fiM. The controls without cells, 
cells without any dnig/compound are also set up simultaneously. The cultures are 
allowed to grow ftirther at 26"C for at least 72 hours. After 72 hours, 10^1 of MTT 
solution (5 mg/ml prepared in the sterile culture medium) is added to each well and 
the plates are incubated further for 4 hours. 100 \i\ of solubilising reagent 
(containing 10% Triton X-100 in DMSO) is then added to each well. This reagent 
lyses the Leishmania cells and solubilises the crystals of formazone salt of MTT 
producing purple colour. The intensity of colour produced is directly proportional to 
the number of metabolically active proliferating Leishmania promastigotes. The 
intensity of colour is quantitatively read by recording the absorbance by a microtitre 
plate reader at the filters of 540 nm. The leishmanial activity of compound is 
computed as below (Beekman et al., 1996): 
Absorbance of culture containing 
the test compound 
Percentage inhibition = 100 x 100 
Absorbance of the culture without 
drug/compound 
ii) Amastigotes: The discovery that macrophages infected with amastigotes can be 
maintained in vitro has solved many problems which were being faced with 
screening against promastigotes. This system (macrophage-amastigote) has received 
favour since the system provides more or less in vivo environment for parasites. 
Accordingly m vitro tests have been carried out using tumor macrophages (Mattock 
& Peters, 1975), rodent peritoneal macrophages (Berman & Wyler, 1980; Haidaris 
& Bonventre. 1983; Neal & Mathews, 1982; Neal & Croft, 1984; Neal et ai, 1988; 
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Bhatnagar ci ai. 1989), and human monocyte derived macrophages (Berman et ai, 
1979; Looker ct ai, 1986). Assessment of leishmanicidal activity of compound/drug 
can be done by either Giemsa staining or [""H]- hypoxanthine incorporation. 
1.8.1.2 Mechanism-based screens 
Parasite-specific enzymes, receptors, transporters, genes and metabolic 
pathways are exploited as potential chemotherapeutic targets. 
i) Purine metabolism. Unlike mammalian cells, all the protozoan parasites studied 
thus far appear to be unable to synthesize purines de novo. The reutilization of 
purines and their derivatives obtained fi^om the degradation of nucleic acids and 
nucleotides, commonly known as the salvage pathway, is the only means for 
Lcishmania to synthesize purine nucleotides. The fiinctioning of various purine 
salvage pathways is therefore essential to the parasites' survival (Wang, 1983). 
Substitution of a purine base by a structurally similar heterocycle may be recognized 
by purine metabolizing enzymes and the manner in which the interference may 
occur is described in figure. 
What leishmanial 
body does 
Normal way 
of protein 
synthesis 
\ 
, Normal RNA 
Inosine 
-Hypoxanthine 
What a purine 
antagonist does 
Inhibition of 
protein synthesis^ 
Allopuhnol iv^ 
Abnormal > 
RNA 
Allopurinol>;;-
riboside 
Figure : Mode of interference by purine antagonist 
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Lelshmania species contain a unique salvage enzyme, purine nucleoside 
phosphotransferase, which transfers the phosphate group from a variety of 
monophosphate esters to the 5'-position of purine nucleosides. The enzyme has a 
broad substrate-specificity and phosphorylates purine nucleoside analogues also 
such as allopurinol riboside, formycin B and thiopurinol riboside, converting them to 
the corresponding nucleotides (Marr & Berens, 1982). These purine nucleotide 
analogues are eventually incorporated into nucleic acid, killing the cells (Rainey & 
Santi, 1983). In L. donovani three distinct enzymes have been reported to catalyze 
the transfer of phosphoribosyl groups to purines, one is concerned with 
hypoxanthine and guanine the second with adenine and the tliird with xanthine 
i^ Mukherjee c( ai, 1990). One salvage enzyme hypoxanthinguanine phosphoribosyl-
transferase (HGPRTase) has been found to be associated with the glycosome in 
Laishmania spp. The other phosphoribosyltransferases are found in the cytosol 
(Hammond el oL, 1985). HGPRTases of A. donovani (Tuttle & Krenitsky, 1980) 
convert aHopurinol into allopurinol ribonucleotide more efficiently than the 
mammalian counterpart, killing the parasites. Xanthine phosphoribosyl transferase is 
a unique biochemical target site since mammalian tissues do not contain this enzyme 
(Lafon ct al., 1982). Similarly, succino-AMP synthetase (adenylosuccinate 
synthetase) is another enzyme which may serve as a target since this enzyme has a 
narrow substrate specificity but accepts Inosine-5'-phosphate (IMP) analogues 
including allopurinol ribonucleotide. Yet another such enzyme is GMP-reductase 
which catalyzes the reduction of GMP to IMP. Spector & Jones (1982) have 
demonstrated that leishmanial GMP-reductase is different from human GMP-
reductase with respect to inhibitor specificity. 
ii) Pyrimidine Metabolism: Many mammalian cells can either synthesize 
pyrimidines de novo from the precursors glutamirie, ATP, HCO "^ and aspartate or 
salvage pre-formed pyrimidine bases or nucleosides. Leishmania can utilize both 
salvage and de novo biosynthetic pathways (Fairlamb, 1989). 
In Leishmania. the subcellular localization of some of the enzymes can differ 
substantially. For example, in the Kinetoplastida, orotate phosphoribosyltransfrase 
(OPRTase) and orotidine-5'-decarboxylase (ODCase) are associated with the 
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glycosome while in mammals it is cytosolic. The conversion of dihydroorotate to 
orotate, is one of the key reactions in de novo synthesis of pyrimidines. The enzyme 
catalysing this reaction dihydroorotate dehydrogenase, is associated with the 
mitochondrion of mammalian cells, whereas it is cytosolic in Leishmania. 
iii) Trypanothione metabolism: Most, if not all cells, contain high (millimolar) 
concentrations of at least one low molecular weight thiol (Fahey & Newton, 1983). 
In most eukaryotic organisms the major component is glutathione (GSH; y-glutamyl-
cysteinyl-glycine). GSH plays many important roles in cellular metabo lism, 
including regulatory, protective and cofactor functions (Meister & Anderson, 1983). 
Together with glutathione reductase, GSH maintains the correct intracellular thiol-
redox balance and has been implicated in the control of DNA and protein synthesis 
and regulation of enzyme activity. GSH also serves to protect the cells against 
oxidative damage by non-enzymatic scavenging of free radicals and by enzymatic 
removal of peroxides by glutathione-dependent peroxidases and glutathione-S-
transferases (GST). This latter class of enzymes also flmctions in the detoxification 
of certain xenobiotics (Ketterer et al., 1988). GSH also serves as a coenzyme in 
certain metabolic pathways such as the methylglyoxal pathway and in some cells, 
GSH is involved in amino acid transport. 
Dithiol trypanothione [N',N'*-bis(glutathionyl) spermidine] is taily unique to 
the trypanosomatidae. Although trypanosomatids contain GSH, they do not contain 
glutathione reductase and use trypanothione and trypanothione reductase instead to 
regulate their intracellular thiol-redox balance. Trypanothione serves as an anti-
oxidant by trapping free radicals removing peroxides and reducing disulphides by a 
mixture of enzymatic and non-enzymatic reactions. 
A number of existing therapeutic drugs and experimental compounds are 
known to interfere with the trypanothione system. Biosynthesis of tiypanothione can 
be affected by inhibition of polyamine, glutathione S-adenosyl methionine 
metabolism; and maintenance of trypanothione in the reduced fomi can be affected 
by inhibition of trypanothione reductase. Although this indicates that these 
pathways are vital for the growth or survival of the parasite, it does not conclusively 
prove that trypanothione metabolism per se is a drug target (Fairlamb, 1996). 
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To date, the enzyme has been purified and characterized (Cunningham, 
1995). The enzyme Hke ghitathione reductase, is a member of the flavoprotein 
disulphide oxidoreductase family of enzymes. Importantly, the parasite and host 
enzymes show pronounced specificity for their respective disulphide substrates (i.e. 
T(S)2 or glutathionylspermidine disulphide for trypanothione reductase and 
glutathione disulphide for glutathione reductase). This pronounced discriminating 
ability is vital for the design of selective inhibitors. 
iv) A specific target : the superoxide dismutase of Leishmania donovani: 
Superoxide dismutases (SOD's) are enzymic scavenger of toxic oxygen radicals, 
which are responsible for cell damage. These are metalloproteins which cause the 
dismutation of superoxide radical to oxygen (O2) and hydrogen peroxide (H2O2). 
The enzyme exists in three different forms (Fridovich, 1995). Of these, Fe-SOD is 
the main forni that has been demonstrated in parasitic protozoa, including 
Leishmania species (Meshnick and Eaton, 1981). Plasmodium falciparum however, 
contains Mn-SOD (Ranz and Meslinick, 1989). Another isofonn, which uses Cu/Zn 
as the cofactor, was found to be present in Eimeria tenella (Michalski & Prowse, 
1991). 
Cu/Zn-SOD has been reported to be localized in a microbody like organelle, 
known as the peroxisomes in mammalian cells (Dhaunsi el al., 1992) while in 
Leishmania, Cu/Zn-SOD is confined to a unique organelle, the glycosoine (Dey & 
Datta, 1994). SOD plays an active role in the survival of this pathogen, suggesting a 
new approach towards chemotherapy of leishmaniasis. Dey el al (1995) have 
demonstrated that cAMP has a direct impact on the host parasite interaction by 
inhibiting Leishmania SOD. The leishmanial SOD is cyanide and 
diethyldithiocarbamate insensitive while azide- and peroxide- sensitive. Mammalian 
SODs are inhibited by diethyl dithiocarbamate. Thus, Leishmania contain a SOD 
which is different from its host's enzyme. A specific inhibitor of this enzyme might 
serve as an antileishmanial agent, 
v) Poly amine metabolism 
Poly amine metabolism is cnicial for both prokaryote and eukaryote survival. 
Polyamines viz putrescine, spermine and spermidine are polycationic compounds 
and their role has been conclusively demonstrated in malignancy, during cellular 
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growth and proliferation (Pegg, 1986; Sciles, 1990). Use of an irreversible inhibitor 
of the key biosynthetic enzyine of polyamines, ornithine decarboxylase (ODC) has 
been recommended for use as an antiparasitic agent in diseases like 
trypanosomiasis, the Afirican sleeping sickness. Large variations in the mechanism 
of regulation of polyamine metabolism in different organisms occur for fulfilling 
their physiological requirements. It is hypothesized that polyamines have a role in 
DNA binding and in its stabilization (Cohen, 1971). 
There is considerable difference in the properties of ODC associated with the 
host and the parasite. Thus, compounds which can alter the catalytic activity of 
ODC could be targeted at the active sites of ODC to bring about an alteration in the 
levels of polyamines and subsequently could be designed as an antiparasitic agent. 
The gene for ODC has been isolated and cloned (Keithley, 1989) and recombinant 
ODC may be used for structural studies and drug design. 
vi) Dihydrofolate Reductase/thymidylate synthetase: Dihydrofolate reductase 
(DHFR) and thymidylate synthase (TS) is a biftinctional protein and catalyzes 
consecutive reactions in the de novo synthesis of dTMP. In protozoa, in contrast to 
most other cells, these two enzymes are fused, resulting in a DHFR-TS protein. The 
enzyme DHFR, which catalyzes the reduction of dihydrofolate to tetrahydrofolate, is 
an important target for chemotherapy (Borst & Ouellette, 1995). The anti-DHFR 
drugs are termed antifolates and are used in the treatment of parasitic infections 
caused by /^ falciparum and Toxoplasma gondii in humans. However, none of the 
currently available antifolates is suitable for treatment of leishmaniasis in patients. 
Lcishmania spp. have a common folate/antifolate transporter, and mutations in the 
gene for this transporter lead to methotrexate resistance. 
vii) Proton Pump: It is responsible for maintaining the physiological pH of the 
parasite as it grows in the acidic (pH 5.0) environment within the phagolysosome. 
Some tricyclic antidepressant drugs can inhibit the membrane-bound ATPase 
involved in the maintenance of pH, and thereby suppress leishmanial growth. 
Structure-function analysis of some tricyclic derivatives indicated that, those which 
possessed antileislimanial activity, were devoid of neuroleptic activity and the 
neuroleptic and the anti leishmanial activities were structurally separable. 
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viii) Cysteine Protease: Inhibition of cysteincproteases which are responsible for the 
major proteolytic activity of the organisms may offer a new lead for drugs effective 
against leishmaniasis and other protozoal diseases (Mckerrow cl al., 1995). A 
breakthrough in the design of non-toxic inhibitors of proteases is the synthesis of 
peptide of fluoromethylketones for the inliibition of cysteine proteases. A non-toxic 
peptide, Z-Phe-ala-fluoromethyl ketone (ZPA-FMK) has been shown to be effective 
against P. falciparunh E. histolytica and T. cnizi in vitro. The leishmanial enzymes 
have been isolated and will be used for screening more peptides. This system will be 
used for dnig design following stnicture-fimction analysis of active sites of 
recombinant enzymes and synthesis of other peptides (TDR, 1990). 
ix) Lipid metabolism: Leishmania synthesize sterols ck novo and these are 5-
dehydroepisterol and ergosterol. The initial step of the biosynthesis of episterol 
involves demethylation of lanosterol and interference by ketoconazole (Holz, 1985) 
in this biosynthetic step has furnished a possible target site for the deisgn of 
antileishmanial agents. In fact 14, 14a-dimethyl and 14a-methyl sterols have been 
isolated from Leishmaniae which were exposed to the treatment of Ketoconazole. 
Another possible target site relates to the impairment with the surface membrane 
functions of Leishmania sterols (Muklierjee et ai, 1990). 
x) Tubulins: Fong & Chang (1981) have reported that leishmanial tubulins are 
developmentally regulated proteins and they increase during amastigote to 
promastigote differentiation and decrease during the reverse process. It has been 
observed that antisera prepared against a- and p-tubulins from other sources 
recognise leishmanial tubulins (Brodier el al., 1982). Antitubulin herbicides such as 
trifluralin inhibit tubulin assembly of some protozoa including L. amazonensis. 
Trifluralin has been shown to preferentially bind leishmanial tubulin and to have no 
effect on the mammalian (mouse) macrophages (at concentrations used) in which 
they were assayed (Chan & Fong, 1990; Chan et al., 1995). 
1.8.2//I v/vo Tests 
Convincing examples are on record where the very potent clinically used 
antiparasitic drugs have failed to exert action in vitro, since they work either through 
host defence system or through their metabolites. Dmgs have different indices of 
bioavailability and biotransformation which is completely lacking in in vitro 
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s\ stems. Therefore, the choice must go in favour of tests in animals. The in vivo 
drug testing is always cumbersome and time consuming. A proper, easy and quick 
system may be adopted for rapid turnover of screening results. 
1.8.2.1 Empcrical testing of drugs 
In the early days, the main hindrance in dnig development was the 
non-availability of a suitable animal model wherein the action of a new synthetic 
compound or other anti leishmanial agents could be screened. The first report of 
effective treatment of leishmaniasis came from Vianna (1912) who successfully 
treated Sovith Amencan mv\co-cutaneous leishmaniasis with tartar emetic.Towards 
the end of the 19th century a devastating epidemic of kala-azar swept through 
Bengal, Assam and the Brahamputra valley with a mortality rate reaching upto 
95%. Rogers (1915) was the first to use tartar emetic with success in kala-azar 
patients in India (Muir, 1915; Mackie, 1915; Dicristina & Caronia, 1915). This 
could save countless lives in an epidemic which occurred in 1918 (Rogers & 
Megaw, 1942). However, antimonial preparations of the tartar emetic type are 
liable to cause broncho-pneumonia, with collapse and in some cases sudden death. 
Thus tartar emetic was soon replaced by better tolerated drug, sodium antimony 
tartarate. In 1911 Schmidt discovered a method of synthesising quinquivalent 
antimonials. A large number of compounds were synthesized and proved to be 
much less toxic than trivalent antimonials. Brahmachari (1915) in India used both 
tartar emetic and sodium antimony tartarate in the treatment of kala-azar patients 
and recognizing their drawbacks, launched a research programme for synthesising 
newer organo-antimony derivatives. One of these, "Urea stibamine' discovered in 
1922, proved to be very effective. Between the years 1933-1936 this drug saved 
nearly 3.25 lacs of lives in Assam alone. Later several organo-antimonial 
compounds were studied in Europe to develop a more efficient antimonial drug 
and two new pentavalent antimonials proved to be less toxic and well tolerated. 
These were sodium stibogluconate or pentostam (Schmidt, 1950; Kikuth & 
Schmidt, 1937) and N-methylglucamine antimoniate or glucantime (Durand el 
al.. 1946; Sen Gupta, 1950). 
Although the pentavalent antimonials are the drugs of choice even today, 
being less toxic and more effective than trivalent antimonials, they are not without 
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toxic hazards altogether. Moreover, there are increasing reports of 
development of drug unresponsiveness in the parasite against these dmgs which 
has led to the search for alternatives to antimony therapy. Three new aromatic 
diamidines viz: stilbamidine, pentamidine and propamidine synthesized for the 
treatment of African trypanosomiasis, were tried against human kala-azar (Ashley 
el al., 1942, 1946). Propamidine was found to be neuro- and respiratory toxic, 
while Pentamidine was least toxic and more effective and till today is the drug 
of choice. However, it is known to produce disturbances in sugar metabolism 
(sometimes of a permanent nature) and kidney damage of varying degrees 
(Snapper, 1952; Sen Gupta, 1944). 
1.8.2.2 Critical testing of drugs 
While standard antimalarials and trypanocidal dmgs were being screened 
for detecting antileishmanial efficacy, attempts were being continued to find a 
suitable laboratory animal host wherein the target Leishmania donovani infection 
could be established and maintained for new dnig development and for 
manipulative research. Further, an ideal model should interact with host immune 
system and with chemotherapeutic agents in a way comparable to those observed 
in clinical cases. 
A critical review of literature showed that the golden hamsters take the L. 
cJonovani infection very well. These are sturdy animals and liave been shown to 
withstand repeated biopsies very well (Goodwin, 1945; Beveiidge, 1963; 
Shankhdhar, 1986). These are suitable for studying the sequential effects of drug in 
the same animal. Balb/c mice to certain extent also fiilfil the requirements of a 
good host and in modem screening methods both these animals are generally 
used. 
Screening techniques 
Recent research on chemotherapy of leishmaniasis included trial of both 
antimonials and aromatic diamidines in experimental leishmaniasis in animals. 
Several screening techniques have been developed for this purpose. Goodwin 
(1945) described a method of evaluating the activity of a drug in hamsters. 
Vandyke & Gelhom (1946) used a method for routine experimental evaluation of 
drugs against visceral leishmaniasis in hamsters, hi 1950, Gemiuth and his 
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associates observed the rate of disappearance of L. donovaiii from the spleen of 
the infected hamster using pentavalent antimonials. Staiiber el al.. (1958) 
introduced the minimum time taking procedure of eight days for screening 
compounds against L donovani in golden hamster. It was for the first time that the 
intracardiac route of inoculation was adopted. In this technique the target organ for 
assessment of activity was liver, depending on the fact that the parasites go to 
liver initially and then at a later stage to the deeper organs. The results 
obtained flom this technique were encouraging bvit even the highest dose failed 
to completely eliminate the parasite count in the liver. Further, tiie time factor 
being very short, the activity of the slow acting compounds was likely to be 
missed. Beveridge (1963) suggested that while screening the potential compounds 
they should always be administered only after the infection has been established 
(3-4 weeks post infection). Mikhail (1975) introduced another technique, stretching 
upto 45 days, where the treatment starts 15 days post inoculation. Varying drug 
dosesofstibanate were taken up but in none of them complete cure was observed. 
At this stage study of both the organs i.e. liver and spleen was introduced. 
However, due to a very long duration of this procedure the activity of certain 
compounds could be missed. Then came Hanson's technique (1977) which was 
a slight modification of Stauber's method, administering dnig three days post 
inoculation instead of 24 hours. Here too, considerable amount of decrease in 
parasite in liver was observed but total cure was not achieved. In 1978, Raether 
devised a technique where the treatment was given for 6 days PI and results could 
be obtained within a month, by counting the parasites in liver. Standard drugs by 
this method showed moderate activity. Trotter (1980), used NMRl mice showing 
the efficacy of pentostam and meglumine antimoniate using Raether's technique. 
A critical appraisal of the screening techniques described shows that 
none of them is able to provide comprehensive infonnation about the total 
efficacy of a potential dmg. This is due to the fact that total effect of a potential 
drug depends on two factors; the effect of the dmg directly on the parasites and 
its effect on host immune response. In other words, the host immunity modifies 
the action of the dmg. Thus, the idea is that the screening method should assess 
the action of the dmg in conditions similar to the clinical conditions in a patient. As 
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would be evident from the techniques described by Stauber (1958), Hanson 
(1977), Raether (1978) and Trotter (1980), the assessment of a potential dnig is 
based on its effect on day 8 to 12 post-inoculation on the parasites in the liver only. 
This is far from the actual situation. In clinical practice, where the VL cases are 
more chronic, the parasites are found in deeper organs like spleen and bone 
marrow. Moreover, these methods completely ignore the modulating effect of 
host immunity. Beveridge's (1963) method looks to be more logical as here the 
spleen biopsy is conducted for assessment. In this case however, the animals are 
sacrificed on day 7 post treatment and the belated action of the dmg could be 
missed. In other words, if the treated animals are allowed to live longer, better 
assessment could be possible. Mikhail (1975) started treating animals on day 15 
post-inoculation and sacrificed on day 45 post-inoculation. This technique 
could detect belated action of a dmg fairly well but not the early action. 
Shanklidhar (1986) modified Beveridge's technique conducting repeated spleen 
biopsies on the same animal i.e. on day 7, 14 and 28 to assess drug action. This is 
a more rational method of screening potential antileishmanial compounds but 
needs detailed study especially regarding the complete cure, survival time and 
host immunity. 
1.9 THERAPY 
1.9.1 Chemotherapy 
There have been relatively few new developments in m\Xi-Leishmania 
chemotherapy in recent years. The pentavalent antimonial compounds, sodium 
stibogluconate (Pentostam) and meglumine antimonate (Glucantime) still remain 
the primary therapeutic agents for all forms of leishmaniasis (Bryceson, 1987). 
However, these dnigs are known to be fairly toxic, their mechanism of action is 
poorly understood (Berman etai, 1985), and their success rate is variable and 
poor particularly in immunosuppressed individuals (most notably in patients with 
acquired immunodeficiency syndrome, (AIDS) (Rizzi et al., 1988). Many workers 
have suggested that the intracellular environment is a barrier against successful 
chemotherapy. However, the phagocytic potential of the macro-phage as well 
as the confinned lysosomal nature of the parasitophorous vacuole offer intriguing 
[)ossibilities for specifically targeting dmgs against parasite. Thus, by 
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encapsulating dmgs in liposomes (New e( al, 1978; Alving & Steck, 1979) or 
niosomes (Hunter ct al, 1988), which are preferentially phagocytosed by the 
macrophages of the spleen and liver, chemotherapy against VL has been 
markedly improved by delivering large quantities of the dmgs directly to the 
parasitophorous vacuole. 
Not only do amastigotes reside within phagolysosomes but they themselves 
contain many lysosomes which display high activity of a variety of enzymes, parti-
cularly proteinases (Coombs, 1988). Thus, the lysomotropic drugs would not only 
accumulate in the parasitophorous vacuole, but also in the parasite lysosomal 
compartments (Rabinovitch, 1989). It has been shown that the lysomotropic amino 
acid esters, viz. the L-aminoacid methyl ester of leucine concentrate in parasite 
lysosomes, where they are hydrolysed to fonn the permeable amino acids which 
accumulate to cause osmotic disruption and parasite lysis. Unfortunately these 
ammo acid esters are also toxic to mammalian cells and hence can not be used 
therapeutically unless their selectivity for parasites could be increased (Coombs, 
1988). To improve chemotherapy, dmgs could be attached to substances for which 
macrophages have high affinity receptors (Hart and Lawrence, 1988; 
Mukhopadhyaye/o/.. 1989). 
An alternative approach to chemotherapy would be to enhance chemically 
the macrophage microbicidal activity of the host. Several chemotherapeutic 
agents, particularly electron carriers which induce the release of toxic free 
radicals like superoxides and singlet oxygen, have been shown to be highly 
effective in killing parasites in vitro e.g. chlorpromazine (Pearson ct al., 1984). 
However, these dmgs are poorly effective in vivo and are often toxic. A more 
acceptable approach to increase macrophage microbicidal activity might be the 
use of immunological modulators in conjunction with chemotherapeutic agents. 
1.9.2 Antileishmanial Compounds 
Following is a brief account of different series of compounds which have 
been tested for their antileishmanial activity in experimental animals as well as 
human host. 
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i.9.2.1. The antimonials 
Organic pentavalent antimonials forni the standard first line treatment for 
kala-azar (VL) for over 40 years. These are available in the forni of sodium 
stibogluconate (SSG; Pentostam, Wellcome Foundation, U.K.; containing 100 mg, 
Sb/ml), and meglumine antimoniate solution (Glucantime, Rhone Poulenc, France, 
containing 85 mg Sb/ml). Pentavalent antimonials were first used in 1920s, and 
SSG first became available in 1945 (Berman, 1988). The mechanism of action 
of pentavalent antimonials is not totally clear, but inhibition of amastigote bio-
energetics appears to be one factor. Antimony is efficient in inhibiting parasite 
glycolytic and fatty acid oxidation activity. This leads to decreased reducing 
equivalents for antioxidant defence and decreased energy for metabolism. Although 
the manufacturers recommend different dosage regimens, phannacokinetic data 
suggest the dosages to be based on equivalent amounts of antimony (Chulay at 
al., 1988). Frequent adverse reactions include sterile abcesses, venous thrombosis, 
cardiotoxicity, nephrotoxicity, hepatotoxicity, myalgias, gastrointestinal distur-
bances, arthralgias and headache. Occasionally, immediate hypersensitive reac-
tions, fever, palpitations, weakness, dizziness, insomnia and nervousness occur. 
Monitoring of therapy should include ECG's, and hepatic and renal function tests. 
Parasitological cure should be confimied by biopsy or splenic aspiration (McGreev>' 
&Marsden, 1986). 
Recently, increasing resistance to pentavalent antimony (Sb') has been 
reported in many countries (Grogl e( al., 1989, 1992). The WHO guidelines (WHO, 
1990) reflect the increasing unresponsiveness to Sb", and 20 mg Sb'/kg/day for > 
20 days is recommended. In India, primary Sb^ resistance occurs in about 10% of 
cases and a regimen of 20 mg Sb^/kg/day for >40days has been recommended 
(Thakur et al., 1993). Zijlstra et a/.. (1991) showed that Sbv at a dose of 10 mg/kg 
every 12 h for 15day was better than 20 mg/kg/day for 30day. Chulay et al., (1983) 
and Gachhi et al., (1992a) showed that 10 mg Sb^/kg every 8 h for 10 days was 
also more effective than 20 mg/kg/day for 30 days. 
1.9.2.2 The aromatic diamidines 
Aromatic diamidines first gained attention in 1930s for their treatment 
against protozoal diseases (Kopac, 1945; Elson, 1945; Sands et al., 1985; 
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Vonderfecht e/fl/., 1988; Jones et al., 1990). The antimalarial activity of aromatic 
diamidines and di-imidazolines has been established (Bell et a/., 1990). 
Pentamidine is effective for kala-azar in over 90% of cases (Thakur e/a/., 
1993), but has been abandoned as first line therapy as it is probably more toxic 
than pentavalent antimonials. In India, treatment with pentamidine 4 mg/kg on 
alternate days for 6 to 8 doses gave 98% salvage' cures in antimony resistant kala-
azar patients (.Flia, 1983). 
Several toxic effects of pentamidine are hypotension, sterile abcesses, 
hypoglycaemia, nephrotoxicity, ECG changes and sudden deatli. Encapsulation of 
pentamidine within human red cell ghosts (Berman e/a/.. 1986) and liposomes (Pal 
el al., 1995) improved the efficacy and reduced the toxicity. 
The other aromatic diamidines which were also tried in experimental 
chemotherapy are HOE668 (Reather et al., 1978), diamidines from furans, pyrrole, 
thiophene oxazole and thiadiazole (Das et al., 1977a, 1977b), diamidines and 
their cyclic congeners (Dann el al., 1970; Das el al.. 1977a), ai^ yl amidines 
(Chauhan et al., 1993), 4,4-diamidino-diazoamino-benzene diminazene (Berenil) 
and methylglyoxal bis(guanyl-hydrazone) (Mukhopadhyay & Madhubala, 1995). 
1.9.2.3 Oxygen heterocyclics 
Amphotericin B is an effective drug both for CL (Bjorvatn & Neva, 1979) 
and MCL (Marsden et al., 1985). Excellent response has been observed in cases 
resistant to the antimonials and diamidines and also in the cases involving 
nasopharyngeal regions. It is also found to be active against the cases of 
antimony and diamidine resistant kala-azar (Thakur et al., 1993). It is a polyene 
antibiotic. In hamsters and monkeys infected with L donovani, amphotericin B 
was up to 400 times as potent as SSG (Berman et al., 1992). Its usefiilness is 
limited by adverse reactions including anaphylaxis, thrombocytopenia, flushing, 
generalized pain, convulsions, chills, fever, phlebitis, anaemia, anorexia, decreased 
renal tubular and glomerular fimctions and hypokalemia (Bryceson, 1987). 
Thakur et al (1991) found it more effective and less toxic than pentamidine. 
Ampho tericin B binds to sterols in the plasma membrane, fonning pores and 
disturbs the permeability of membrane through which the ions leak. It binds 
preferentially to 24 substituted sterols such as ergosterol, which is the major cell 
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membrane sterol of Lcishmania and of fungi, but not of mammalian cell membranes 
(Bennan e/al., 1992). It binds to a lesser extent to cholesterol in membranes in 
humans, which is responsible for its toxicity. 
The other oxygen heterocyclics tested for antileishmanial activity include 
nystatin, a fungicidal antibiotic (Ghosh & Chatterjee, 1962). Fungizone, fiimagillin 
and xerosin (Cappucino & Stauber, 1959), rifampicin, an antitubular antibiotic 
(Selim & Kandil, 1972; Iskander, 1978; Evan-Paz et al., 1982; Bernian & Lee, 
1986;El-On ct a/., 1986) and 2-substituted 5-nitrofurans (Restrepo & Velaquez, 
1973; Croft e/a/.. 1985; Guerra er a/., 1981; Costa era/.. 1985). 
1.9.2.4 Sterol biosynthesis inhibitors 
The existence of biochemical pathways unique to the parasite make good 
therapeutic target by selective inhibition of such pathways. One special feature of 
Lcishmania is the sterol biosynthetic pathway, by way of production of 24a-
alkyl sterols such as ergosterol (Goad et al.. 1985). These sterols are the target 
of amphotericin action. Some intennediate steps in sterol biosynthesis of 
Lcishmania are also sensitive to antiftmgal agents and the leishmanicidal activity 
may arise fiom either the accumulation of toxic intermediates or from the 
blocking of the production of essential end products. One such example is 
treatment with ketoconazole, which leads to accumulation of toxic 14a-methyl 
sterols (Goad el ai, 1985; Albanese et aL, 1989; Navin et aL, 1992; Rashid et al, 
1994). Haughan et aL, (1995) have however, reported that inhibition of 
endogenous sterol bio-synthesis may be compensated for to a certian extent by 
the uptake of host cholesterol. Clotrimazole has been found effective against CL 
(Larbie/cr/.. 1995). 
1.9.2.5 Purine analogues 
i) AUopurinol and related compounds: As mentioned above Lcishmania 
parasites appear to be incapable of synthesizing purines t/e «r;vr;. Hypoxanthine 
is considered to be the main source of purine to these organisms (Mar et aL, 1978; 
LaFon et aL, 1982; Marr & Berens, 1986). Allopurinol, a hypoxanthine oxidase 
inhibitor, used as an uricosuric dmg, has been reported to inhibit growth of 
/x7.v/7/7?o/7/a (Marr er a/.. 1978) and has been used in the treatment ofkala-azar. 
Berens et al (1980), Kager et o/ (1981), Jha (1983), Neal ct al (1985) and Neal 
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(1987) have reported the activity of some purine analogues against L. tropica and 
L. donovani. AUopurinol ribonucleosides were found to be potent anti leishmanial 
agents (Nelson et ai, 1980). Inosine analogues of carbocyclic inosine (C-Ino), 3'-
deoxyinosine (3'-dI), and 3'-deoxy-3'-fluorosine (3'-FI) have also been found 
effective against the promastigotes of L c/o/?ova/7/ and L Iropica CWatya et ai, 
1990). 
ii) Formycin B: Oral efficacy and toxicity of formycin B in the infected 
hamsters was reported by Berman et ai, (1987) and against mice by Neal et ai, 
(1985) and Rojas & Avila (1987). In 1981, Carson & Chang studied the 
phosphorylation and antileishmanial activity of formycin B in hamsters. 
1.9.2.6 8-Aminoquinolines 
The 8-aminoquinolines are known to show marked antileishnia nial activity 
in experimental studies and a series of them have been shown to possess superior 
antileishmanial activity than the antimonials and aromatic diamidines (Johnson 
& Werbel, 1983; Berman & Lee, 1986; White et ai, 1989; Idowu et ai, 1995) e.g. 
WR 6026 is several hundred times more active than Sb^  in experimental VL 
(Neal, 1987) and has recently completed a second-phase clinical trial. Only 50% 
patients were cured after 4 weeks of treatment but there appears to be scope for 
increased dose levels (Chance, 1995). 
1.9.2.7 Aminosidine (paromomycin) 
Aminosidine is an aminoglycoside antibiotic with powerfiil anti-
leishmanial activity in vitro and in animal models (Neal, 1987). It also acts 
synergistically with Sb^ in vitro (McCoy & Neal, 1989). However, ototoxicity 
and nephrotoxicity may occur and may call for maintenance of aminosidine 
levels vis-a-vis renal functions. Studies in Kenya, India and the U.K. have shown 
that it is a safe and effective 'first line' alternative to Sb^ for the treatment of 
newly diagnosed and unresponsive VL (Olliaro & Bryceson, 1993). For VL cases it 
must be administered systemically while for CL its topical use has been 
recommended (El-On et ai, 1992, Neal et ai, 1994, Bryceson et ai, 1994; Krause 
&Kroeger, 1994). 
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i.9.2.8 Combination therapy 
Altliough tliere are few biochemical clues for the rational basis of 
choosing drug combinations, several studies have attempted to show the usefiilness 
of combinations in clinical trials. The necessity of long treatments of VL cases in 
hidia, Kenya and Southern Sudan resulted in a trial of aminosidine plus SSG in 
order to establish the possibility of a shorter regimen (Thakur cl al., 1995). A 
combination of 12 mg/kg/day aminosidine and 20 mg/kg/day SSG for 20 days 
appeared to be an effective and safe replacement of SSG for 40 days. Several 
other combinations ofdnigs tried include transacotinic acid along with 
stibanate/pentamidine/allopurinol (Kar et a/.,1993); adenosine analogue For-mycin 
A, in combination with inhibitor of nucleoside transport, nitrobenzyl thio-inosinate 
(Ogbunude & Al-Jaser, 1992) and chlorpromazine with N-meglu-mine 
antimonate (Rubinstein ct al., 1986). A combination of hematoporphyrin and 
menadione has been found to cause destmction of the parasite without affecting the 
host macrophage (Kusia e( al., 1988). Mode of action of this combination has been 
discussed with reference to the production of superoxide and H2O2 originating from 
redox cycling of menadione. It has been suggested that the generated H2O2 
decomposes to give more reactive hydroxyl radical The combination therapy has 
an added advantage in that it is comparatively economical. 
1.9.2.9 Miscellaneous compounds 
In v/vo effect of eflomithine (DFMO) and some related compounds on L 
infantum (Gradoni et cr/..1989), Acivicin, a highly active potential chemotherapeutic 
agent against VL, which irreversibly inactivates both in vitro and in vivo carbamyl 
phosphate synthetase II (Mukherjee et al., 1990), several novel lipopeptides 
(Zehra et al., 1995), 9-anilino-acridines (Mauel et al., 1993), and some antioxidants 
(Mukliopadhyay & Madhubala, 1994) against L. donovani have been established. 
The antitumor dnig methotrexate has been shown to have profound antileishma-
nial effects (Scott et al., 1987, Mukhopadhayay et al., 1989; Chakraborty et al., 
1990) probably by checking the turnover of DNA in multiplying amastigotes as 
compared to non multiplying host macrophages. Anticancer drug Doxorubicin 
which is an anthracycline antibiotic, has been tested in vitro and in vivo for activity 
against L donovani (Sett et al., 1992). 5-Substituted benzyl-2,4-diaminopyrimidines 
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are potent antileishmanial agents (Sirawarapom e( al., 1988) which selectively 
inhibit parasite dihydrofolate reductase. However, Trimethoprim, Pyrimethamine 
and Cycloguanil are less active against Leishmania promastigotes (Mukherjee et al., 
1990). The activity of Sineftingin is many times higher than that of Meglumine 
antimoniate. It inhibits protein methylases, DNA polymerase and pyrophosphatase. 
Bacharach at al., (1980) have reported that the antileishmanial activity of Sinefiingin 
is due to the inhibition of transmethylation or inhibition of polyamine biosynthesis or 
both (Nolan, 1989). 
1.9.2.10 Drug delivery systems 
One of the most exciting developments in the chemotherapy of 
leishmaniasis has been the use of dmg-delivery systems. Three groups indepen-
dently reported that liposomal encapsulation of Sb" increased the dmg efficacy in 
rodent models of VL by 300-700 fold (Black et al., 1977; Alving e/a/.. 1978; New 
ci al., 1978).This was due to targeting and subsequent retention of Sb^ in the 
infected cell. The commercial production of liposomal Sb\ however, was aban-
doned due to its toxicity in monkeys. Many other dmgs and drug carriers have 
since been studied in experimental VL (Croft et al., 1989). Of these, only 
liposomal amphotericin B in different lipid complexes was found to be more 
potent and less toxic than free dmg (Berman et al., 1992; Croft el al., 1991; 
Hashim et al., 1995). Two lipid amphotericin B fomiulations developed for ftmgal 
infections, AmBisome and amphocil have been used in animal and human VL 
(Croft etal., 1991; Berman, etal., 1992; Dietze et al., 1992). Based on the pre-
liminary results of trials with AmBisome in Europe, Davidson and Croft (1993) 
suggested that short courses and low doses may reliably cure immunocompetent 
VL patients, whereas patients co-infected with HIV may require maintenance 
therapy (Thakur et al., 1994; Rosenthal et al., 1995; Gangneux et al., 1996/ Medda 
el al. (1993) have shown that the sugar coated liposomes in dmg delivery are 
more potent as compared to nornial liposomes. Mannose coated liposomal 
hamycin in treatment of experimental leishmaniasis in hamsters was found to elicit 
enhanced microbicidal acitivity and reduced toxcity. Recently five non-ionic 
surfactants were screened for their ability to produce vesicles for the delivery of 
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sodium stibogluconate and their antileishmanial activity has been evaluated. 
(WiUiamse/a/., 1995). 
1.9.3 Immunotherapy 
Various immunopotentiators, including Bacillus Calmette-Guerm (BCG) 
(Fortiere/a/., 1987), killed promastigotes (Mayrink e/a/., 1992), BCG plus killed 
promastigotes (Blackwell et al, 1994), levamisole (Rifaat et ai, 1989), cyclosporin 
A (Bogdan at ai, 1989), Cryptosporidium parvum (Hill, 1987) and glucan (Cook 
(it ai, 1980) have been used to modify the course of Leishmania infections 
largely through their ability to activate macrophages non-specifically. However, 
most of them have been excluded from human usage due to potential undesirable 
side effects and also due to the fact that they may not always produce the desired 
therapeutic effect: BCG, for example, has been reported as exacerbating L. 
mexicana lesion growth in laboratory mice (Grimaldi et ai. 1980). However, the 
current availability of recombinant cytokines has provided a new generation of 
tools with which we can influence the immune response against Leishmania in a 
more controlled and effective fashion. Conse-quently, there are many recent 
reports of workers trying to manipulate the growth of Leishmania by local or 
systemic injection of these substances (Carter er a/.. 1989; Murray, 1990; Neva, 
1990, Murray et a/., I995a,b; Sundar & Murray, 1995; Nabors & Farell, 1995). 
Results using cytokines have been variable and at times contradictory. In 
part, this may reflect the species of parasites used, the genetic background of the 
host, the route and dosage of cytokine administration and the state of disease 
progression atthetimeoftreatment.lt would be expected that cytokines which 
are known to promote macrophage leishmanicidal activity, such as GM-CSF 
(Weiser et ai. 1987; Ho et ai. 1990) and TNF-a (Liew et ai. 1990 a,b) would be 
protective in vivo, while those generally associated with inhibiting microbicidal 
activity such as lL-3 (Liew era/., 1989) would exacerbate disease. T-cell-cytokine 
macrophage interplay is complex and awaits the detailed study, but the prospects 
for future cytokine immunotherapy in leishmaniasis remain exciting. 
1.9.4 Combined Chemotherapy and Immunotherapy 
The success of any chemotherapeutic regimen is often dependent on the 
potential or latent immimological response of the patient. It is generally accepted 
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that successflil chemotherapy of leishmaniasis in humans results in the 
veneration of antigen specific T-cells and delayed hypersensitivity. However, with 
patients havmg a defective immune response (e.g. AIDS patients), chemotherapy 
is invariably ineffective (Rizzi et al., 1988). This close association between 
chemo-therapy and cell mediated immunity calls for a dual approach to therapy 
(Berger & Fairlamb, 1992). Several workers have examined the ability of a variety 
of immunomodulators and adjuvants to enhance the effects of standard antileish-
inanial drugs and have achieved notable success. Thus, synergistic activity between 
muramyl dipeptide encapsulated in liposomes (Adinolfi el al.. 1985) or in 
('orynehacicrium parvum (Haidaris & Bonventure, 1983) along with pentavalent 
antimonials has been demonstrated in experi-mental VL. The immunopotentiator is 
presumed to fimction by non-specifically activating macrophages. A combined 
regimen of immunostimulation with CP-46, 665-1 (synthetic lipoidal amine) and an 
antimonial dnig is more effective in treatment of L cionovani infection both in 
vHro and in vivo than either treatment alone (Adinolfi and Bonventure, 1985). 
More recent experimental as well as clinical studies have successfully used recom-
binant IFN-y as the macrophage activating agent in this dual therapy approach to 
treatment (Murray et al., 1989, 1991; Badaro et al., 1990; Kurkcuoglu & 
Tandogdu, 1990, Squires et at., 1993; Sundar et al., 1994). 
1.9.5 Plants Extracts 
More than 20 plant species from as many taxonomic families have been 
shown to contain compounds with significant activity against various species of 
Lcishmania. The active constituents of some of the plants have been isolated and 
their activity confirmed by in vivo studies and clinical evaluation. In some cases, 
only in vitro activity of extracts has been reported, and studies on the isolation of 
the compounds responsible for the biological activity and confinnatory in vivo 
evaluation are under way. The activity of the antileishmanial plant extracts has been 
attributed to compounds belonging to diverse chemical groups. Among the most 
promising chemotypes are the benzylisoquinolines, the P-carboline alkaloids, the 
iridoid and steroidal glycosides and the quinones. Therefore, modem therapy 
derived from medicinal herbs promises a practical approach to the development of 
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effective, readily available and less costly dmgs needed in Lcishmania endemic 
countries (Kaur e( al.,. 1991; Iwu e( al.,. 1994; Sauvain ct al.,. 1996). 
1.10 HEPATOPROTECTIVE AND ANTILEISHMANIAL ACTIVITIES 
OF PICRORHIZA KURROA 
During the last ten years, Central Drug Research Institute, has carried out 
considerable experimental work on the development of Picroliv (standardised 
iridoid glycoside fraction isolated from roots and rhizomes of Picrorhiza 
kiirrod) as a hepatoprotective agent. The biological activity of Picroliv has been 
established in a variety of animal and cell culture models. The evaluation of 
hepatoprotective activity in experimental animals in terms of biochemical changes 
has been related to liver ftinctions. 
The major ftmctions of liver are (Lehninger, 1984): 
Synthesis and storage of glycogen 
Metabolism of lipids, cholesterol and bile acids. 
Synthesis of plasma proteins and other proteins 
4. Metabolism of heme and formation of bile pigments. 
5. Detoxification of drugs and xenobiotics 
Phagocytosis by liver kupffer cells. 
Picrorhiza kurroa under the name of Kutki (Hindi) forms an ingredient of 
many Indian herbal preparations and is commonly used as a remedy for treatment 
of liver disorders in Northern India in Traditional System of Medicine (Handa ei 
ai, 1986). 
Ansari et al (1988) reported that the alcoholic extract of root and rhizomes 
of P. kurroa exhibited profound hepatoprotective activity in rats toxicated with 
carbontetrachloride or galactosamine and mastomys infected with Plasmodium 
herghei. The active principle was identified as Kutkin and the Kutkin-free fractions 
of the extract were devoid of any hepatoprotective activity. 
Based on these investigations, standardised iridoid glycoside fraction from 
roots and rhizomes of Picrorhiza kurroa was prepared and tenned as PICROLIV. 
On the basis of HPLC and TLC, Picroliv contained about 60% of Picroside I and. 
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Kutkoside in the ratio of 1:1.5, along with 40% of minor constituents (Fig. ). Aswal 
CI al., hidian patent NO. 450/DEL/89, dated 25/05/89; US Patent No. 5.145,955 
dated 8/9/92 and European patent Application No. 92304538.9 
The hepatoprotective activity of Picroliv has been reported against several 
experimental hepatotoxic models like carbontetrachloride (Dwivedi et al., 1990), 
lanthanum chloride (Dwivedi et al., 1991a), paracetamol (Dwivedi e( al.,, 1991c) 
and Plasmodium berghei infection (Chander et al., 1990). Lipid peroxidation was 
implicated to be the major mechanism of liver injury. In all these cases and Picroliv 
provided significant protection by reducing the level of lipid peroxides. It also 
restored the activity of the enzyme superoxide dismutase, decreased after 
carbontetrachloride and during P. berghei infection. The levels of DNA, RNA and 
proteins in liver altered by hepatotoxicants such as thioacetamide (Dwivedi et al., 
199Id), monocrotaline (Dwivedi et al., 1991b), aflatoxin Bi (Dwivedi et al., 1993), 
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Amanita phalloid (Dvvivedi ct ai, 1992a) and galactosaniine (Dwivedi et ai, 
1992b) were very effectively restored by Picroliv. Toxicant induced changes in liver 
lipids, phospholipids, cholesterol as well as activities of various enzymes related to 
subcellular organelles of hepatocytes were also significantly reversed by Picroliv. 
Further, Picroliv, Picroside I and Kutkoside were shown In vitro to be potential 
scavangers of oxygen free radicals (Chander et ai, 1992). 
Liver protective activity of Picroliv has been reported against paracetamol 
and thioacetamide induced decrease in oxygen uptake, viability and activity of 
gkitamate oxaloacetate transminase (GOT), gkitamate pyruvate transminase (GPT) 
and alkaline phosphatase in isolated hepatocytes {ex-vivo) of rats (Visen et ai, 
1991a, 1991b). 
Picroliv showed significant immunoprophylactic activity in golden hamsters, 
when challenged with L donovani promastigotes. It caused decrease in parasite 
burden in all the three major sites of infection viz. spleen, bone marrow and liver. 
The protection provided by Picroliv was atleast of the same order as that provided 
by muramyl di peptide, a well-known immunomodulator (Puri et ai, 1992). This 
observation assumes added importance in view of the fact that leislimaniasis is 
accompanied by suppression of the immune response and complete eradication of 
the disease is not possible by specific chemotherapy alone. Moreover, the present 
dmgs against Leishmania are toxic. In view of this ftirther investigations will 
desirable to find out whether Picroliv can be used for the complete eradication of the 
parasite from Leishmania patients, as an adjunct to chemotherapy, and in 
potentiating the efficacy of antileishmanial dnigs. 
Picroliv has been found to be safe in acute and subacute toxicity studies in 
two species of experimental animals and has no mutagenic and teratogenic activity. 
Permission was obtained from the Drug Controller of India to conduct phase I 
clinical trials in human volunteers wherein it was found to be safe and non-toxic. 
Currently the phase II efficacy trials are in progress. 
Mode of Action of Picroliv 
The mechanism of hepatoprotective action of Picroliv appears to be based 
upon the (I) disposal of free radicals generated during hepatotoxicity (Dwivedi et 
ai, 1990, 1991a, 1991c; Chander et ai, 1990, 1992). (ii) increased turnover of 
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biopolymers such as DNA, RNA and protein in liver as well as stabilisation of the 
damaged intracellular membranes and mebranous organelles of hepatocytes. In 
addition it interferes in a hitherto or known manner in reversing the toxicant-induced 
changes in hepatotoxic models which are based on inhibition of protein biosynthesis 
(Dwivediero/.. 1991b, 1991d, 1992a, 1992b, 1993a, 1993b). 
1.11 CHEMICAL & BIOCHEMICAL CHANGES IN PROTOZOAL 
INFECTIONS 
The infection of a normal host by parasites leads to a number of 
biochemical changes apart, fi'om biological deformities. The liver which is the 
key organ of metabolism and excretion is adversely affected during such 
infections. In normal conditions human liver is not susceptible to infections 
because of the resistance oifered by parenchymal cells and the phagocytic activity 
of kupffer cells, however, during the later stages of infection different degree of 
changes are noticed in liver in terms of biochemical markers. 
l .n . l Liver Function Tests 
The following tests known as liver function test are routinely carried out in 
serum to determine the status of liver in human beings. 
1. Serum Glutamic oxaloacetic transaminase (aspartate amino trans ferase, 
SCOT) 
It is a mitochondrial enzyme distributed in various tissues but with maximum 
concentration in liver. Whenover there is tissue damage, the SGOT level in 
senim increases due to its release from the damaged cells. 
2. Serum Glutamic pyruvic transaminase (Alanine aminotransferase, 
SGPT) 
This enzyme is present in cytosol with maximum concentration in liver. 
Although the absolute amount of this enzyme in liver is less than that of 
glutamic oxaloacetic transaminase, a greater proportion of it is present in 
liver as compared to heart and skeletal muscles. Increase in its senim level 
is therefore, more specific for liver damage. 
5?. 
y Alkaline phosphatase (Orthophosphoric monoester phospho-hydrolase, 
ALP) 
Alkaline phosphatase, a microsomal enzyme is ubiquitous in distribution, the 
largest amount being in the liver. The enzyme is tightly bound to lipid 
membranes, particularly those in the canalicular area. Any disorder 
interfering with bile flow increases the synthesis of this enzyme. The level 
of alkaline phosphatase rises considerably in cholestasis and to a lesser extent 
in hepatocyte damage. 
4. Bilirubin 
Bilinibin, the end product of heme is excreted in bile. In hepatocyte lesions 
and in obstructive jaundice, excretion of bilirubin in bile is hampered and 
hence, its level in blood increases. A rise in the level of senim bilinibin, is 
thus indicative of jaundice or liver damage due to some toxins. 
5. y-Glutamyl transpeptidase |(Y-glutamyl)-peptide: aminoacid y-glutamyl 
transferase) 
It is a very sensitive enzyme related to liver diseases. This enzyme occurs 
partly bound to cell structure and partly in soluble fonn. The latter form is 
present in serum. The activity of this enzyme increases in liver diseases 
and extremely high values are indicative of cholestasis. It is also a marker 
enzyme of hepatobiliary disease. 
1.11.2 Malarial Infection 
Malarial infection is caused by protozoan Plasmodium which has a 
complex life cycle involving a vertebrate host and a female mosquito. The degree 
of liver damage varies considerably and is dependent to some extent on the 
species of parasite involved and the severity of the infection. Signs of liver 
damage such as hepatomegaly and tenderness, sometimes associated with 
jaundice have been reported. 
Impairment of liver function in acute P. falciparum & P. vivax infections has 
been reported (Mishra et ai, 1992). After the availability of serum enzymes as 
marker of liver disease, Sadun et al, (1966) reported a significant increase in 
senmi levels of alanine amino transferase (SGPT) but not of aspartate 
aminotransferase (SGOT) with a marginal decrease of alkaline phosphatase (ALP) 
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in infected patients. Definite indications exist suggesting that human malaria affects 
the carbohydrate functions of the hver. Often there have been reports of a marked 
hypoglycemia in the host during the later stages of infection (Mercado 8c Von 
Brand, 1954; Chatterjee & Sengupta 1957). Liver glycogen has been observed to 
decrease progressively with increasing parasitemia (Saxena et ai, 1981). A 
progressive decrease in serum albumin and an increase in globulin (mostly y-
globulin) and a decline in liver proteins is usually encountered in parasitic 
infections (VonBrand, 1973). Formation of free radicals impairing oxidative stress 
on host tissues, due to plasmodial infections has also been reported (Srivastava et 
al., 1994). 
1.11.3 Trypanosoma! Infections 
Disturbances in the carbohydrate metabolism of the host have been reported 
in protozoal infestations like the abnormalities in blood sugar level where the 
pathogenic trypanosomes drain considerable amount of sugar from the blood 
stream resulting in exhaustion of the carbohydrate reserves of the host, leading to 
inhibition of glycogenesis and gluconeogenesis (Mercado & Von Brand, 1960; 
Marciaq & Seed, 1970). Increase in serum levels of transaminases especially 
glutamate pymvate trsmsaminase (Lippi & Sebastiani, 1958; Moon et al., 
1968) and succinate dehydrogenase (Corso & Frugoni, 1961a,b) has been 
reported during trypanosomal infection. 
I . l l . 4 Leishmanial Infection 
Visceral leishmaniasis induced by Leishmania donovani is essentially a 
disease of the reticuloendothelial system and viscera and involves periportal 
cellular infiltration and accumulation of parasites in macrophages (Sengupta et 
al., 1956; DaSilva & De Paola, 1961; Sen Gupta, 1983). 
Hepatosplenomegaly is the most important phenomenon usually occurring during 
L donovani infection. The histopathological changes in man during fatal infections 
of L donovani are characterized by macrophage infiltration in most of the host 
organs (Andrade & Andrade, 1966). Electron microscopy reveals that kupfifer cells 
bearing the parasite are generally hypertrophied. These infected kupffer cells 
have deformed mitochondria, disrupted endoplasmic reticulum and localized 
rupture of cell membrane. The hepatocytes in the vicinity of damaged kupfifer cells 
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also show degenerative changes within electron dense mitochondria (Tanikawa & 
Hqjiro. 1965; Miwa & Tanikawa, 1965). Shrott (1923) showed that L. 
donovani infects many species of experimental animals, some responding in a 
manner similar to that seen in a fatal human infection i.e. marked macrophage 
proliferation and granuloma formation in liver and spleen. 
Eversince the discovery of L donovani in the human viscera, extensive 
research on various aspects of the parasite including metabolic processes, 
membrane structure and functions and enzymic machinery on the one hand and on 
chemotherapy and immune system of host on the other, have been carried out. 
Comparatively little, however, is known about the sequential changes that 
occur in various biochemical markers viz. macromolecules and enzymes of the 
host during the course of L. donovani infection. 
1.11.5 Reactive Oxygen Species and Antioxidant System 
A balance between the pro-oxidant and antioxidant systems is essential for 
the better survival of an organism. As a consequence of environmental, 
physiological, toxicological or pathological disturbances, life may be endangered by 
the over production of reactive oxygen species (ROS). Wlien ROS are generated in 
vivo, many antioxidants come into play. Their relative importance depends upon 
which ROS is generated, how, where, and what target of damage is measured. 
Targets, damaged by ROS includes: protein, DNA and many other small molecules 
(Halliwell, 1995). ROS and their scavengers have been shown to play an important 
role in the establishment of parasite infections. Several enzymes have evolved 
whose primary fiinctions appear to decrease the amount of potential oxidants in the 
body and, therefore, to serve a protective function with respect to biological 
oxidants. 
Superoxide dismutase: This enzyme, discovered by McCord and Fridovich (Mino, 
1992) catalyzes the dismutation of super oxide (O2') to hydrogen peroxide: 
201+2Fr > O2 + H2O2 
Catalase: One of the products of the action of SOD is H2O2. This molecule can be 
detoxified by catalase, which catalyzes the following reaction: 
2H2O2 > 2H2O + O2 
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In the absence of these enzymes, and in the presence of transition metals such 
as iron or copper, the following reaction occurs which generates the extremely 
reactive hydroxy 1 radical OH. 
O2 + Fe'^ > 02"^  + Fe^ ^ 
H2O2 + Fe^ ^ > OH* + 0H '+ Fe'^ 
Glutathione peroxidase : It is a remarkable enzyme in that it contains a covalently 
bound selenium (Se) atom in the form of selenocysteine. The selenium is essential 
for the enzyme's activity. It fiinctions in removing toxic peroxides that form in the 
course of growth and metabolism under aerobic conditions: 
2GSH + R-O-O-H > GSSG + H2O + R-OH 
Glutathione reductase: Under physiological conditions glutathione reductase (GR) 
rapidly reduces any oxidized glutathione (GSSG) to the reduced, thiol form (GSH), 
so that more than 98% of intracellular glutathione is GSH. The rest is present within 
the cell as the oxidized, disulfide form (GSSG), as mixed disulfides (mainly GSS-
protein) and as thioethers. 
Glutathione and its anti-oxidant function 
Glutathione, a tripeptide thiol found in virtually all cells, functions in 
metabolism, transport, and cellular protection. It participates in the reduction of 
disulfides and other molecules, and conjugates with compounds of exogenous and 
endogenous origin. It protects cells against the destnictive effects of reactive oxygen 
intermediates and free radicals. 
Two aspects of the structure of glutathione directly determine the enzymatic 
pathways capable of metabolizing it. In glutathione the N-tenuinal glutamate and 
cysteine are linked by the y-carboxyl group of glutamate, which is cleaved by y-
glutamyl transpeptidase, that occurs on the external surface of certain cell 
membranes. Glutathione therefore resistant to intracellular degradation and can only 
be cleaved by cell types that have y-GT on the cell membrane. 
Glutathione plays a major role in detoxifying many reactive metabolites by 
either spontaneous conjugation or reactions mediated by GSH-S-transferase (GST). 
GST catalyzes the conjugation of the SH groups of GSH with the highly reactive 
electrophillic molecules which tend to become water soluble and are thus easily 
excreted out from the body. 
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The ROS lead to the llirther production of toxic oxygen metabohtes that 
cause hpid peroxidation and hence disnipt metabohc processes. Glutathione is the 
predominant defense against these toxic products of oxygen metabolism. 
Glutathione sequestered within the mitochondria is particularly important in the 
defense against both physiologically and pathologically generated oxidant stress. 
Endogenously produced H2O2 is reduced by GSH in the presence of selenium 
dependent GSH peroxidase. As a consequence GSH is oxidized to GSSG, which in 
turn is rapidly reduced back to GSH by glutathione reductase at the expense of 
NADPH, thereby forming a closed system. The reduction of organic hydroperoxides 
by GSH may be catalyzed by either selenium dependent GPx or by selenium-
independent peroxidase activity which is provided by GST (DeLeve & Kaplowitz, 
1991). 
PEROXISOME 
H2O2 ^Q^Q'QSQ > H2O + O2 
ROOM 
.NADP 
NADPH 
2GSH^ 
GSHS-
transferase y 
ROH + H2O 
GSSG 
Figure : Anti-oxidant pathways. Hydrogen peroxide is metabolised by 
Glutathione peroxidase in the cytosol and by catalase in peroxisome. Organic 
peroxide can be reduced by either Glutathione peroxidase or Glutathione-S-
transferase (DeLeve and Kaplowitz, 1990). 
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SECTION 2.0 
MATERIALS AND METHODS 
2.1 PARASITE 
Leishmania donovani strain UR6 (MHOM/IN/78/UR6) was originally 
isolated from the bone marrow of a patient admitted in the Calcutta School of 
Tropical Medicine. Since then, promastigotes of this strain have been maintained 
in Ray's modified medium (1932) with subculture at 72 hr intervals. Strain UR6 is 
said to have loss of virulence as a result of passaging of the promastigotes in vitro 
for long periods of time. 
The virulent strains of L. donovani isolated from confirmed kala-azar 
patients in Bihar and routinely maintained in our laboratory in different monophasic 
and biphasic media were: Dd8 (MHOM/IN/80/Dd8), obtained from WHO 
Collaborating Cenfre, U.K.; AG83 (MHOM/IN/83/AG83) obtained from Dr. R. 
Madhubala, Jawaharlal Nehru University, New Delhi; RMRI 
(MHOM/rN/90/RMRI 68), obtained from Prof N.K. Ganguly, PGI, Chandigarh. 
Subcultures of all tliese strains were made on fourth day. 
2.2 HOST 
Syrian golden hamsters (Mesocricetus auratus) were originally obtained 
from Hindustan Antibiotics Ltd., Pune, in 1964 and since then are being main-
tained at the C.D.R.I, animal house. 
2.3 ANIMALS 
3-4 months oldhealthy rabbits (CD.R.I. strain) weighing around 2.5-3.0 kg 
were used for blood to be used in cultures. 
2 4 CHEMICALS 
Agarose, Bromophenol blue, Pronase, RNase, Ethidium bromide, PEG 
8000, Y -Glutamyl-p-nifroanilide HCl, Glycyl glycine, para Nitroaniline, para 
Nitrophenol, Nitro blue tetrazolium, Phenazine methosulphate. Reduced glutathione 
(GSH), Oxidised glutathione (GSSG), 0-phthaldehyde, Nicotin-amide adenine 
dinucleotide phosphate (reduced) Nicotinamide adenine dinucleotide (reduced). 
Glutathione reductase, Sodium azide, N-ethyl-maleimide, 1-chloro, 2,4-
dinitrobenzene. Bovine serum albumin (BSA) and Ethylene diamine tetra acetic 
acid (EDTA), were purchased from Sigma Chemical Company St. Louis, USA. 
Sodium acetate. Potassium ferricy-anide. Sodium succinate. Citric acid, 2,4-
dinitrophenyl hydrazine (DNPH), 2-thiobarbituric acid (TBA), Aminonaphthol 
59 
sulphanillic acid (ANSA) and Uranyl acetate were procured from BDH, Poole, 
England, while Cystein HCl, a-ketoglutarate. Perchloric acid (PCA) and 
Trichloroacetic acid (TCA) were obtained from E. Merck, AG. Dermstadt, 
Germany. p-Nitrophenyl phosphate (PNPP), Adenosine-5-monophosphate (AMP), 
Ribonucleic acid (RNA), Glucose-6-phosphate (G-6-P04), DL-aspartate and 
DL-alanine were purchased from SISCO, Research Laboratory, Bombay 
(India). All other chemicals used were of analytical grade. 
2.4.1 Antibiotics 
Benzyl penicillin and streptomycin sulphate were purchased from Alembic 
Chemical Works Co. and Indian Dmgs and Pharmaceuticals Limited, India 
respectively. Gentamycin was purchased from Hi Media Laboratories Pvt. Ltd., 
Bombay, India. 
2.4.2 Media 
Dehydrated Brain Heart Infrision and Agar powder were purchased from 
Hi-Media, India. RPMI-1640, Leibovitz's L-15 and Medium 199 were purchased 
from GIBCO Limited Scotland, UK , Foetal Calf Serum was purchased from 
Sigma Chemical Co., U.S.A. 
2.5 MAINTENANCE OF CULTURE 
2.5.1 Maintenance of Promastigote Culture oi Leishmania donovani in vitro 
The promastigote form can be cultured in vitro in different biologic 
media (Evans, 1989). These promastigotes when injected in susceptible animals 
are engulfed by macrophages and transfonned into amastigote fonns causing 
leishmaniasis. Thus, it is apparent that for carrying out experimental research on 
leishmaniasis, the basic requirement is the easy availability of the target parasite 
in both fonns: the promastigotes in culture and the amastigotes in a susceptible 
small, handy laboratory animal. L. donovani Dd8, RMRl and AG83 are being 
maintained as a routine in vitro cultures in this laboratory, in N.N.N. (Novy, 
MacNeal and NicoUe) biphasic medium with RPMI-1640 as overlay and, L-15 and 
M-199 supplemented with 10% PCS (monophasic medium) After few subcultures, 
the sfrain is passaged through hamsters in vivo to retain its infectivity which is 
often diminished by continuous m vitro cultures (Sanyal, 1994). 
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2.5.1.1 Preparation of N.N.N, medium 
Ingredients of agar base: 
Bacto agar 15.50 gm 
Sodium chloride 6.60 gm 
Triple distilled water (TDW) 1 litre 
Bactoagar and sodium chloride were added in a flask and volume made upto 
1 litre with TDW. The contents were boiled and pH was adjusted to 7.2. It was 
then autoclaved at 15 lbs pressure for 30 mins. Antibiotic gentamycin was added to 
a concentration of 40 }ig/ml. Defibrinated rabbit blood (20%) was then added to the 
agar and medium stored at 4°C if needed. 
2.5.1.2 Collection of rabbit whole blood 
Rabbits were anaesthetized with the help of nembutal (25mg/kg), injected 
intraperitoneally. Required amount of blood was collected from the heart 
asceptically with the help of a sterilized syringe and needle by cardiac puncture. 
The blood was defibrinated in a screw capped flask containing several glass 
beads. One ml of this defibrinated blood was poured in a tube containing 2 ml 
thioglycollate medium and kept at 37°C for 24 hr for sterility testing. 
Cultures were maintained in screw capped round bottom test tubes and 
also in screw capped vials. One ml of defibrinated rabbit blood was added to 
5.0 ml of molten agar (50-56°C) which was mixed thoroughly by gently rolling 
the tubes or vials. The tubes were kept in a slanting position so as to produce a 
slant and the vials were kept as such. When the slant hardened, the tubes and vials 
were kept at 37°C for 24 hr to test sterility and were finally stored at 4"C. 
2.5.1.3 Preparation of the overlay RPMI-1640 
Powdered RPMI-1640 medium with glutamine but without bicarbonate was 
used. 10.4 gin of the powdered medium was supplemented with: 
HEPES (N-2 hydroxyethylpiperazine 
N'-2 ethane sulphonic acid) 5.94 gm 
NaHCO, 2.2 gm 
Glucose 2.00 gm 
Triple distilled water(TDW) 1 litre 
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The solution was stirred for an hour with the help of a magnetic stirrer, pH 
was adjusted to 7.2 and sterihzed by fihering tlirough a Sartorious millipore filter 
(0.22 |im porosity). Gentamycin was added at a concentration of 40 |ig/ml. After 
sterility testing in thioglycolate medium, the medium was finally stored at 4°C 
till needed. 
2.5.1.4 Preparation of L-15 medium 
Leibovitz's L-15 
HEPES buffer 
NaHCO? 
Glucose 
TDW 
powder 14.7 gm 
5.94 gm 
2.20 gm 
2.0 gm 
800 ml. 
The above ingredients were mixed, stirred and filtered. Tryptose phosphate 
broth (5.9 gms/100 ml) was autoclaved at 15 lbs for 20 min. The complete L-15 
medium contained 10% tryptose phosphate broth, 10% foetal calf serum and 40 
|.ig/ml of gentamycin. 
2.5.1.5 Preparation of Locke's solution 
NaCl 
KCl 
CaCl2.2H20 
KH2PO4 
Glucose 
Triple distilled water(TDW) 
8.0 gm 
200 mg 
200 mg 
300 mg 
1.25 gm 
1 litre 
The above ingredients were dissolved in TDW and pH of the solution was 
adjusted to 7.2. The medium was filtered through Sartorious membrane filter 
(porosity 0.2 |im). 40 |ig/ml of gentamycin was added to it and the medium was 
stored at 4°C after sterility test. 
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Leishmania donovani promastigotes strain UR6; a non-pathogenic strain 
was cultured in Brain Heart Infusion Agar supplemented with rabbit blood as 
semisolid and liquid media (Chakraborty, era/., 1988). 
2.5.1.6 Preparation of semisolid media 
The composition of semisolid medium was : 
A. Brain Heart Infusion Powder 24.0 gm 
Agar Powder 9.0 gm 
Triple distilled water 500.0 ml 
B. D-Glucose 10.8 gm 
Triple distilled water 100 ml 
The preparation of semi-solid media was done as follows: The Brain Heart 
Infusion and agar powder were dissolved into 500 ml. TDW and autoclaved at 10 
lbs pressure for 10 min. The medium was allowed to cool upto 50"C and the pH of 
the media was adjusted to 7.4-7.6 with O.IN NaOH. D-Glucose (10.8 gm) was 
dissolved in 100 ml TDW. The media and D-glucose solution were sterilized 
separately at 10 lbs pressure (121.6°C) for 30 minutes. 
5-6 ml fresh rabbit blood was added to the cooled D-glucose solution. To 
this were added 50 I.U./ml of benzyl penicillin (30,000 I.U.) and 50 f.ig/ml (30 mg) 
of streptomycin. The media was allowed to cool upto 50°C. The glucose solution 
was then added to the cooled media and mixed thoroughly. The mixture was then 
poured into sterilized culture tubes as well as petri dishes and was kept at room 
temperature for 2-3 days. These were stored at 4°C until used (Saha et al., 1986). 
To the culture tube containing approximately 5 ml of semisolid media 6-8 
colonies of promastigotes were inoculated while 10-16 colonies were inoculated on 
the petri dishes. These tubes and petri dishes were incubated at 26 + 1"C in a 
BOD incubator for 72 lir. The viability of the organisms was routitiely checked 
microscopically under X 400 magnification. 
To start the primary culture of promastigotes (pathogenic strain) in vitro a 
heavily infected animal was sacrificed and its spleen removed under asceptic 
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conditions. The spleen was then cut into small pieces which were dispersed into 
culture vials or tubes containing approximately 10-20 ml of RPMl-1640 medium. 
The primary cultures were kept at 26+rc, and examined every day. 
Approximately 5x10^ promastigotes were obtained from each culture in log phase 
which were added to fresh culture tubes. Any tube showing even the slight haziness 
indicated the contamination and was discarded immediately after autoclaving. The 
parasites multiplied by longitudinal binary fission producing a large number of 
flagellates which were subcultured weekly. 
2.5.2 In vitro (ex-vivo) Culture of Amastigotes 
Macrophages were isolated from the peritoneal fluid from BALB/c-mice in 
RPMI-1640 medium. These macrophages were cultured at 37"C + T'C in RPMl-
1640 supplemented with 20% foetal calf serum in Leighton tubes. The macrophage 
culture was inoculated with promastigotes, which converted into amastigotes inside 
the macrophages after 24 hr. In this way amastigote-macrophage culture was 
maintained. 
2.5.2.1 Isolation of macrophages 
Male BALB/c-mice weighing around 15-20 gm were injected with 2 ml of 
I % soluble starch intraperitoneally on day 0 and on day 2, mice were anaesthetized 
with ether and a slit was made in the abdomen to expose the peritoneal cavity. 8 ml 
of RPMI-1640 (without serum, with heparin) was injected through the slit in the 
peritoneal cavity and after gentle massage of viscera, medium was aspirated and 
pooled in centriftige tubes at 4°C. Aspirate was centriftiged at 500 rpm for 10 min. 
The sediment containing red blood cells was discarded and the supernatant was 
recentrifiiged at 3000 rpm for 20 min. The supernatant was discarded and the 
sediment was resuspended in known volume of RPMI-1640 with 10% foetal calf 
serum and number of macrophages was ascertained. Suspension was then so 
adjusted that 1 ml of medium contained 5 x 10^  macrophages. Suspension was 
transferred to Leighton tubes which contained a cover slip. Leighton tubes with 
macrophages were incubated at 37°C in an atmosphere of 5% CO2. 
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2.5.2.2 Harvesting of parasites 
The parasites were centrifliged at 5000 rpm for 15 min. The 
supematants were discarded and pellets were washed thrice with phosphate 
buffered saline. The pellets were pooled and stored at -70°C for ftirther use. 
2.5.2.3 Inoculation of parasites 
The medium (RPMI-1640) from the Leighton tubes was carefully aspirated 
without disturbing the macrophage cell line. To these tubes, 1 ml of parasite 
suspension (5 x 10^  promastigotes in RPMI-1640 obtained from log phase culture) 
was transferred and kept in culture chamber maintained at 37°C in an atmosphere of 
5% CO2. Medium was replaced for fresh supply of nutrients every alternate day. 
Leighton tubes were divided into two groups, infected control and drug freated 
infected. Coverslips from these two groups were taken out, air dried and fixed in 
methanol and stained in Giemsa (10% v/v) for 30 min. Stained coverslips were 
mounted on microslides with the help of DPX and examined for numerical 
estimation of parasites within the macrophages. The number of parasites in drug 
treated infected macrophages was compared with infected control macrophages and 
the efficacy was calculated as percent inhibition of amastigotes using the following 
fomiula; 
ATx 100 
Percent inhibition = 100 -
AC 
(where AT = actual number of amastigotes per macrophage cell in drug freated 
infected sample, AC = actual number of amastigotes per macrophage cell in confrol 
infected samples). 
2.6 IN VIVO MAINTENANCE OF INFECTION 
2.6.1 Infecting Animals with Promastigotes 
The infection was maintained in hamsters by inoculating -10 million 
promastigotes obtained from 7-14 day old culture, infracardially. A piece of 
spleen was surgically removed from the infected animal, 25-30 days post 
inoculation (PI). Under asceptic conditions, dab smears were prepared, fixed in 
methanol, stained in Giemsa and infection was assessed. 
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2.6.2 Infecting Animals with Amastigotes 
The hamsters were also infected by inoculating amastigotes isolated 
from the spleen of heavily infected animals. The animals with well established 
infections were sacrificed and their enlarged spleens were removed asceptically. 
The spleens were then cut into small pieces in sterile Locke's solution or 
RPMI-1640 medium to remove excess blood. These were then washed thrice in the 
same solution. The small spleen pieces were then homogenized in sterile Locke's 
solution or RPMI-1640 with the help of a motor driven tissue homogenizer 
consisting of a glass tube and a teflon pestle. The homogenized suspension was 
then centrifiiged at 500 rpm for 10 mins at 4°C so as to settle all the debris or 
unwanted material. The supernatant was removed and centrifiiged again at 3000 
rpm for 20 min at the same temperature. The sediment consisted of amastigotes, 
which were then resuspended in Locke's solution and their number counted by 
Neubauer haemocytometer chamber. The inoculum was adjusted to contain 10 
million parasites in 0.1 ml of suspension. 
Each hamster was inoculated intracardially with 10 million amastigotes in 0.1 
ml of medium RPMI-1640. By this route the infection develops in a short time and 
there is an uniformity in infection in animals. The intraperitoneal route of inoculation 
takes longer time to manifest and considerable variation appears in the intensity 
of infection amongst animals (Hanson e^  a/., 1977). 
2.6.3 Assessment of Infection 
The assessment of the intensity of infection was carried out by examining 
spleen, obtained by biopsy or post-mortem and making dab smears . Small pieces 
of spleen were dabbed on clean glass slides which were dried, fixed in absolute 
methanol and stained with 10% Giemsa in phosphate buffer (pH 7.2) for 45 min. 
The slides were examined under oil immersion lens of a microscope and 
classified according to the number of amastigotes/100 cell nuclei as follows: 
+ = I-10 amastigotes/100 cell nuclei 
++ = 11-50 amastigotes/100 cell nuclei 
+++ = 51-300 amastigotes/100 cell nuclei 
++++ = > 300 amastigotes/100 cell nuclei 
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Hamsters infected with 10 million amastigotes of L. donovani Dd8 became 
positive after 25 days and death occurred in about 120 days, at the maximum. By 
the time of death the intensity of infection was found to be +4 stage. By this time, 
the animals showed proliferation of reticuloendothelial tissues of the spleen, liver 
and bone marrow. 
2.6.4 Method of Conducting Spleen Biopsy 
Male golden hamsters were inoculated as described above. It has been 
observed in earlier studies that when spleen biopsies are conducted from time to 
time afer such inoculation to assess the degree of infection, all animals invariably 
become positive for leishmaniasis by day 25 post inoculation (PI). It was, 
therefore, decided to conduct the biopsy on day 25 post inoculation to confirm 
establishment of infection. 
For biopsy, hamsters were anaesthetized by injecting 50-60 mg/kg of 
Nembutol (sodium phenobarbital) intraperitoneally. Their abdomens were shaved 
and an incision (approximately 1cm long) was made over the gastro-splenic 
omentum. As the omentum was slowly drawn out through the incision, the 
attached lower end of the spleen appeared. A small piece of spleen was cut and 
dipped in sterile Locke's solution. The rest of the spleen was then returned to the 
peritoneal cavity, and the inner muscle layer was stiched with the help of a suturing 
needle and nylon tliread. Thereafter, the outer layer was stiched. Neosporin, an 
antibiotic powder, was apphed on the cut surface and was sealed with tincture 
benzoin. The small piece of spleen dipped in Locke's solution was then blotted on 
the filter paper to remove Locke's solution and excess blood. It was then dabbed 
on a clean microslide which was dried, fixed in absolute methanol and stained 
with 10% Giemsa in phosphate buffer (pH 7.2) for 45 min. 
2.7 ISOLATION OF kDNA 
The pellet of harvested cells (promastigotes) was weighed and dissolved in 
required amount of NET-100 buffer (NaCl 100 mM, 250 mM EDTA and Tris 10 
niM, pH 8.0) to a final concentration of 20%. Pronase (20 mg/ml) and SDS (20%) 
were added to a final concentration of 2 mg/ml. and 1% respectively. The solution 
was incubated at 37°C for 2 hr or more (as required for complete lysis). A clear 
sample could be seen after lysis. The lysate was sheared by passing it through a 
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syringe with a 22 gauge needle for about 25-30 times. 15 ml of NET-100 
containing 20% sucrose was pipetted out into autoclaved centrifiiged tubes. The 
sheared samples were layered on top of the NET-100.The tubes were 
ultracentrifliged using SW-28 rotor at 20,000 rpm at 15"C for 1 hr. The 
supematants were transferred into a sterile beaker and the pellets were 
dissolved into 100 ^1 of NET-100 buffer each and kept at 4"C overnight. RNase (10 
mg/ml) was added to a final concentration of 100 (xg/ml and incubated at 37°C for 
1 hr. Pronase (20 mg/ml) and SDS (20%) were added again to a final concen-
tration of 0.2 mg/ml and 0.1% respectively and incubated at 37"C for 1 hr. To this 
an equal volume of phenol was added. The tubes were vortexed, kept on ice for 1 
minute and centrifiiged at 12,000 rpm for 10 min. Upper phenol layer was discarded 
and lower aqueous layer retained. The extraction was repeated twice. An equal 
volume of chloroform:iso-amyl alcohol (24:1) was added in each tube, vortexed and 
centrifiiged at 12,000 rpm for 5 min. The upper aqueous layer was retained and 
the lower chloroform layer was discarded. This step was repeated once more. To 
this aqueous layer, 10 N NaOH was added to a final cone, of 0.2N NaOH. This 
was followed by addition of 2M HCl to bring the pH to 8.5. 1M NaCl was added to 
a final concentration of 0.5 M. The contents were extracted once with phenol and 
once with chloroform:isoamyl alcohol. To this, 1.5 volumes of a solution of 13% 
PEG 8000 in 1.6 N NaCl was added and the tubes were kept at -20"C overnight. 
The tubes were centrifiiged at 12,000 rpm for 15 min, the supematants were 
discarded and the pellets retained. The pellets were dissolved in 300 )il of 0.05 x 
SSC (standard saline citrate: 150 mM NaCl; 15mM trisodium citrate) and then 
3M sodium acetate was added to a final concentration of 0.3M. To this, 2 volumes 
of distilled ethanol was added and lefi overnight. The ethanol precipitated kDNA 
was centrifiiged, the supematants were discarded and the pellets were washed 
with 70% ethanol. The kDNA pellets were finally dissolved in 10-20 jil of 
0.05mM EDTA. 
2.7.1 Agarose Gel Electrophoresis 
Agarose (appropriate amount) was dissolved in 100 ml of 1 X TBE (0.089M 
Tris buffer, 0.089M Boric acid, 0.002M EDTA of pH 8.0) in a boiling water bath, 
cooled to 60"C and poured into a gel chamber that was set with a comb of desired 
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thickness and number of wells. The gel was allowed to harden and then the comb 
was removed carefully. The plate containing the gel was transferred to the electro-
phoresis tank. The tank was then filled with mnning buifer (1 X TBE). The DNA 
samples were mixed with loading buffer (0.0025 gm of bromophenol blue in 1 ml 
40% sucrose) and loaded into the wells. The electrodes were placed such that 
the cathode was nearest to the sample wells, and the potential was applied 
between the electrodes. Electrophoresis was conducted at lOV/cm gel length for 2-
3 hr until the dye moved to the bottom. The gel was removed and satained for 
30 min in ethidium bromide solution (0.5 |ig/ml) at room temperature. The 
gel was destained in water with gentle shaking for 15-20 min. DNA bands were 
visualized under UV light using the FOTODYNE MP-4, at a transmitted 
wavelength of 302 nm. The aperture was adjusted to 4.5 and the light was made 
to pass through an orange wratten 22A filter. The image of the bands was 
obtained on a Polaroid Type 57 or 667 (ASA 3000) film. 
The lengths of DNA firagments were determined fi-om their mobility in gels 
relative to a set of coelectrophoresed reference molecules derived fi-om phage X 
DNA double digested with endonucleases Hind III and Eco RI. 
2.7.2 Southern Blotting 
The kDNA fi-agments were transferred fi-om the agarose gels to 
nitrocellulose paper or hybond N* essentially by the method of Southern (1975). 
The kDNA was bound to the filter by baking it at 80°C for 1 hr under vacuum. 
2.7.3 In vitro Labelling of kDNA 
Purified kDNA was radiolabeled by 'Nick Translation' using ^^P-labelled 
dCTP (fi-om BARC, Trombay) according to the manufacturers protocol. ^^P-dCTP 
was obtained in 1:1, ethanol : water at a concentra-tion of 1 mCi/ml (specific 
activity 3000 Ci/mmol). This was lyophilised, reconsfituted and 10 |iCi was used 
for each labelling reaction. 
2.7.4 Hybridisation 
The hybridisation of kDNA fi-agments on the blot, with probes was carried 
out according to protocol of Sambrook e( al. (1989). Prehybridisation was carried 
out for 2 hr and hybridisation over night at 42"C. The filter was washed after 16-
18 hr of reaction, in varying concentrations of saline sodium citrate (SSC) and 
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sodium dodecyl sulphate (SDS) at different temperatures with a final washing in 
O.lXSSC + 0.5% SDS at 68°C for 30 min. The filter was exposed to a Kodak 
XAR-2 X-ray film supplemented with an intensifying screen KIRAN Hi-speed 
class 100 at -20°C for a period of 5 days and then developed using an automatic 
X-ray film processor. In some experiments, nylon membranes were reused after 
washing off the hybridised probe in 50% formamide + 2 X SSPE for 1 hr at 65°C 
and then, rinsing in 0.1 X SSPE at room temperature. 
2.8 PREPARATION OF TISSUE HOMOGENATES 
On desired days, the animals were sacrificed by anaesthetizing with 
chloroform. Liver, spleen, thymus and lymph nodes were excised immediately, 
washed with chilled normal saline (145 mM) and blotted with filter paper. These 
were weighed and 10% (w/v) homogenates were prepared in 154 mM potassium 
chloride with the help of Potter Elevehjem homogenizer fitted with teflon pestle. 
These tissue homogenates were used for enzyme assays and chemical estimations. 
Exudate cells fi^om the peritoneal cavity and marrow from femur and tibia 
bones of each animal were collected separately in Hanks buffered salt solution 
(HBSS; pH 7.4). Peritoneal exudate cells (PEC) as well as bone marrow cells 
(BMC) were recovered by centrifugation at 500 rpm for 10 min and suspended in 
1.0 ml of KCl (150 mM). The homogenates of spleen, thymus and lymphnodes (LN) 
as well as PEC and BMC suspensions were sonicated by cell disniptor model W-
220 F (Heat System Ultrasonic, USA) for I min. at 1.5 A°, and the suspension was 
centrifiiged at 11,000 rpm for 20 min. The supematants were used for enzyme 
assay. 
The subcellular fractionation of liver was done according to the method of 
Schneider and Hogeboom (1950). Liver homogenate was centriftiged at 2000 rpm 
for 10 min to sediment the nuclei, unbroken cells and red blood cells and 
supernatant was used for estimation of hepato specific enzymes. Then the 
supematnat was centriftiged at 11,000 rpm for 20 min. The supernatant so obtained 
was post-mitochondrial fraction (PMF) and used for estimation of enzymes of 
antioxidant system. 
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2.8.1 Chemical Estimations 
2.8.1.1 Protein 
Total proteins from homogenate were precipitated with an equal volume of 
10% (w/v) trichloroacetic acid (TCA). The precipitate was washed twice with 
5% (w/v) TCA. Trichloracetic acid was discarded by centrifligation and 
precipitate was dissolved in 0.1 N sodium hydroxide. Protein was estimated by the 
method of Lowry et al (1951) using bovine serum albumin as standard. 
2.8.1.2 Bilirubin 
Total bilirubin was estimated according to the method of Jendrassik & Grof 
(1938). The sample (0.2 ml) was mixed with 0.2 ml of sulphanilic acid (0.029M in 
0.17 N HCl); 50 \i\ sodium nitrite (25 mM) and 1 ml caffeine reagent (0.26 M 
caffeine and 0.52 M sodium benzoate solution in water). The reaction mixture was 
incubated in a dark place at 25''C for 30 min. Afterwards 1 ml of Na-K-tartrate (0.93 
M in 1.9 N sodium hydroxide) was added and further incubated for 15 min. The 
absorbance of the colour developed was measured at 578 nm in dark against a 
reagent blank and compared with appropriate standard of pure bilirubin. 
2.8.1.3 Lipid peroxides 
Lipid peroxides were estimated according to the method of Ohkawa et al 
(1979). The tissue homogenate (0.2 ml) was mixed with 0.2 ml of 8.1% (w/v) 
sodium dodecyl sulphate; 1.5 ml of 20% (v/v) acetic acid (pH 3.5) and 1.5 ml of 
0.8% (w/v) thiobarbituric acid (pH 7.0). This was heated at 95"C for 2 hr in a water 
bath. Thiobarbituric acid reagent was prepared just before use. The red colour, 
produced after heating was made upto 5 ml with TDW. The tubes were centriftiged 
at 4000 rpm for 20 min and the absorbance of the supernatant was measured at 532 
nm, against water blank. Aliquots of the solution of 1,1,3,3-tetramethoxy propane in 
water (5-50 nmoles) were simultaneously incubated to give a standard plot of the 
pink colour developed against different concentrations. Extrapolation of the optical 
density of the colour, developed on the standard plot gave the amount of 
malonyldialdehyde which was taken as the direct measure of the lipid peroxides 
formed. 
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2.8.1.4 Reduced and oxidised glutathione 
These were estimated according to Hissin and Hilf (1976). A Perkin-Elmer 
fluorescence spectrophotometer was used for all determinations of fluorescence 
intensity. Homogenate for estimation of reduced glutathione (GSH) and oxidised 
glutathione (GSSG) was prepared freshly in 0.1 M sodium phosphate, 0.005 M 
ethylene diamine tetra acetic acid buffer (pH 8.0), centrifliged at 4"C at 11,000 rpm 
for 30 min and kept on ice until used. 0-phthaldehyde (OPT) solution was prepared 
freshly in reagent grade absolute methanol. 
GSH assay: To 0.5 ml of 11,000 rpm supernatant, 4.5 ml of the phosphate-EDTA 
buffer (pH 8.0) was added. The final assay mixture (2.0 ml) contained 0.1 ml of the 
diluted tissue supernatant, 1.8 ml of phosphate-EDTA buffer and 0.1 ml of O-
phthaldehyde solution containing 100 |ig of OPT. After thorough mixing and 
incubation at room temperature for 15 min, the solution was transferred to a quartz 
cuvette, Fluoresence was determined at 420 nm with the activation at 350 nm. 
GSSG assay: A 0.5 ml portion of the original 11,000 rpm supernatant was 
incubated at room temperature with 0.2 ml of 0.04 M N-ethyl maleimide (NEM) for 
30 min to interact with GSH present in the tissue. To this mixture, 4.3 ml of 0.1 N 
NaOH was added. A 0.1 ml portion of this mixture was taken for measurement of 
GSSG using the procedure outlined for GSH assay, except that 0.1 N NaOH was 
emplo> ed as diluent rather than phosphate-EDTA buffer. 
2.8.2 Enzyme Assays 
Details of the reaction mixture used for various enzymes have been described 
under each assay. Spectrophotometric measurements were made in final volume 
(more than 2 ml) using Shimadzu double beam spectrophotometer (UV 190) with 
silica cuvettes (1 cm light path) against appropriate blanks. In control, substrate 
was added after stopping the reaction and absorbcUice was recorded. For all 
enzyme assays, the concentrations of the substrates, coenzymes, enzyme protein 
was such chosen as to give maximal reaction rate. 
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2.8.2.1 Y'^lut^niyl transpeptidase 
(Y -Glutamyl-peptide;amino acid y-glutamyl transferase, EC 2.3.2.2) 
The assay of the enzyme was carried out according to tlie procedure of 
Boelsterii & Zbinden (1979). The assay mixture consisted of 0.1 M Tris-HCl 
buffer, pH 7.6; 75 mM glycylglycine; 10 mM MgCb; 4 mM y-glutamyl p-
nitroanilide hydrochloride and suitably diluted enzyme. The incubation was carried 
out at 37"C for 30 min and the reaction was stopped by addition of 3 ml of 
10% (v/v) acetic acid. Colour intensity of the clear supernatant after centrifiigation 
was read at 405 nm. 
2.8.2.2 Acid phosphatase 
(Orthophosphoric-monoester phosphohydrolase, EC 3.1.3.2) 
The enzyme was determined in liver homogenate following the method of 
Wright et al. (1972). The assay system in 3 ml of final volume, consisted of 43 mM 
acetate buffer, pH 4.5; 2.33 mM p-nitrophenyl phosphate and suitably diluted 
enzyme. After 15 min of incubation at 37°C, the reaction was terminated with 
2 ml of 1 N sodium hydroxide. The intensity of the colour was read at 405 nm. 
2.8.2.3 Acid ribonuclease 
(Ribonuclease 3'-pyrimidino oUgonucleotidohydrolase, EC 3.1.4.22) 
The enzyme was assayed according to deDuve et al. (1955). The 
reaction mixture, in a final volume of 1 ml, contained 0.4 ml of 100 mM acetate 
buffer, pH 5; 0.1 ml RNA (15 mg/ml); 0.4 ml distilled water and 0.1 ml of 
suitably diluted enzyme. The incubation was carried out for 15 min at 37"C and the 
reaction was terminated with 1 ml of perchloric acid and uranyl acetate mixture 
[0.75% (w/v) uranyl acetate in 25% (v/v) perchloric acid]. The reaction mixture 
was kept in cold for one hour, centrifiiged and absorbance of the clear supernatant 
was read at 260 nm. 
2.8.2.4 Succcinate dehydrogenase 
(Succinate:(acceptor) oxidoreductase, EC 1.3.99.1) 
The enzyme was assayed according to the procedure of Slater & Bonner 
(1952). The reacfion mixture in a final volume of 2.7 ml, contained sodiimi 
phosphate buffer (O.IM, pH 7.4); sodium succinate (13 mM); potassium 
ferricyanide (1.3 mM); potassium cyanide (10 mM) and suitably diluted enzyme. 
73 
The reaction was temiinated with 3 ml of TCA (10% w/v) after incubation at 37°C 
for 15 min and centriftiged at 2000 rpm for 15 min. The supernatant was read at 
410 run against water blank. 
2.8.2.5 Glucose-6-phosphatase 
(D-Glucose-6-phosphate phosphohydrolase, EC 3.1.3.9) 
The activity of enzyme was determined by the method of Hubscher & West 
(1965). The assay mixture in a final volume of 1 ml, consisted of 30 mM sodium 
citrate buffer pH6; 2.8 mM EDTA; 1.4 mM sodium fluoride; 40 mM glucose-6-
phosphate and suitably diluted enzyme. The reaction mixture was incubated at 
37"C for 30 min. The reaction was stopped by 1 ml of TCA (10%, w/v). The 
supernatant was taken out after centrifuga-tion and inorganic phosphate was 
measured by the method of Fiske & Subbarow (1925). The blue colour obtained 
was read at 625 nm. 
2.8.2.6 Glutamate oxaloacetate transaminase (GOT) 
(DL-Asparate: 2 oxoglutarate aminotransferase, EC 2.6.1.1) 
The enzyme was assayed by the method of Reitman and Frankel (1957). 
The assay mixture consisted of 0.5 ml substrate (200 mM DL-aspartate, 2 mM 
a-ketoglutarate in 0.1 M Na-K-phosphate buffer, pH 7.4) and 0.1 ml of suitably 
diluted enzyme. The reaction mixture was incubated at 37°C for 30 min and reaction 
was terminated with 0.5 ml of 2,4-dinitro-phenyl-hydrazine (1 mM) and kept for 20 
min at room temperature. 5 ml of sodium hydroxide (0.4 N) was then added 
and absorbance of the colour was read at 540 nm. 
2.8.2.7 Glutamate pyruvate transaminase (GPT) 
(DL-Alanine: 2 oxoglutarate aminotransferase, EC 2.6.1.2) 
The activity ofthisenzyme was also assayed by the method of Reitman & 
Frankel (1957). The reaction mixture contained 0.5 ml substrate (200 mM DL-
alanine, 2 mM a-keto-glutarate in 0.1 M Na-K-phosphate buffer, pH 7.4) and 0.1 
ml suitably diluted enzyme. Incubation was carried out at 3TC for 30 min and 
reaction was stopped by addition of 0.5 ml 2,4-dinitrophenylhydrazine (1 mM). 5 
ml of 0.4 N sodium hydroxide was added after 20 min and absorbance of colour 
was read at 540 mn. 
74 
2.8.2.8 Glutathione reductase 
[NAD{P)H:oxidised glutathione oxidoreductase, EC 1.6.4.2] 
The enzyme was assyed according to the method of Racker (1955). 50 |iM 
potassium phosphate buffer, pH 7.6; O.l |iM NADPH; 3.3 |iM oxidised 
glutathione (GSSG) and suitably diluted enzyme in a final volume of 1.0 ml were 
mixed. The reoxidation ofNADPH was followed at 340 nm at 30 sec interval. 
2.8.2.9 Glutathione peroxidase 
(Glutathione:hydrogen peroxide oxidoreductase EC 1.11.1.9) 
It was determined by the method of Awasthi et al (1975). The standard 
reaction mixture consisted of 0.1 M postasium phosphate buffer, pH 7.0; 4 mM 
ethylene diamine tetra-acetic acid (EDTA); 4 mM sodium azide; 4 mM reduced 
glutathione (GSH); glutathione reductase (1 unit); 10 mM H2O2, 0.2 mM NADPH 
and suitably diluted enzyme in a final volume of 1.0 ml. The reoxidation of 
NADPH was followed at 340 nm at 30 sec interval. 
2.8.2.10 Glutathione-S-transferase 
(Glutathione-S-aryltransferase, EC 2.5.1.18) 
The activity of the enzyme was determined by the method of Habig et al. 
(1974). The assay mixture in a final volume of 1 ml consisted of 0.1 M postassium 
phosphate buffer, pH 7.0; 1 mM reduced glutathione; 1 mM CDNB (1 chloro 
2,4-dinitrobenzene) and suitably diluted enzyme. The rate of reaction was 
measured by following the increase in absorbance at 340 nm at 30 sec interval. 
2.8.2.11 Superoxide dismutase 
(Superoxide:superoxide oxidoreductase, EC 1.15.1.1) 
For assay of SOD two methods are used: 
a) The enzyme was assayed in post mitochondrial fi-action as described by 
Kakkar et al (1984) adopted fi-om the original method of Nishikimi et al 
(1972). The assay system in a total volume of 3 ml consisted of 52 mM 
sodium pyrophosphate buffer, pH 8.3; 0.186 mM phenazine methosulphate; 
0.3 mM nitroblue tetrazolium; 0.78 mM NADH and suitably diluted 
enzyme. After incubation at 30°C for 90 sec, the reaction was stopped by 
adding 1 ml glacial acetic acid and absorbance of the colour was read at 560 
nm. 
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b) According to Misra & Fridovich (1971), the total 2 ml assay mixture 
consisted of 1.5 ml sodium carbonate buffer (0,2m, pH 10.2); 0.1 ml 
epinephrine (10 mg/ml); 0.3 ml TDW and 0.1 ml suitably diluted enzyme, the 
autoreduction of epinephrine was measured at 480 nm at 15 sec. intervals. 
2.8.2.12 Catalase 
(Hydrogen peroxide: hydrogen peroxide oxidoreductase, EC 1.11.1.6) 
The enzyme was assayed according to the procedure of Aebi (1984). The 
assay mixture contained 1.0 ml of 0.2 M sodium phosphate buffer, pH 7.0; 0.1 ml 
H2O2 (diluted 1 ml to 100 ml); 0.8 ml TDW and 0.1 ml suitably diluted enzyme. The 
rate of reaction was measured by following the decrease in absorbance at 240 nm. 
2.8.2.13 Xanthine oxidase 
(Xanthine-oxygen oxidoreductase, EC 1.2.3.2) 
The enzyme was assayed according to the method of Horecker & Heppel 
(1949). The total reaction mixture of 2 ml consisted of 0.1 ml xanthine (2 mg/ml); 
0.1 ml cytochrome C (3 mg/ml); 0,2 ml catalase (1.3 units/ml); 0.5 ml sodium 
phosphate buffer, pH 8.0 and suitably diluted enzyme. The increase in absorbance 
was read at 550 nm. 
2.8.2.14 NADPH oxidase 
A reaction mixture containing phosphate buffer (0.2 M, pH 7.4); BSA (15 
mg/mi); NADPH (1 ml/ml), appropirately diluted enzyme and water in a total 
volume of 2 ml was prepared and a decrease in O.D. was measured at 340 nm 
(Fioravanti, 1981). 
STATISTICAL ANALYSIS 
The mean and standard deviations were calculated fi*om all the variables 
using standard procedures and significance of change was estimated by using 
student's "f test. Percent reversal (protection) by drug was calculated in each 
parameter using the following formula. 
Infected - (Infected drug treated) 
% Protection = x 100 
Control - Infected 
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SECTION 3.0 
ANALYSIS OF RESTRICTION FRAGMENT 
LENGTH POLYMORPHISM IN THE 
KINEOPLAST DNA OF L. DONOVANI 
3.1 INTRODUCTION 
Identification of a Leishmania isolate is important to determine prognosis and 
correct chemotherapeutic regimes and also for epidemiological and basic biological 
studies. The goal of molecular characterization of Leishmania species and strains is 
being pursued by many different biochemical and immunochemical approaches 
(Giannini ei al., 1986; Rious et ai, 1990). The differentiation between closely 
related organisms by restriction analysis of specific DNA molecules has ahready 
been applied in a number of cases (Nathans et al., 1975; Potter et al., 1975). It has 
been shown that restriction endonuclease digestion of kinetoplast DNA (kDNA) can 
be used for characterization of kinetoplastid flagellates, even at the strain level 
(Wirth & Pratt, 1982). In this report, we describe restriction fragment length 
polymorphism (RFLP) in kDNA of different strains of L donovani originating in 
India. This will contribute to the understanding of the evaluationary and taxonomic 
status of these organisms as well as in designing specific primers for DNA based 
diagnostics. 
3.2 MATERIALS AND METHODS 
3.2.1 Parasite: 
Four strains of the parasite were taken; a nonpathogenic strain of L. donovani 
UR6 (MHOM/IN/78/UR6) and three different pathogenic strains viz. DdS (MHOM/ 
IN/80/Dd8), AG83 (MHOM/IN/80/AG83) and RMRI (MHOM/IN/QO/ RMRI 68). 
3.2.2 Isolation of kDNA 
kDNA was isolated from promastigotes according to the method described by 
Dasgupta et al (1986). The individual circles in the kDNA which are covalehtly 
closed double stranded (ds) DNA comparable to plasmids, have the advantage of 
being resistant to mild shear forces. Deproteinized cell lysates were passed through 
a syringe for about 25-30 times, ensuring the shearing of nuclear DNA and 
reduction of lysate viscosity. kDNA was isolated from whole cell DNA by 
employing differential centriftigation through a 20% sucrose bed. 
Pelleting of kDNA was followed by RNase and pronase treatment, and the 
deproteinized mixture was extracted with phenol and chlorofonn. Alkali 
denaturation, to which kDNA networks are resistant, was done to remove any 
contaminating nuclccir DNA. Extraction of single stratjg[^4|^p^)NA by phenol 
^f Ace No. 1-1 
depends upon an optimum salt concentration (obtained by adding NaCl) at which 
the exposed bases of ss DNA tend to enter the organic phase while phosphate 
groups try to remian in the aqueous phase, thereby concentrating the ss DNA at the 
interphase. Enriched kDNA networks contained in the aqueous phase were 
concentrated by polyethylene glycol (PEG) at high salt concentration. PEG was 
subsequently removed by ethanol precipitation and washing with 70% ethanol. The 
kDNA pellet finally obtained was dissolved in 0.5 mM EDTA and used in fiirther 
experimentation. The protocol for kDNA isolation is given in section 2.7. 
3.2.3 Restriction endonuclease analysis 
One ).ig of DNA was digested with 5 units of restriction endonuclease in a 
final reaction volume of 20 jil. The buffer conditions for each enzyme were adjusted 
by addifion of lOX buffer (recommended by manufactiu-er-Bangalore Genei). The 
reaction was carried out for I hr at the appropiate temperature required by the 
endonuclease. Control experiments showed that digestions were complete under 
these conditions. After incubation the samples were electro-phoresed for restriction 
analysis. 
Lambda DNA double digest (EcoRl and Hind 111 ) was used as a DNA 
molecular weight marker. X DNA was completely digested with EcoRI and Hind III 
and yielded 13 fi-agments of 21.2, 5.1, 4.9, 4.2, 3.5, 2.0, 1.9, 1.5, 1.3, 0.98, 0.83, 
0.56 and 0.12 kb. 
Sequence recognition and cleavage 
I. Mspl: From E. colt strain that carries a plasmid with the cloned Msp I gene fi:om 
Moraxella species. 
I 
C C G G Incubation temperature : 
^ ' G G C C ^ ' 37°celsius 
t 
ii) TaqI: From Thermus aquaticus Y TI 
^ T C G A ^ Incubation temperature 
3 ' A G C T ^ ' 65°celsius 
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iii) EcoR I : From Escherichia coli 
^ G A A T T C Incubation temperature: 
3 ' C T T A A C ? 370celsius 
T 
iv) Hae III ; From Haemophilus aegyptius 
\ 
" ^ G G C C ^ Incubation temperature; 
^ ' C C G G ^ ' 37°celsius 
t 
v) Hind III: From Haemophilus influenzae strain d 
5' -r3' 
A A G C T "P^ Incubation temperature : 
3 ' T T C G A A ^ 370celsius 
T 
3.2.4 Agarose Gel Electrophoresis (AGE) 
The standard method used to separate, identify and purity DNA fragments is 
agarose gel electrophoresis. This simple technique can be perfonued rapidly and is 
capable of resolving mixtures of DNA fragments that cannot be separated 
adequately by other procedures, such as density gradient centrifiigation. The DNA 
can be visualized by staining the gel with low concentrations of a DNA-intercalating 
dye, ethidium bromide, that emits a pink fluorescence in UV light. The 
electrophoretic migration rate of DNA depends upon four parameters: the molecular 
size of the DNA, its conformation, the agarose concentration and the applied 
voltage potential. Tlie procedure for carrying out AGE has been discussed in section 
2.7.1. AGE was carried out af^ er isolation of kDNA, and its restriction analysis. 
3.2.5 Southern blotting 
The kDNA fragments were fransferred from the agarose gels to nitrocellulose 
paper essentially by the method of Southern (1975). The kDNA was bound to the 
filter by baking it at 80°C for 1 hr under vaccum. Purified kDNA was radiolabelled 
by nick translation using -^ ^PdCTP. The hybridization of kDNA fraginents on the 
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blots was carried out with probes according to protocol of Sambrook et al (1989). 
The detailed protocol has been discussed in sections 2.7.2, 2.7.3 and 2.7.4. 
3.3 RESULTS 
In the present study, kinetoplast DNA was isolated from four different strains 
of L. donovani viz: UR6, RMRI, Dd8 AG83. These strains have been isolated from 
splenic aspirates of confirmed kala-azar patients and then adapted to growth in in 
vitro conditions. Our preliminary' work started with strains UR6 (avirulent) and 
Dd8 (vimlent). Later on we went on to characterize strains RMRI and AG83 also in 
detail by hybridization experiments. The later two strains are highly vimlent (Sanyal 
ef al., 1994; Chakravorty et al., (1994) and responsible for much of the havoc in the 
eastern region of India. 
Initially, samples of kDNA were isolated from each strain (Fig. I). They were 
then digested with restriction endonuclease EcoRI with 6 bp recognition sequence. 
It produced only a single fragment in all the strains examined (Fig. 2). This single 
fragment represents a linearised minicircle of 0.875 kb. 
Comparison of minicircle fragment profile of strains Dd8 and AG83 after 
digestion with Hind III (6 bp recognition sequence) and Mspl (4 bp recognition 
sequence) is shown in Fig. 3. Flind III cleaved Dd8 kDNA at a single site of 0.89 kb 
(not clearly shown in photograph) while in AG83, a band of 0.98 kb was obtained. 
AG83 kDNA digested with Mspl showed 4 bands in the region of 0.83 kb-0.12 kb, 
whereas in case of Dd8, a linearised minicircle fragment of 0.83 kb was observed 
(not clearly visible). 
To study the restriction pattern of the kDNA minicircles from these strains, 
samples of kDNA from Dd8, RMRI and UR6 were then digested with enzymes Hae 
III, Hind III and Taq I. (Fig. 4). Hae III and Taq I have tetrameric recognition 
sequences and released most of the kDNA minicircles from its highly concatenated 
fonti. UR6 kDNA when digested with TaqI produced 2 bands, one intense band of 
0.83 kb, whereas the other band was of 0.12 kb. In case of Dd8, 5 bands were 
produced in the region of 0.98 kb-0.l2 kb. RMRI kDNA digested with Hae III 
produced 4 bands migrating between mol. wt. region of 0.83 kb- 0.12 kb. In case of 
Dd8, 2 bands were visible in the region of 0.56-0.12 kb (only one band clearly 
sliown in the photograph). When Dd8 kDNA was digested with Hind HI, a single 
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Legend to Fig. 1 : Electrophoresis pattern of total kDNA isolated from the 
promastigotes of different strains of L. donovani 
Lane 1 : Lambda DNA Hind III/EcoRI double digest 
Lane 2 : Total kDNA of UR6 
Lane 3 ; Total kDNA of AG83 
Lane 4 : Total kDNA of Dd8 
Lane 5 : Total kDNA of RMRI 
Legend to Fig. 2 : Electrophoresis pattern of kDNA of different strains of/. 
donovani with the enzyme EcoRI 
Lane 1 : Lambda DNA Hind III/EcoRI double digest 
Lane 2 : RMRI kDNA digested with EcoRI 
Lane 3 : Dd8 kDNA digested with EcoRI 
Lane 4 : AG83 kDNA digested with EcoRI 
Lane 5 : UR6 kDNA digested with EcoRI 
1 2 3 4 5 6 7 8 
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Legend to Fig. 3 : Electrophoresis pattern of kDNA of Dd8 and AG83 strains of 
/.. donovani digested with the enzymes EcoRI, Hind III and Mspl 
Lane 1 : Lambda DNA Hind III/EcoRI double digest 
Lane 2 : AG83 kDNA digested with EcoRI 
Lane 3 ; AG83 kDNA digested with Hind III 
Lane 4 : AG83 kDNA digested with Mspl 
Lane 5 : Dd8 kDNA digested with EcoRI 
Lane 6 : Dd8 kDNA digested with Hind III 
Lane 7 : Dd8 kDNA digested with Mspl 
Legend to Fig. 4 : Electrophoresis pattern of kDNA of UR6,Dd8 and RMRI 
strains of L. donovani digested with the enzymes EcoRI, Hae III, Hind III and Taq 
1 
Lane 1 : Lambda DNA Hind III/EcoRI double digest 
Lane 2 : UR6 kDNA digested with Taq I 
Lane 3 : Dd8 kDNA digested with Taq I 
Lane 4 : RMRI kDNA digested with Hae III 
Lane 5 : Dd8 kDNA digested with Hae III 
Lane 6 : Dd8 kDNA digested with Hind III 
Lane 7 ; UR6 kDNA digested with Hind III 
Lane 8 : Dd8 kDNA digested with EcoRI 
Lane 9 ; UR6 kDNA digested with EcoRI 
1 2 3 4 5 6 7 8 
1 2 2 4 5 3 7 S 9 
Legend to Fig. 5 ; Autoradiogram of Southern hybridisations between kDNA 
restriction fragments of UR6, RMRI and nick translated ^^ P kDNA of UR6 
Lane 1 : Lambda DNA Hind III/EcoRI double digest 
Lane 2 : UR6 kDNA digested with EcoRI 
Lane 3 : RMRI kDNA digested with EcoRI 
Lane 5 : UR6 kDNA digested with Hae III 
Lane 6 : RMRI kDNA digested with Hae III 
Lane 8 : UR6 kDNA digested with Hind III 
Lane 9 : RMRI kDNA digested with Hind III 
Legend to Fig. 6 : Autoradiogram of Southern hybridisations between kDNA 
restriction fragments of Dd8, AG83 and nick translated ^^ P kDNA of UR6 
Lane 1 . Lambda DNA Hind III/EcoRI double digest 
Lane 2 : AG83 kDNA digested with EcoRI 
Lane 3 : AG83 kDNA digested with Hind III 
Lane 4 : AG83 kDNA digested with Mspl 
Lane 5 : Dd8 kDNA digested with EcoRI 
Lane 6 : Dd8 kDNA digested with Hind III 
Lane 7 : DdS kDNA digested with Mspl 
±^.3^4 5 6 7 8 
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linearised minicircle band of 0.89 kb was observed, but in case of UR6 2 bands 
between 0.83-0.58 kb region were observed (not clearly visible in photograph). 
On Southern blot analysis of restriction patterns of kDNA of different strains 
of L. donovani isolated, using nick translated -^ P^ kDNA of UR6 as probe, following 
results were observed. In Fig. 5, UR6 kDNA digested with Eco RI, Hae III & Hind 
III (lanes 2, 5, 8) hybridized strongly. RMRI kDNA digested with EcoRI and Hind 
111 (lanes 3 & 9) showed 2 bands between 0.98-0.83 kb and in case of Hae III (lane 
6), 5 bands below 0.83 kb were observed. 
AG83 and Dd8 kDNA digested with EcoRI, Hind III and Mspl respectively, 
on hybridisation with nick translated ^^ P kDNA of UR6 showed somewhat similar 
patterns (Fig. 6). AG83 & Dd8 kDNA digested with Eco RI & Hind III (lanes 2,3 & 
5,6) showed 3 bands in the region of 2.0-0.83 kb. However, when AG83 and Dd8 
kDNA were digested with Msp I (lanes, 4 & 7), 4 bands were observed migrating 
between molecular weight regions of 0.83-0.12 kb. 
3.4 DISCUSSION 
An important pre-requiste in the study of Leislimaniasis is the characterization 
of the different strains of the parasite isolated from patients. It has been shown that 
restriction endonuclease digestion of kinetoplast DNA can be used for the 
characterization of kinetoplastid flagellates, even at the strain level (Wirth & Pratt, 
1982). 
Our hybridisation experiments agree well on a qualitative level with the 
differences in restriction patterns of four different strains of A. donovani viz: RMRI, 
Dd8, AG83 and LrR6. Such a cline of genetic variability in numerous strains from 
other species have already been reported by various investigators who have 
characterized their kDNA using restriction enzyme analysis (Mattei cf al., 1977; 
Morel et al., 1980; Kidane et al., 1984; Carreno et al., 1977; Angelici ct al, 1989). 
The cross hybridization observed by us in the region of around 0.98-0.12 kb 
sequences of kDNA have to be determined to identify this region of homology. But 
this showed that within the fragments of kDNA generated from each strain, there 
were some which contained sequences shared by all and some which contained 
sequences unique to each strain. A common feature in the sequence organization of 
minicircles that has been reported, is the presence of a conserved sequence region of 
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100-300 bp. (Barrois et ai, 1981). This sequence contains the 13 bp universal 
minicircle sequence or UMS (Universal Minicircle Sequences) which has been 
found to be perfectly homologous in all the minicurcles that have been sequenced to 
date (Barrois et al 1981; Jasmer and Stuart 1986; Singh et al., 1993). The 13 bp 
UMS is thought to be the minicircle origin of replication. Outside this conserved 
region the minicircle have only limited homology and this region is termed as the 
variable region. 
Hence, the main conclusion is that, restriction endonuclease digestion of 
kDNA isolated from four Indian strains of L donovani, followed by electrophoresis 
showed that each strain produced more or less an unique pattern of kDNA 
fragments and on hybridisation, each sfrain seems to contain sequences unique to it 
as well as sequences common to all the other strains. This study has focussed 
primarily on the strians having origin in India among which RMRI DdS and AG83 
iiave presently been attributed to be inflicting maximum damage. It has been 
reported that probes developed from UR6 minicirle sequences are not specific for 
detecting VL cases as they hybridize to PKDL (Dasgupta et al., 1991). Therefore, 
further work based on visceral strains through their specific sequences might prove 
usefiil towards understanding at length, the parasite responsible for much of the 
iiavoc in the Indian sub-continent as well as in designing specific primers for DNA 
based diagnostics. 
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SECTION 4.0 
IN VITRO AND IN VIVO SCREENING OF 
NEWLY SYNTHESIZED AND KNOWN 
ANTILEISHMANIAL DRUGS/COMPOUNDS 
AGAINST L DONOVANI 
4.1 INTRODUCTION 
Dnig development against leishmaniasis is a challenging problem firstly 
because, the parasites are well protected in the macrophages and secondly the 
infection is competent enough to put the host defence system out of gear. These two 
major obstacles make the job of the medicinal chemists extremely difficult. For the 
compound to be effective against Leishmania species, it has to reach the parasite 
overcoming the beuriers presented by the host cell. Further the compound should be 
such that it does not disturb the already suppressed immune system of the host. 
Besides these properties, the compound should be able to block the life-supporting 
flmctions of the pathogen leading to its death with least toxicity to the host. 
The increase in number of cases resistant to antimony therapy due to 
intermittent drug exposure (Grogl et ai, 1989; WHO, 1995), the isolation of 
antimony resistant Leishmania strains from patients unresponsive to antimonial 
treatment (Grogl et ai, 1992; Ho et al., 1994), and more recently, the numerous 
cases of VL patients infected with the human immunodeficiency virus (Trorre-
cisneros et al., 1995) indicate the urgent need of finding new therapeutic agents for 
the treatment of leishmaniasis. 
A rational approach to the design of new antileishmanials has identified a 
number of metabolic pathways in Leishmania biochemistry which may be exploited. 
One such target is the intracellular superoxide dismutase (Fe-SOD) unique to 
Leishmania sp. This enzyme is considered to be vital for parasite defence. 
Leishmania contains 23 units of iron containing SOD per mg of protein. This 
metalloprotein is different from mammalian SOD which contains Cu/Zn or Mn. The 
ability of amastigotes but not of promastigotes to remove H2O2 can be inhibited by 
aminotriazole or sodium azide. The observation that vertebrate SOD is inhibited by 
diethyldithiocarbamate to which the parasite enzyme is insensitive, makes it possible 
to envisage the development of specific inhibitor of parasite SOD. In principle, an 
agent capable of depressing parasite SOD and boosting up host SOD would be of 
great value as a chemotherapeutic agent (Mukherjee et al., 1990). 
Large number of known drugs and chemical agents exhibiting antileishmanial 
activity in animals have been Hsted (Mukherjee et al., 1990). Yet no clinically 
acceptable dmg is available for the treatment of leishmaniasis. The survival and 
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multiplication of Leishmania parasite in the host is governed by several biochemical 
processes which operate at the level of various enzymes. Biochemistry of 
Leishmania sp. has been reviewed (Glew et al., 1988) and the available information 
on this subject indicates that a number of biochemical targets may be utilized for 
dnig design. Keeping this in mind some new compounds have been synthesized and 
tested for their antileishmanial activity in vitro and in vivo. These include some 
analogues of the known drugs and some compound with new nuclei. 
Diamidines are known to possess potent anti protozoal activity due to their 
property of binding with minor groove of DNA. Pentamidine or l,5-bis-(4'-amidino 
phenoxy) pentane, is the most known aromatic diamidine and is used to treat cases 
of antimony resistant leishmaniasis. Yet, it suffers from limited clinical application 
due to its adverse and toxic side effects. Earlier attempts towards improving its 
chemotherapeutic potential and/or diminishing its toxicity which include 
mtroduction of variations in the length of alkyl bridge and isosteric replacement of 
ether oxygen with nitrogen in the pentamidine molecule, did not yield any dramatic 
improvement (Bell et al., 1990). 
The diamidines also cause disruption of mitochondrial function, damage to 
kDNA core and inhibition of RNA polymerase. The biosynthesis of nucleic acids, 
proteins, phospholipids and polyamines is also inhibited (Muklierjee cl al., 1990). 
Recent studies have shown the presence of a novel arginine transport in /.. donovani 
promastigotes which is inhibited by pentamidine (Kandpal et al., 1995). In view of 
the above, some novel analogues of pentamidine have been synthesized, some have 
bis substitution such as alkyl, cycloalkyl, aralkyl and aryl groups on the amino group 
while in other compounds the nitrogen of the amino group represents one of the five 
membered heterocyclic ring system. 
Pyrimidines and imidazole rings, being an integral part of nucleic acid bases 
and various bioactive substances are involved in diverse phannacological functions 
in living organisms. It was contemplated that pharmacological profiles of 1,3-
dithiolanes and imidazoUdine derivatives being isosteres of imidazole will 
analogously demonstrate high degree of lesihmanicidal activity in presence of 
specific substituent at specific position which may play a crucial role in potentiating 
the biodynamic property of molecule. The importance of pyrimidines as 
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leislimanicides (Steck, 1974; Ram, 1989) aroused considerable interest in 
developing its rigid analogues as pyrazolo[3,4-d]pyrimidines, thiadiazole [2,3-
d]pyrimidine and pyrimido[3,4-d]pyrimidine derivatives which would not only 
demonstrate leishmanicidal activity but would also effectively modulate natural 
defence of the host and restore the impaired immune systems. 
Based on pattern recogmtion approach and past observations it was 
rationalised that N-C-N or S-C-N structural unit is the minimum requirement for 
displaying leishmanicidal as well as immuno-stimulant properties (Chauhan et ai, 
1983). Thus, it was presumed that simulation of either of the structural units in 
flexible and rigid forms or repetition of such moieties in fiised heterocyclic systems 
may potentiate the antileishmanial activity. Further, the antiparasitic property of 
azoles is well documented and their attachment with other heterocycles of^ en 
ameliorates or diminishes the bioresponse, depending upon the type of substituent 
and position of attachment. 
The nitroalkanes are another group of compounds which are synthesized 
with the aim of creating an intracellular bioenvironment which would lead to the 
destruction of parasite defence mechanism. Induction of this envisaged 
bioenvironment may become possible if compounds after reaching the locus of 
action are capable of generating free radicals. These free radical intennediates may 
then interact with parasite enzymes responsible for evading host defence 
mechanisms. It is also possible that the compounds at the site of action may 
generate NO2' radicals which could then become lethal to parasites. 
Aplysinopsin, an indole derivative, which was first isolated from the extract 
ot Australian barrier reef sponge Thorecta aplysinopsis, l-'ascaplysinopsis 
reticulata^ and later on from a Caribbean sponge Verongia spengc/ll. Dcndmphylla 
sp., a Mediterranean anthozoan Astroides calycularis and a Japanese coral 
Tuhastrea aurea exhibited inhibitory activity {in vivo) against P 388 in mice and 
CNtotoxicity against the cancer cell lines KB, P388 and L1210. It was also found 
active in vivo against B16 (melanoma) assays (Gulati et al., 1994). It was therefore, 
thought worthwhile to observe the biological activity of this class of compounds 
auainst leishmaniasis. 
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The naturally occurring polyamines putrescine, spermidine and spennine are 
organic cations widely distributed in both prokaryotic and eukar>'otic organisms, 
including parasitic species and are known to play an important role in growth and 
proliferation of parasites. In Leishmania as in other organisms, the levels of 
putrescine, spermidine and spermine fluctuate during the growth cycle. The addition 
of a-difluoromethyl ornithine, an irreversible inhhitor of ODC, to L. donovani 
promastigote cultures reduced growth and intracellular polyamines. Therefore, it 
appeared that interference with polyamine biosynthesis was a possibility for the 
chemotherapy of leishmaniasis. The use of polyamine analogues which interfere 
with biosynthesis and function of the natural polyamines has been another approach 
to the disniption of polyamine metabohsm (Bitonti et a/., 1989). Baumann et al 
(1990) have reported that the bis (benzyl) polyamine analogue MDL 27695 is active 
against both antimony susceptible and antimony resistant L donovani. This lead us 
to study the antileislimanial effect of some polyamine analogues. 
Perhaps the most important, naturally occurring antileislimanial compound 
fi^ om a clinical view point is the quaternary isoquinoline alkaloid, berberine (Iwu et 
al., 1994). Laboratory studies have confirmed that this compound, its congeners and 
derivatives, possess signficant activity, in vitro and in vivo against various species 
of Leishmania. The benzyhsoquinoline alkaloids are widely distributed in nature 
and have been isolated from several plants used in traditional medicine for the 
treatment of parasitic diseases. Keeping this in mind, some of the new compounds 
belonging to quinolines, bisquinolines and isoquinolines were synthesized 
chemically and their biological activity was monitored against L. donovani. 
Levamisole an immuno-modulator, has been shown to be useful in treating 
leishmaniasis. One of the major metabolite of levamisole [1-P mercaptoethyl 4(5)-
phenyl imidazolidin-2-one] has been found to have 4-5 folds more activity than 
parent dmg. N-phenyl-1,3 imidazole-2-one is an structural analogue of tins active 
metabolite and few compounds of this structure have been synthesized to evaluate 
their antileislimanial activity. A new class of compounds phenyl acetonitrile a-
anilino (an intermediate foimd in the synthesis of N-phenyl-1,3 iniidazole-2-one) 
have been synthesized to see their leishmanicidal activity. However, there exists no 
literature about such class of compounds. 
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Since there is a lack of prototype structure(s) for fhiitfiil design of effective 
leishmanicides, it was considered useful to evaluate the compounds prepared during 
the present study for their in vitro and in vivo anti-leishmanial activities. 
An integrated approach is being followed for screening of novel molecules 
designed and synthesized at this Institute for leishmanicidal activity. The molecules 
synthesized are first tested for their effect on growth and proliferation of L 
donovani promastigotes using in vitro culture systems. In separate systems nucleic 
acid biosynthesis is evaluated by incorporation of [^H]-thymidine, geiierai metabolic 
activity is assayed colorimetrically by following the reduction of MTT and the 
killing is monitored by counting the number of promastigotes in the culture 
microscopically. The compounds showing positive activity in these test systems are 
then evaluated for their ability of selective inhibition of leishmanial superoxide 
dismutase (SOD). This enzyme plays a predominant role in establishment of 
Leishmania parasite within hostile environment of macropiiages by constant 
detoxification of reactive oxygen intermediates. Advantage is taken of the fact that 
SOD of L donovani is distinctly different from the mammalian counterpart with 
regards to its molecular characteristics. The compounds shov '^ing positive activity 
are then screened in amastigote-macrophage system and finally tested in v/vo.This 
systematic approach not only helps to delineate a definite in vitro-in vivo correlate 
but is also of great value in evolving a quick and reliable test system for sieving out 
inactive molecules in a large variety of structural analogues of a particular lead 
structure. 
In this section we report the antileishmanial effect of various compounds 
synthesized in Medicinal Chemistry Division of Central Drug Research Institute as 
well as the potential antileishmanial by using [^ H] thymidine uptake test and parasite 
enzyme SOD inhibition test as in vitro; macrophage-amastigote ex-vivo system as 
primary screening models and reduction in amastigotes number in host spleen as in 
vivo system. 
4.2 MATERIALS AND METHODS 
4.2.1 Parasite : L donovani (MHOM/IN/80/Dd8) 
4.2.2 Host: Syrian golden hamsters {Mesocricetus auratus) 
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4.2.3 I'^ HI-thymidine incorporation : To assess the growth of /.. donovani 
promastigotes in the presence of standard dmgs as well as the synthesized 
compounds/analogues, the promastigotes growing in the exponential pliase were 
plated in the well of a 96-well microtitre plate at a density of 2 x 10^ ' cells per well 
along with the sterile dnigs/analogues at 100 |iM concentration and incubated at 
26"C for 72 hrs. Each concentration of the dmg was set up atleast in triplicates. The 
control cultures without dmg were also set up simultaneously. The cultures in each 
well were pulsed with 0.1 |.iCi of [^ H] thymidine and were allowed to grow further 
atleast for 18 hrs. The cells were harvested on glass-fiber filters (Whatman GF/C) 
using a cell harvester. Radioactivity on the glass fiber diskettes was measured using 
a liquid scintillation counter (LKB, 1209 RACK-BETA) after placing the diskettes 
in scintillation cocktail (60 gm naphthalene, 4 gm PPO and 200 mg POPOP in 1 It. 
of 4:1 dioxane:methanol mixture) (Grogl et al., 1989). In vitro efficacy of the dmg 
was evaluated by calculating the percentage inhibition observed after comparing the 
radioactive counts with those of controls without the drug. 
4.2.4 Biochemical Assays : Harvested parasites were sonicated in 5 mM tris HCl 
(pH 7.2) and centrifi.iged at 10,000 rpm for 30 mins. The supernatant was used for 
assay of superoxide dismutase (SOD; Kakkar at ai, 1984), catalasc (CAT; Aebi, 
1984); glutathione peroxidase (GPx; Awasthi et al., 1975), glutathione reductase 
(GR; Leopold & Wolfgang, 1984); Xanthine oxidase (XO; Horecker et al., 1949) 
and NADPH oxidase (Fioravanti, 1981). All the dmgs/compounds were tested at 50 
nM cone, and time of incubation with dmg/compound was 10 mins. The effect of 
the compounds as also observed on host SOD taking liver homogenate. 
4.2.5 Ex vivo screening : macrophage-amastigote culture system 
This test method used is similar to Bhatnagar et al (1989) except minor 
modifications. Each compoimd was tested at 100 ^g/ml in triplicates (two different 
experiments). The detailed protocol is described under section 2.5.2. The number of 
parasites in dmg treated infected macrophages was compared with infected control 
macrophages and the efficacy was calculated as percentage inhibition of amastigotes 
using the following fonnula: 
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ATx 100 
Percent inhibition =100 
AC 
(where AT = actual number of amastigotes per macrophage cell in dmg treated 
infected sample, AC = actual number of amastigotes per macrophage cell in control 
infected samples). 
4.2.6 In vivo screening 
Male golden hamsters weighing 45-50 gms were inoculated with 1 x 10^  
amastigotes/animal by intracardiac route., as described earlier (section 2.6). The 
biopsy was conducted on day 25 PI of amastigotes. Spleen dabbings were made, the 
slides stained with Giemsa and examined under light microscope for assessing 
intensity of infection. 
Animals showing 10-25 amastigotes per 100 spleen cell nuclei were used for 
screening. A solution of the compound/dmg was obtained by suspending or 
dissolving accurately its weighed amount in 0.1% Tween 80 and diluting it with 
TDW. The required amount of the dmg solution/suspension was then injected 
iiitraperitoneally, once daily for 5 consecutive days. The first dose was administered 
3 days after conducting the biopsy, allowing the incision wound to heal up. For 
screening, infected animals were divided into two groups of five animals each. All 
the animals of group T' received the same dmg dose while the other group of 
untreated infected animals constituted the control group (group II). The efficacy of 
the compound was assessed in each animal separately by sacrificing the animals on 
day 7 of the completion of treatment. 
Assessment of activity or efficacy: The antileishmanial activity of compound was 
expressed in tenns of percentage inliibition in the multiplication of amastigotes in 
the spleen, in comparison to that of untreated infected controls. This was calculated 
as per the following fonnula. 
AN X 100 
Percent inliibition = 100 
INA X TI 
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where, AN - actual number of amastigotes after treatment, INA-initial number of 
amastigotes, TI - fold/time increase in the number of amastigotes in infected 
untreated control animals on the corresponding days of biopsy of treated animals. 
Drugs/Analogues used: The following antileislimanial dmgs/analogues were used 
in the present study. 
1. Sodium stibogluconate (10 mg/kg/day x5) 
2. Pentamidine isethionate (2.5 mg/kg/day x 5) 
3. Pentamidine analogues (10 mg/kg/day x 5) 
4. Fused pyrimidines (50 mg/kg/day x 5) 
5. Nitroalkane derivatives (50 mg/kg/day x 5) 
6. Phenylacetonitrile derivatives (50 mg/kg/day x 5) 
7. Malonitriles (50 mg/kg/day x 5) 
8. Imidazoles (50 mg/kg/day x 5) 
9. Polyamine analogues (50 mg/kg/day x 5) 
4.3 Results 
Fig. 1 & 2 show the in vivo effect of sodium stibogluconate {10 mg/kg/day x 
5, i.p.) and pentamidine isethionate (2.5 mg/kg/day x 5, i.p.) on the parasitic burden 
in liver and spleen. The number of amastigotes per 100 cell nuclei declined from 46 
to 5.4 (88.3% decrease) in liver and from 96.0 to 15.0 (84.4% decrease) in spleen 
by stibanate. Pentamidine caused 79% decrease (from 17.74 to 3.72) in liver and 
89% decrease (from 146.69 to 15.60) in spleen. 
The compounds showing > 80% in [ 'H] thymidine uptake, > 10% inhibitory 
effect on parasite SOD, no effect or stimulating effect on host SOD, > 80% activity 
in ex-vivo system while > 75% activity in reducing amastigote number in spleen 
against L. donovani infection in golden hamsters were considered active. 
Table-1 presents the effect of standard antileishmanials viz. sodium 
stibogluconate, pentamidine isethionate, allopurinol and nystatin (all at 50 \\m cone) 
on SOD, CAT, GR and GPx. Enzymes XO and NADPH oxidase were not detected 
in parasite. Stibanate and pentamidine inhibited all the four antioxidant enzymes 
namely SOD, CAT, GR, GPx, to a significant exteiit varying from 30% to 70% 
v^hile allopurinol and nystatin inhibited only SOD and had no inhibitory effect on 
other tliree enzymes. 
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Table-2 demonstrates the antileishmanial effect of eiglit pentamidine 
analgoues. All compounds except 96/72 were found positive in [^H]-thymidine 
uptake. All showed inhibition of parasite SOD and stimulation of different degrees 
of host SOD (except 93/655 which inhibited host SOD as well). 96/72, 93/655 and 
93/656 were found to possess 50%-79% activities in ex-vivo system. Of these 
94/174 and 94/694 showed 80% antileishmanial activity in in vivo while 93/655, 
93/656, 94/88, 94/692 & 94/693 showed moderate activities (50% to 73%). 
Antileishmanial activity of fiised pyrimidines has been siiown in Table-3. 
Total twenty three compounds of this series were synthesized. Out of these nine 
compounds viz: 93/418, 94/138, 94/139, 94/60, 94/62, 94/63, 94/65, 94/67 and 
94/68 showed very good (72%-100%) leishmanicidal activity in //; viiro [^U] 
thymidine uptake system. In parasite SOD system nine compounds showed positive 
response, six were inactive and eight showed negative activity. In c.x-vivo system 
94/65 and 94/78 were found to be toxic, 94/68 and 94/76 had 91%-95% activities 
while some of the compoimds tested were found to be inactive. 94/60 (80%), 94/62 
(78.3%), 94/65 (81.3%) and 92/304 (79%) exhibited in vivo antileishmanial activity. 
Leishmanicidal activity of forty nine nitroalkane derivatives has been listed in 
Table-4. All eleven compoimds of the series l-(cycloalken-l-yl)-l-nitro-2-
substituted phenyl ethenes showed positive activity in ["^ H] thymidine uptake test. Of 
these all compounds except 93/215 and 93/568 showed positive activity in SOD 
system as well. 93/211 was found to be toxic in ex-vivo system. The compounds 
tested in in vivo system remained inactive. Total eight compounds of I -(cycloalken-
l->l)-l-nitro-l-(2-substituted ethyl)-2-substituted phenyl ethenes were synthesized. 
Out of these, six compounds possessed 90%-99% activity in in vitro [^ H] thymidine 
uptake, while five compounds showed positive activity in SOD system. 94/456, 
94/466 and 94/461 were found to be toxic while 94/458 possessed 80% activity in 
ex vivo system. 94/458 was the only compound of this series which possessed 74% 
biological activity in golden hamsters. Two compounds of the chemical structure 4-
cycloalkenyl-4-nitro-5-substituted phenyl ethyl pentanoate were found to possess 
positive activity in all assay systems except ex-vivo. sixteen compounds of the series 
1-methyl-3-nitro-3-substituted ethyl-4-substituted phenyl pyrrolidines were 
synthesized, out of which, six were found positive in [^ H] thymidine uptake test. 
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However, all the sixteen compounds were found to be inactive in SOD system. 
Therefore, it was not considered worthwhile to test in other systems. Out of four 
compounds of 3-substituted ethyl-4- substituted phenyl-1-methyl-lH-pyrroie-2,5-
dione series, only t\vo compounds (96/308, 96/556) showed positive activity in in 
viiro ['^ H] thymidine uptake system. However, none was positive in SOD assay 
system. 1 H-4-(3-azido-cyclohexen-l -yl)-5-substituted phenyl-1,2,3-triazoles 
(96/332, 96/333) were found to be positive only in [^ H] thymidine uptake system. 2 
compounds of l-(cyclohex-2-ene-l-yl)-2-methoxy-l-nitro-2-substitiited phenyl 
ethylidine were positive only in ["^ H] thymidine uptake system. 4 compounds of 1-
cyclohex-( 1-methoxy) -yl-4-methoxy-3-substituted phenyl-1 H-pynole-2,5-diones 
were synthesized, out of which 96/548, 96/550 and 96/551 showed positive 
response in ['H] thymidine uptake test. 96/548 and 96/551 were found to be positive 
in SOD test while 96/549 was inactive in both the in vitro tests. 93/550 was toxic in 
ex vivo but inactive in in vivo test system. 
Table-5 demonstrates the biological activity associated with phenyl 
acetonitrile derivatives. Six compounds of phenyl acetonitrile a-anilino series were 
synthesized, out of these, three compounds (93/584, 93/588, 96/280) showed 
positive activity in [-^ H] thymidine uptake test, while 93/557, 93/558, 93/584 
showed significant inhibition of parasite SOD. 92/187 was found to be highly active 
in e;c-v;vo and in vivo tests but inactive in in vitro tests. 93/557, 93/558, 93/584, 
93/588 possessed moderate activity (50%-74%) in in vivo system while 96/280 
remained inactive, fourteen compounds of a-anilino a-chloroacetyl phenyl 
acetonitrile were synthesized. Out of these, five compounds (95/417, 95/418, 
95/419, 95/420 & 95/364) caused 100% inhibition of parasite growth in vitro. 
96/343, 96/345, 96/595 & 96/598) showed positive response in vitro. 5 compounds 
(95/417, 95/419, 95/423, 95/532 and 96/598) were found positive in SOD system. 
95/422 was found to be toxic in ex-vivo system but inactive in in vivo system. 
95/418, 95/419 and 95/420 possessed a good antileishmanial activity in in vivo 
(74%-88%). 95/419 was toxic in ex vivo system. 
Table-6 represents the biological activity associated with malonitrile 
derivatives. It was found that none of the compounds tested in vitro showed 
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antileishmanial activity, hence it was considered Mile to test in otlier systems 
except 94/690 and 94/691 which showed positive response while inactive in in vivo. 
The antileishmanial activity of bisquinolines, quinolines and isoquinolines is 
summarized in Table-7. Four compounds of 4-aminoquinoline series were 
synthesized. Out of these four, 95/472 and 95/473 inhibited parasite proliferation, all 
the four compounds inhibited parasite SOD to a very significant level. 95/555 was 
found to be toxic in ex-vivo system. Out of the three compounds of 5-amino 
isoquinoline series, 95/155 & 95/372 were found to be active in in vitro system but 
inactive in ex-vivo system. Bisquinolines were found to be inactive in [^ H] 
tlnmidine uptake system. 
Table-8 comprises compounds of different series of exploratory nature (viz. 
imidazoles, aplysinopsin analogues, chalcones and indoles). Only 93/79 (100%), 
94/637 (61%), 94/638 (73%) showed activity in in vitro system. Chalcones were 
totally inactive in all the in vitro systems. 91/515 (-29%), 93/127 (-27%), 93/158 (-
20%), 96/72 (-53%), 96/69 (-24%), 93/397 (-50%), 93/79 (-41%) and 92/454 (-
47%) inhibited parasite SOD significantly. 96/69 and 96/72 showed some activity in 
ex vivo system (50-60%). 92/453, 91/58, 93/127, 93/397, 93/79 and 92/454 caused 
significant reduction in amastigote number to the extent of 70% to 80%. 
4.4 DISCUSSION 
The peculiar intra-macrophage habitat of leishmanial parasites has made 
screening of potential antileishmanial agents conceptually difficult and complicated. 
In an established case of VL undergoing treatment, the parasite has to interact with 
host immune system and chemotherapeutic agents. Clinically, in human subjects, 
treatment is started only when symptoms of the disease become evident. 
A similar situation is observed while making an assessment of any candidate 
antileishmanial agent or drug, after the establishment of infection in an experimental 
animal. The success of chemotherapy depends on the removal of the parasite and an 
improvement in the immune status which is drastically suppressed during infection. 
In established cases of VL in golden hamsters, it is seen that stibanate, causes 
inhibition of multiplication of L donovani amastigotes in spleen by 84% at a dose 
schedule of 10 mg/kg/day x 5, i.p. Even by increasing the dose or number of days to 
near toxic levels, this drug fails to bring about total elimination of the parasites. 
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Even an early start of drug treatment after infection when the parasite load was very 
low did not produce the desired results. This suggets that a particular dnig though 
active, fails to kill and eliminate all the parasites. The surviving parasites increase in 
number in course of time. Tliese findings also suggest that in human patients as well, 
all the parasites are not killed, and the surviving few which remain are taken care of 
by the host immune system. It has been seen clinically also that those cases which 
fail to respond to stibanate therapy are immunologically suppressed. 
Pentamidine, the second line drug used in stibanate unresponsive cases, also 
failed to clear all the parasites, tiiougji at optimum dose level of 2.5 mg/kg/day x 5, 
i.p., there was 89% inhibition in parasitic burden in spleen. 
The most unusual feature observed with both these drugs was that though 
they caused significant inhibition in the multiplication of the parasites, there was no 
increase in the survival time of animals as compared to the untreated infected 
control. Normally with the elimination of the paraites, the treated animals should 
have lived much longer, but no definitive reason has been suggested to explain this 
phenomenon. However, it seems that there is a sudden release of large amount of 
antigen in the form of dead parasites as a result of chemotherapy which may cause 
anaphylactoid reaction, causing death. 
It should be noted that direct comparison between the efficacies of drugs 
against infection is not always possible. Many factors such as bioavailability toxicity 
and drug metabolism may influence in vivo activity. 
Defining the mode of action of various drugs in the treatment of leishmaniasis 
is of considerable interest since a better insight into these processes may explain the 
mechanism of drug resistance and identification of alternative pathways for 
chemotherapy and eventually lead to the synthesis of new and more potent drugs. In 
til J present study we have demonstrated the biological activity associated with 
analogues of different drugs/compounds {viz. pentamidine, flised pyrimidines, 
nitroalkanes, phenyl aceto nitriles, malonitriles, aplysinopsin, imida-zoles, indoles, 
chalcones, quinolines, bisquinolines, isoquinolines and polyamines). 
Leishmanial infection induces a strong increase in oxygen consumption of 
macrophages, which leads to a significant generation of oxidative metabolites 
(H2O2, OH'OI), through NAD(P)H oxidase system and resulting barrage of 
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activated oxygen may then destroy tlie ingested microorganisms. Leishmania 
parasites are provided with a number of substances that serve to neutrahze or 
ehminate oxidative metabolites. Leishmania parasites contain a very high activity of 
SOD enzyme, w h^ich causes dismutation of Ol to H2O2. Leishmanial SOD has an 
unusual pattern of responses to known SOD inhibitors. Sodium cyanide, which 
inhibits Cu/Zn SODs, causes no inhibition of SOD activity of Leishmania. In 
contrast, the SOD activity of Leishmania is rapidly inibited by H2O2, whereas Mn-
SODs are insensitive to inhibition by H2O2. Leishmania SOD is inhibited by as 
much as 70% by sodium azide, an inhibitor of Fe-SODs. Hence, Leishmania contain 
an SOD which is different from host SOD and hence a specific inhibitor of it may 
serve as a usefiil antileishmanial agent. 
Effect of standard antileishmanials viz; stibanate, pentamidine isethionate, 
allopurinol and nystatin on parasite SOD inhibition showed consistency, hence this 
enzyme was selected as a model developing for enzyme based in vitro screening of 
newly synthesized antileishmanial compounds. Inhibition of parasitic antioxidant 
enzymes by stibanate and pentamidine isethionate suggests that, this may be one of 
the mechanisms of their antileishmanial activity. 
Results of the in vitro and ex-vivo screening of compounds indicate that very 
few compounds exhibit antileishmanial activity in all the three assay systems. Of the 
three assay systems, parasite growth inhibition monitored by [^ H] thymidine uptake 
iloes not suggest any possible mode of action while the effect of the compounds on 
parasite SOD does indicate a possible mechanism of action. The effect of test 
compound(s) can be classified under the following heads: 
(i) Compounds capable of depressing parasite SOD and elevating host SOD 
activities, 
(ii) Compounds capable of depressing parasite SOD activity without affecting 
host SOD, 
(iii) Compounds capable of influencing only host SOD, 
(iv) Compounds capable of depressing both host and parasite SODs, 
(v) Compoimds which do not interact with either host or parasite SOD. 
In principle, a compound causing specific inhibition of leishmanial SOD with 
no significant effect on the host enzyme may be a potential leishmanicidal agent. 
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Activity was tested at 50 ^m concentration of the drug/compound. The compound 
showing more than 10% inhibition of the parasite enzyme and no inhibition of the 
host enzyme was considered as positive. All the standard antileishmanial drugs 
showed good correlation with parasite SOD inhibition together with boosting up 
host SOD. 
Several attempts have been made in the past to find out more potent and/or 
less toxic congeners of pentamidine (Bell et al., 1990). The results presented here 
show that the addition of benzyl, cyclopropyl or cycloheptyl moities diminish the 
antileishmanial activity while substitution with ethyl, isopropyl, piperidino-3-propyl 
moities showed significantly better antileishmanial activity in vivo. Differential 
cellular uptake of these diamidines may be responsible for this variation Aromatic 
diamidines bind reversibly to A+T rich sites in the minor groove of p-fonn of DNA 
duplexes (Dampor & Paton, 1976). Although biological effects of diamidines have 
been correlated with their DNA binding activity, the mechanism for their selective 
antiprotozoal/ antileishmanial action is still poorly understood. All the diamidines 
tested against parasite SOD showed inliibition of the enzyme to varying degree 
suggesting SOD inhibition as one of the factor responsible for antileishmanial 
activity of these compounds. 
Interruption in polyarriine metabolism has been identified as a potential target 
for chemotherapy of protozoal infections including leislimaniasis. Poly amines play 
an important role in cellular proliferation and differentiation. The inhibitors of 
polyamine biosynthesis however, have not shown promising results in the treatment 
of leishmaniasis. Another approach therefore, has been identification of cytotoxic 
polyamine analogues. The polyamine analogues may act on the parasites through 
different mechanisms. First, they may interfere with the biosynthesis of polyamines 
by inhibiting the enzymes of this pathway. Secondly, they may be taken up by the 
cells through polyamine transporters and may have stronger affinity for the DNA 
than the natural polyamines. Both the actions are likely to cause selective depletion 
of natural polyamines and check the growth and proliferation of parasitic cells. All 
the polyamine analogues tested showed parasite SOD inhibition, however, none of 
these analogues tested showed promising antileishmanial activity in vivo. The 
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analogues are either not able to reach the target site or are rapidly metabolized 
through poly amine oxidase system. 
Bisbenzyl analogues of polyamines have been reported to have potent 
antileislimanial activity Stabilization of the positive charge resulting in more potent 
interaction of bis benzyl analogues with the leishmanial DNA than the parent 
compound may be responsible for better antileishmanial action of these analogues 
(Steiger & Meshnik, 1977; Bera, 1987). 
Various compounds belonging to different series were synthesized in order to 
explore the potential antileishmanial efficacy. Only three compounds (94/60, 94/62 
& 94/65) of pyrazolo pyrimidine series showed an activity of about 79-81% in vivo. 
All the three compounds showed positive activity in [^ H] thymidine uptake system. 
However, in parasite SOD test whereas 94/62 and 94/65 showed inhibition, 
compound 94/60 behaved the other way thus giving a false negative result in 
parasite SOD test system, suggesting that, this class of compounds can not be tested 
through parasite SOD system. In nitroalkane series, 4-cyc!oalkenyl-4-nitro-5-
substituted phenyl ethyl pentonate showed 70% antileishmanial activity. 92/187 
(phenyl acetonitrile a-anilino) was found to be 80% active at 50 mg/kg/day x 5, i.p 
but by varying doses and duration of administration, the activity of this compound 
could not be improved. Also, it does not affect the parasite growth and SOD in 
vitro. This suggest that, it might be converted into a metabolite in vivo which is 
active. Five analogues of 92/187 were synthesized with various substitutions to 
improve the antileislimanial activity but this could not be achieved. Two compounds 
of a-anilino, a-chloroacetyl phenyl aceto nitrile (95/419, 94/420) possessed very 
good antileislimanial activity in vivo. 91/58 (pyrrozolone) and 93/127 (3 substituted 
indole) are 75%, 80% active in vivo and showed significant inhibition of parasite 
SOD with boosting of host SOD. 
Thus we may conclude that parasite SOD inhibition shows a good correlation 
with the in vivo antileishmanial activity of the compounds and can be used as an in 
vitro screen as far as the compounds of these series diamidines, nitroalkanes, 
polyamines, malonitriles, imidazoles, quinolines, isoquinolines, bisquinolines are 
concerned. In case of pyrazolo pyrimidines and phenyl aceto nitriles, some 
compounds gave false negative results (negative in SOD test but active in in vivo) 
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and hence SOD assay will not be a proper in vitro screen for the compounds of this 
series. 
All the compounds have so far been screened in vivo on the 7th day post 
ueatment. The efficacy of these compounds in countering leishmanial infection with 
increasing post treatment intervals is yet to be measured. Further, the studies have to 
be undertaken to find out whether these compounds can potentiate the host immune 
system (post infection) signficantly or restore it to its original state. 
Till date, a very good correlation has been obtained betv.'een in vitro-in vivo 
activity. The compounds of some series viz: pyrazolopyrimidines and phenyl 
acetonitriles showed significant false negatives. The compounds of diamidines, 
nitroalkanes, malonitriles, quinolines, bisquinolines, isoquinolines, aplysinopsin, 
indoles, imidazoles, chalcones may be primarily screened through SOD system. 
There are certain limitations associated with the in vitro screening systems. 
1. The compounds acting through "modulation of host immune system" would 
escape tlirough these screens e.g. some plant products and lymphokines. 
2. The compounds which lead to leishmanicidal action after "primary metabolic 
biotransformation" would also escape through these screens e.g. sodium 
stibogluconate. 
3. The insoluble compounds can not be tested. 
A better understanding of the mechanisms by which these compounds act 
would greatly aid in the design of more effective antileishmanial agents. The 
continuing emergence of drug resistant parasites makes the development of such 
agents all the more vital. This study has identified certain compounds with 
promising antileishmanial activity that are worthy of ftirther in vitro and in vivo 
studies to assess their therapeutic potential. 
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SECTION 5.0 
STATUS OF OXIDATIVE STRESS AND 
ANTIOXIDANT DEFENCE SYSTEM DURING 
L. Z)OAfOK4iV/INFECTION AND THE 
EFFECT OF SODIUM STIBOGLUCONATE 
TREATMENT IN MESOCRICETUS A URA TVS 
5.1 INTRODUCTION 
Oxidant species such as superoxide anion (Of), hydrogen peroxide (H2O2) 
and hydroxyl radical (OH) have been widely implicated in the pathogenesis of 
multiple diseased states (Fridovich, 1986). Active oxygen species are normally 
generated in vivo, but the presence of superoxide dismutase (SOD), catalase 
(CAT), glutathione-peroxidase (GPx) and a variety of other antioxidants limit 
their concentrations to non-toxic levels (Pryor, 1984). It has also been 
emphasized that oxygen-centred free radicals play a key role in carrying out 
tissue damage. 
Leishmanial infection is a pathological disturbance which affects the host 
biosystem. It exhibits a specific tropism for the mononuclear piiagocytic system. 
It inhabits an acidic lysosomal compartment that has an unrestricted fusion with 
vacuoles containing lysosomal hydrolases. The principal organs which undergo 
deleterious changes are the liver, spleen, thymus, lymphnodes and bone-marrow. 
The abnormalities in liver and spleen during leishmanial infection lead to 
hepatosplenomegaly. Systematic comparison of survival of L donovani in 
different macrophage populations has shown that liver and spleen support the 
maximum growth of parasites (Crocker et ai, 1987). Macrophages, in an 
activated state are endowed with the capacity to generate reactive oxygen 
species, resulting in antimicrobial activity. However, the amastigotes of L 
(hnovani which trigger respiratory burst; are able to survive. This ability of 
survival is attributable to amastigotes having higher levels of GPx, SOD and 
CAT. (Pearson et ai, 1983). Intracellular amastigotes are also capable of down-
regulating the macrophage oxygen- dependent microbicidal potential 
(Buchmuller-Rouiller & Mauel, 1987). Survival of L. donovani amastigotes in 
these tissues and the defence mechanism evolved by the host to cope up with the 
infection is poorly understood. Much work in the field of host-parasite 
relationship, regarding the status of oxidative stress and defence systems has 
been confined to liver only (Singh et ai, 1991; Kausalaya et al., 1992). The 
present study deals with the status of glutathione and antioxidant defence system 
during Leishmania donovani infecfion and the effect of sodium stibogluconate 
treatment in lymphoid tissues of golden hamsters. 
5.2 MATERIALS AND METHODS 
5.2.1 Parasite: L donovani (MHOM/IN/80/Dd8) 
5.2.2 Host: Golden hamster {Mesocricetus auratus) 
5.2.3 Infection and drug therapy: Male golden hamsters (40-45 gins) were 
divided into four groups (i) healthy control, (ii) drug treated control, (iii) infected 
and (iv) dnig treated infected; each group containing 6-8 animals. Animals of 
group III & IV were infected intracardially with 10 million L. donovani 
amastigotes. The infected animals containing 10-20 amastigotes/lOO spleen cell 
nuclei as assessed by spleen biopsy on 25th day PI were used for treatment. The 
drug treatment was carried out by administering sodium stibogluconate at a dose, 
10 mg/kg/day intraperitoneally (ip) for five days in animals of groups II and IV. 
On the 7th day post treatment (PT) all animals were deeply anesthetized w4th 
chloroform after being fasted for 12 hr. The liver and spleen of each animal were 
excised and the degree of infection in both the tissues was monitored as 
described earlier (Bhatnagar et ai, 1989). 
5.2.4 Tissue processing: To isolate peritoneal exudate cells (PEC), animals were 
given intraperitoneally 10 ml of Hank's balanced salt solution (HBSS). After few 
minutes, peritoneal cavity was cut open, peritoneal fluid was collected and 
centrifiiged at 800 rpm for 10 min at 4°C. The sediment of PEC was washed 
twice with 154 mM KCl. Bone marrow cells (BMC) were collected fi-om femur 
and tibia bones. The cells were pelleted by centriftigation at 800 rpm for 10 min 
at 4"C and washed twice as above. Tissues namely spleen, lymplinodes (LN) and 
thymus were excised out and washed with KCl (154 mM). 
5.2.5 Biochemical assays: 10% homogenate of all tissues was prepared in 
isotonic KCl. An aliquot of total homogenate was used for the estimation of lipid 
peroxides (Olikawa et al., 1979). Rest of it was cnetriftiged at 10,000 rpm for 20 
min and supernatant was used for assay of xanthine oxidase (XO; Horecker et 
ai, 1949), superoxide dismutase (SOD; Misra & Fridovich, 1971), catalase 
(CAT; Aebi, 1984), glutathione reductase (GR; Racker, 1955), glutathione 
peroxidase (GPx; Awasthi et ai, 1975), and glutathione-S-transferase (GST, 
Habig & Jakoby, 1981). Oxidized and reduced glutathione were measured in 
deproteinised whole cell homogenate (Hissin & Hilf, 1976). Protein was 
measured by Folin phenol method (Lowry et ai, 1951), using BSA as standard. 
Statistical analysis: All results are reported as mean + standard error. 
Significance was calculated using student't' test. 
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5.3 RESULTS 
Fig. 1 shows the in vivo effect of SSG (10 mg/kg/dayx 5, ip) on the 
parasitic burden in Uver and spleen. The number of amastigotes per 100 cell 
nuclei declined from 46 to 5.4 (88.3% decrease) in liver and from 96.0 to 15.0 
(84.4% decrease) in spleen. 
Biochemical changes 
5.3.1 Spleen: The results obtained show an increased oxidative stress in infected 
spleen (Table-1) as monitored by significant increased levels of LPO (38%), XO 
(71%), SOD (39%), Gpx (38%) and GSH (44%). This was accompained by 
significant decrease in CAT (51%), GST (33%) and GSSG (23%). GR did not 
exhibit any significant change during infection. The deranged parameters of 
antioxidant defence system showed a trend towards nonnalcy after SSG 
treatment. However, parameters of oxidative stress i.e. LPO (55%) and XO 
(88%) exhibited fiirther increase (55% and 188% respectively as compared to 
nornial). SSG treatment to normal healthy animals caused decrease in GR (21%), 
GPx (21%), GSH (21%) and GSSG (12%) and increase in LPO (11%), SOD 
(36%) and GST (28%), while CAT and XO remained unchanged. 
5.3.2 Thymus: XO could not be detected in thymus (Table-2). The activities of 
CAT (18%), GST (882%) and levels of GSSG (65%) and LPO (64%) were 
increased significantly during infection. The levels of SOD (32%) and GSH 
(13%) decreased while GR and GPx remained unchanged during infection. 
Treatment of infected animals with SSG did not cause restoration of either 
oxidative or antioxidative parameters, rather caused significant decrease in GPx 
(18%) activity. SSG administration to normal healthy animals resulted in 
increased activities of CAT (48%), GR (13%), GST (22%) and decreased 
activity of GPx (21%). 
5.3.3 Lymphnodes: Levels of GSH (22%), GSSG (190%), GPx (15%) and GR 
(27%) increased significantly while GST (71%) activity decreased during 
infection. However, the other parameters of oxidative stress and antioxidant 
defence remained unchanged (Table-3). SSG treatment to infected animals 
caused reduction in GST (38%) activity and increase in LPO (87%), XO (14%), 
GPx (34%) and GSSG (278%), however, the levels of GSH reached normalcy. 
SSG treatment to normal healthy aiumals did not cause much damage to thymus. 
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5.3.4 PEC & BMC : PEC and BMC did not exhibit significant alteration during 
infection as evident from unaltered levels of LPO and XO. XO could not be 
detected in PEC and SOD could not be detected in both the cells (Table 4&5). 
There was a singificant increase in activity of CAT (109% in PEC, 25% in BMC) 
and in levels of GSH (84% in PEC, 45% in BMC) and GSSG (61% in PEC). 
SSG treatment of infected animals resulted in increased levels of LPO (41% in 
PEC, 21% in BMC) and restoration of GSH and , GSSG levels when compared 
with nonnal animals. Drug treatment caused significant decrease in GR activity 
in PEC both in normal and infected animals. There is significant increase in GST 
activity in PEC (45%) while decrease in BMC (10%). 
5.4 DISCUSSION 
L donovani infection in golden hamsters results in enhanced oxidative 
stress and decreased antioxidant defence system indices. The involvement of 
superoxide (02 )^ and its related species has been reported in pathophysiological 
disorders caused by various pathogens such as Schistosoma niansoni (Chensue et 
al., 1984), Nippotrongylus hrasiliensis (Smith & Bryant, 1989), Trypanosoma 
hfucei (Arrick et al., \9S\), Acanthocheilonema viteae (Batra et al., 1990) and 
Plasmodium species (Srivastava et al., 1994). Oelshlegel & Brewer (1975) 
reported the generation of superoxide which in turn was hantiftil to the host as 
well as to the parasite. Hence, the present invesfigafion describes the deleterious 
effects of oxidiative stress caused by L. donovani infection and the status of 
antioxidant defence systems of the host during infection and cure. 
L donovani infecfion leads to the formation of activated oxygen species 
such as Oi", which in tiun increase lipid peroxide levels in infected tissues. It was 
also observed that there is increase in activity of XO levels during infection 
which is an index of Of formation. Hodgson and Fridovich (1976) reported the 
formation of 02^ during the aerobic action of XO. Further, SOD, which causes 
the dismutation of 02*"into H2O2 also increased in spleen and thymus. 
Results of the present study show that, during L. donovani infection in 
golden hamsters, significant changes of varying degrees take place in ROS 
generating and scavenging system in lymphoid tissues. However, the overall 
impact of these changes seems to conclude in maintaining the lower 
concentration of ROS in situ that can be scavenged by the parasite antioxidant 
defence system and provides a favourable atmosphere to the parasite to survive. 
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The elevated levels of superoxide anion in infected spleen can be quickly 
removed by elevated levels of GSH, a potent scavenger of ROS (Deleve & 
Kaplowitz, 1991). Decreased GST activity is associated with increased levels of 
GSH. In thymus, the elevated levels of LPO indicate the increased production of 
ROS, which can be scavenged by catalase (TabIe-2). Here, GST activity is 
increased resulting in decreased levels of GSH. Levels of LPO remained 
unchanged in lymphnodes, PEC and BMC but GSH levels increased in all the 
three tissues (Table 3,4,5). 
The exact mechanism of action and basis for selective toxicity of sodium 
stibogluconate remains unknown. However, it appears to disnipt the balance 
between ROS generating and scavenging systems. Several properties of the 
pentavalent antimonial agents have been suggested to contribute to their activity. 
Carbohydrates form water-soluble complexes with antimony and may serve to 
deliver antimonial dnigs to host macrophages. Relatively nontoxic pentavalent 
antimony may be a prodrug that is converted to more toxic trivalent antimony at 
or near the site of action. Interactions of antimony with key sulfahydryl groups 
may be a major mechanism of action and/or toxicity (Roberts et ai, 1995). 
Glutathione, a tripeptide thiol found in virtually all cells, fimctions in 
metabolism, transport and cellular protection. It participates in the reduction of 
disulfides and other molecules and conjugates with compounds of exogenous and 
endogenous origin. It protects cells against the destructive effects of reactive 
oxygen intennediates and free radicals. In spleen and thymus (Table 1 & 2) the 
levels of GSH decreased and that of GSSG increased after drug treatment. This, 
might be due to the interaction of SSG with GSH. Reduced levels of GSH lead to 
more production of superoxides (LPO levels were also increased) as it is of 
major importance in reduction of hydrogen peroxide and organic peroxides by 
reaction catalysed by other proteins which also exhibit GSH-S-transferase 
activity. This was accompanied by normalization/lowering of increased 
antioxidant parameters resulting in increased ROS concentration in situ. These 
altered conditions appear to be injurious to parasite as a result parasite does not 
survive. Intracellular GSH content is closely related to membrane integrity. 
During leishmanial infection and its treatment, increased lipid peroxidation may 
affect the cell membrane integrity due to alteration in defence system. Moreover, 
inhibition of antioxidant enzymes of both host and parasite by sodium 
stibogluconate may represent one of its mode of action for the chemotherapeutic 
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activity and also its toxicity. Thus, the infected treated animals are under pressure 
from two sides viz: burden of L. donovani parasites and retention of drug in these 
tissues due to decreased capacity of mixed function oxidase system to metabolize 
the drug (Mittal et al.. In Press). This is probably the reason that inspite of 
clearance of parasite by stibanate, the survival period of infected animals was 
comparatively larger than that of infected animals treated with stibanate. 
Some recent studies have highlighted the failure of macrophage population 
to generate the toxic oxygen products (McCabe & Mullins, 1990). These studies 
have made it increasingly difficult to explain the role of oxygen metabolites in 
limiting the infection. Importance of T-cell dependent control of acute 
leislunanial infection has also been reported (Squires et al., 1989). This 
information coupled with failure of respiratory burst activity suggests a role for 
an ahemate mechanism of leishmanicidal activity of macrophages. 
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SECTION 6.0 
PROTECTIVE EFFECT OF PICROLIV FROM 
PICRORHIZA KURROA AGAINST 
LEISHMANIA DONOVANIYN¥^CHO^m 
MESOCRICETUS A URA TVS 
6.1 INTRODUCTION 
Sodium stibogluconate (stibanate; SSG), a pentavalent antimonial, remains 
the first line dnig for treatment of visceral leishmaniasis (VL) (WHO, 1990). In 
recent years, higher doses and longer durations of stibanate were administered in 
order to achieve greater efficacy (Ballou et ai, 1987; WHO, 1990; Hepburn et ai, 
1993/ Antimonial chemotherapy increases the survival rate to over 90% (Roberts et 
al., 1995). However, the toxicity of these agents (Martinez et ai, 1988) and 
persistence of side-effects even after modification of the dose level and duration of 
treatment are major drawbacks (Mukherjee et ai, 1990). Despite its clinical use for 
over half a century, the mechanism of action and toxicity of SSG still remains 
unknown. The side effects of the antimony drugs are vomitting, diarrhoea, 
abdominal pain, anorexia, malaise, weakness and muscle pain. Liver and renal 
damage, shock, itching, fever, dizziness, heartburn and headache may also be 
observed (McGreevy & Marsden, 1986). Accumulation of antimony in cardiac 
tissues may produce changes in ECG and cardiac rhythm. Further Grogl et al (1992) 
have reported about the parasite being resistant to antimonials. 
In L. donovani infection, liver is the primary site of infection with marked 
biochemical alterations (Singh et ai, 1989). Kupffer cells in the liver, harbouring 
Leishmania donovani become enlarged, their mitochondria get deformed, the 
endoplasmic reticulum becomes disrupted and there is localized rupture of cell wall 
(Singh et aL^ 1989). Transient abnormalities of serum aminotransferases have also 
been recorded during treatment of cutaneous leishamniasis and these appear to be 
dose dependent (Hepburn et al., 1993). On the other hand, sodium stibogluconate 
though reduces the parasitic burden, itself is associated with significant 
hepatocellular damage and hepatic functional impairment in both clinical and 
experimental leishmaniasis (Hepburn et ai, 1994; Mittal et ai, in press). Thus there 
is an urgent need of an agent which can cumulatively or alone kill the parasites and 
also restore the fimctions of liver and put the system to normalcy. 
Picroliv, a standardized firaction isolated fi:om the ethanol extract of root and 
rhizome of Picrorhiza kurroa (Scrophulariaceae; common name Kutki) containing 
iridoid glycosides is well known for its protective action against liver damage 
caused by various hepatotoxins including parasitic disease e.g. Plasmodium berghei 
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infection in Mastomys natalensis [Saksena et al., 1996; Chander et ai, 1994). It 
possesses strong immunostimulant activity and showed significant protection 
against challenge with L. donovani promastigotes in experimental golden hamsters 
{?\in eta!., 1992). 
The present study was undertaken with a view to study the cidal effect of 
Picroliv and SSG separately on Leishmania parasites and also to exploit the 
possibility of its use in combination therapy. We have also monitored the 
compositional and enzymatic changes in liver during L. donovani infection followed 
by treatment with Picroliv and SSG. 
6.2 MATERIALS AND METHODS 
6.2.1 Parasite : L. donovani (MHOM/IN/80/Dd8) 
6.2.2 Host: Mesochcetus auratus 
6.2.3 Infection & Drug Therapy: The experiment inolved two groups of hamsters; 
normal controls and infected. The second group of hamsters was infected 
intracardially with 1x10^ amastigotes and the first group was sham inoculated with 
Locke's solution. Both the groups were flirther equally divided into four sub groups; 
stibanate, Picroliv, and stibanate + Picroliv treated and untreated groups, giving in 
all eight experimental sub-groups, each containing 6-8 animals: 
Sub-group I Normal untreated 
Sub-group II Normal stibanate treated 
Sub-group III Normal Picroliv treated 
Sub-group IV Normal stibanate + Picroliv treated 
Sub-group V Infected untreated 
Sub-group VI Infected stibanate treated 
Sub-group VII Infected Picroliv treated 
Sub-group VIII Infected stibanate + Picroliv treated 
On day 25 post infection (PI) the infected animals containing 10-20 
amastigotes/100 cell nuclei (as assessed by spleen biopsy) were used for drug 
treatment. The animals of sub-groups II, IV, VI, VIII were treated with stibanate 
(10 mg/kg) intraperitoneally for 5 consecutive days and those of sub groups I, III, V 
& VII received only normal saline and served as simultaneous controls. The animals 
were given rest of 5 days. After which, the animals of groups III, IV, VII and VIII 
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were treated with Picroliv (12.5 mg/kg) for seven consecutive days orally and the 
animals of sub-groups I, II, V and VI received normal saline. 
From each such group five animals were sacrificed by deeply anaesthetizing 
with chloroform, on day 7 and 21 post treatment (PT). Dab smears fi-om spleen were 
prepared to ascertain parasitic burden (amastigotes/100 cell nuclei) (Bhatnagar et 
ai, 1989). The liver of each animal was excised and used for biochemical 
estimations. 
6.2.4 Biochemical Assays: The liver was washed with chilled normal saline and 
10% (WA^) homogenates were prepared in ice-cold 1.15% KCl solution. The levels 
of lipid peroxides (LPO; Olikawa et al., 1979) and bilirubin (Jendrassik & Grof, 
1938) were estimated in total homogenate. The cell debris of the homogenate was 
removed by centrifguation at 2000 rpm for 10 min and following enzymes were 
assayed in the supernatant according to standard protocols. Glutamate-oxaloacetate 
transaminase (GOT) and glutamate pyruvate transaminase (GPT; Reitman & 
Frankel, 1957); y-glutamyl transpeptidase (y-GT; Boelsterli & Zbinden, 1979), acid 
phosphatase (AP04ase; Wright et ai, 1972); acid ribonuclease (ARNase; deDuve el 
ai, 1955); succinate dehydrogenase (SDH; Slater & Bonner; 1952); Glucose-6-
phosphatase (G-6-P04ase; Hubscher & West, 1965). Protein was measured 
according to Lowry et al., (1951) using BSA as standard. 
Statistical Analysis 
The results are expressed as mean + standard error of five animals. The 
values of all groups were compared by students 't' test and P values less than 0.05 
were considered as significant. 
6.3 RESULTS 
Fig. 1 shows the reduction in number of amastigotes in golden hamsters 
treated with SSG (10 mg/kg/day, i.p. x 5) and Picroliv (12.5 mg/kg/day,oral x 7) 
alone and in combination (SSG 10 mg/kg/day, i.p. x 5 followed by Picroliv 12.5 
mg/kg/day oral x 7). The parasite count in spleen was followed on day 7 and 21 of 
the last dose of SSG/Picrolv. The untreated infected control (group V) showed 
148.75 + 10.42 and 219.75 + 25.87 amastigotes/ 100 spleen cell nuclei on 7th and 
21st day respectively while the corresponding values in the SSG treated animals 
were 31.5 + 1.88 and 65.8 + 10.06 indicating 79% and 70% reduction in parasite 
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load. The reduction in parasite number with Picrohv alone was 51.0 + 14.4 (66%) 
and 65.0 + 10.49 (70%) while in combination with SSG it was 22.0 + 7.8 (85%) and 
58.0 + 4.30 (74%) on 7th and 21st day respectively showing better protection and 
reduction in number of amastigotes in combined therapy. 
Biochemical changes 
Figs. 2-10 are the graphical representations of various enzymatic parameters 
in different groups of animals on 7th and 21st day (PT). Picroliv per se did not have 
any effect on biochemical markers when given to normal healthy controls (data not 
presented). SSG (sub group II) at 10 mg/kg/day, i.p. x 5 caused significant changes 
in the levels of hepatospecific enzymes in normal animals. On 7th day PT of last 
dose of SSG, there was significant increase in activities of GOT (10%), GPT (34%), 
SDH (33%), G-6-P04ase (25%), y-GT (76%), AP04ase (33%) and ARNase (23%), 
and in levels of LPO (49%) and bilirubin (36%). On 21st day PT the magnitude of 
change in all the above described parameters was less marked with GOT & SDH 
reverting back to their normal values. 
Picroliv when administered to SSG treated normal animals (subgroup IV) 
significantly protected the altered levels of all the deranged parameters due to the 
effect of SSG to the extent of 39% to 60% in case of 7th day and 15% to 58% in 
case of 21 St day PT of last dose of Picroliv when compared with nonnal stibanate 
treated animals. 
L. donovani infection caused severe liver damage (sub group V) which 
showed an increasing trend as the infection progressed in spleen. It was observed 
that, on 7th day PT, levels of GOT (43%), GPT (36%), SDH (49%), G-6-P04ase 
(43%), Y-GT (179%), AP04ase (55%), ARNase (80%), LPO (103%) and bilirubin 
(70%) were altered significantly. However, on day 21 PT the degree of change in 
aforementioned parameters increased ftirther when compared with normal healthy 
controls. 
SSG when administered to L. donovani infected golden hamsters (sub group 
VI) could not restore the altered parameters to normal levels but further aggravated 
the magnitude of percent change by 10% to 20% in various parameters when 
compared with L. donovani infected untreated animals (subgroup V), on day 7 PT. 
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Legend to Fig. 1: Percent inhibition in amastigote number in spleen of L. donovani 
infected golden hamsters during treatment with Sodium Stibogluconate, Picroliv, 
and Sodium stibogluconate + Picroliv on 7th day and 21st day PT. 
Legends to Fig 2- Fig 10 
Values are mean ± S.E. of 5 animals in each group. Vertical lines on bars indicate 
S.E. values. Values marked with alphabetical letters differ significantly. Values 
inside the vertical bars show the percent change while above the vertical bars show 
the percent protection. 
P values: 
NS', "p >0.05, ^ p > O.Ol, 'p < 0.001 with respect to normal 
NS\ *p>0.05, Jp>0.01, ' ^ < 0.001 with respect to infected 
NS\ ''p>0.05, '^ p > 0..01, 'p < 0.001 with respect to normal stibanate 
NS"*, > >0.05, -p > 0.01, 'p < 0.001 with respect to infected stibanate 
However, on day 21 PT the magnitute of change in the aforementioned parameters 
was less as compared to 7th day PT. 
On 7th day PT when Picrohv alone was administered to L donovani infected 
golden hamsters (subgroup VII), there was a significant protection against the 
altered levels of various biochemical markers viz. GOT (71%), GPT (74%), SDH 
(60%), G-6.P04ase (68%), y-GT (64%), AP04ase (54%), ARNase (75%), LPO 
(57%) and bilirubin (78%). On 21st day PT the protection observed in the levels of 
aforementioned parameters remained almost of the same order (GOT 62%,; GPT 
59%; SDH 47%; G-6-P04ase, 62%; y-GT 42%; AP04ase 34%; ARNase 47%; LPO 
56% and bilimbin 40%). 
Picroliv when given to the SSG treated L. donovani infected animals 
(subgroup VIII) provided significant protection against the changes caused by both 
SSG treatment and L. donovani infection. This protection was to the level of and 
GOT (53%, 33%), GPT (68%, 40%), SDH (35%, 20%), G-6-P04ase (50%, 54%), 
Y-GT (29%, 38%), AP04ase (37%, 20%), ARNase (51%, 51%), LPO (47%, 51%) 
and bilirubin (29%, 53%) on 7th and 21st days respectively, when compared with 
SSG treated L donovani infected golden hamsters. 
6.4 DISCUSSION 
Pentavalent antimonial compounds have been the mainstay of treatment for 
VL. These dmgs are expensive and are also known to have toxic effects on patients 
(Berman, 1988). Relapse (Thakur, 1986) and resistance to these drugs (Grogl et al., 
1992) have also been reported. Recently we have reported an increase in certain 
hepatic markers which are indicative of hepatocellular damage, during SSG 
treatment in experimental VL (Mittal et al, in press). It has been observed that at 
effective dose of SSG, it is not possible to separate the toxic effect fi^om the 
therapeutic effects on the liver in VL. In American cutaneous leishmaniasis, 
treatment with SSG resulted in significant increase in alanine aminotransferase and 
glutathione-S-transferase, confirming that SSG causes hepatocellular damage 
(Hepburn er a/., 1994). 
Goodwin and Page (1943) suggested the possibility of metabolic conversion 
of pentavalent to trivalent antimony in vivo. This is confirmed by analysis of serum 
and urine fi-om treated patients (Petit de Pena et al., 1990; Burguera et al., 1993). 
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Previous in vitro experiments have established that trivalent analogue of SSG is 
more effective than pentavalent SSG (Mottram & Coombs, 1985), confirming the 
reduction of SSG to trivalent antimony species in vivo. The mode of action of 
antimonials in Leishmania species is poorly understood but, as is true with most 
heavy metals, it is thought to be multifactorial. It has been shown that, antimonials 
bind to several Leishmania proteins and high affinity binding of antimonials to one 
key protein is responsible for their therapeutic effect on leishmaniasis (Berman & 
Grogl, 1988; Borst & Ouellete, 1995). In clinical as well as experimental VL, a 
single dose of SSG is more effective than the same amount m multiple doses 
(Berman 1988; Murray, 1990). 
SSG has been shown to induce hepatotoxicity and immunosuppression in 
experimental VL in golden hamsters (Mittal et ai, in press; Pal ci al., 1996). 
Picroliv a standardized fraction firom the root and rhizome of Picrorhiza kurroa has 
been shown to have protective activity against various hepatotoxins in rats (Dwivedi 
cl al., 1992; Saksena et al., 1996) and Plasmodium berghei infection in Mastomys 
natalensis (Chander et al., 1994). Puri et al (1992) have shown that it enhances the 
non-specific immune response as characterized by an increase in macrophage 
migration index, ['''C]-glucosamine uptake, phagocytosis of [''*C]-leucine labelled 
Escherichia coli, chemiluminescence of peritoneal macrophages, and higher uptake 
of ["^ HJ-thymidine in the lymphocytes of treated mice. Keeping the hepatoprotective 
and immunostimulant activity of Picroliv in mind, our efforts have been to study 
whether Picroliv, while maintaining the leishmanicidal activity of SSG, could protect 
the hepatic damage. The dose of Picroliv selected for these studies is based on 
results obtained in other test models and also on extrapolation of therapeutic doses 
of Picrorhiza kurroa used in Ayurvedic system of Indian medicine for treatment of 
liver disorders to rats. Our results show that Picroliv though alone showed some 
antileishmanial activity (70%), it increased the efficacy of SSG in reducing the 
parasitic load (79% to 85%) on 7th day and (70% to 74%) on day 21 of SSG 
treatment. This increase in leishmanicidal activity may be due to the combind effect 
of antileishmanial and immunostimulant activity of Picroliv. Further, the animals 
administered Picroliv survived longer than the animals treated with SSG alone. The 
data in the present study also show that significant protection to the altered levels of 
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hepatic markers is provided by Picroliv in both the cases of hepatic damage, 
whether it is due to infection or SSG treatment alone or in SSG treated infected 
animals. Picroliv may help in the recover)' of the hepatic damage by stabilising the 
integrity and permeability of plasma membrane as well as membranes of subcellular 
organelles viz. mitochondria, lysosomes and microsomes. Picroliv has been found to 
be safe in subacute toxicity studies and is also devoid of mutagenic or terratogenic 
potential in various species of laboratory animals (Dwivedi et al., 1992). Phase I 
clinical studies have demonstrated excellent clinical tolerance and flirther studies are 
in progress to evaluate its efficacy in management of hepatic damage caused by 
various pathogens and toxicants. Therefore, it can be concluded that Picroliv can be 
used as an adjunct to chemotherapy of VL along with SSG and other antileishmanial 
dnigs in potentiating their efficacy. 
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SECTION 7.0 
SUMMARY 
AND 
CONCLUSIONS 
The mortality and morbidity of human population as a result of infections 
have a long history of battle between human intellect and parasite capability to 
overcome therapy. No wonder strategies of chemotherapy have changed from time 
to time for achieving better therapeutic advantages. Discovery of natural products to 
combat the infection has been followed by discoveries of chemical agents which are 
capable of selective interference of parasite and when these have failed because of 
the emergence of drug resistant parasites, search for new molecular structures have 
been initiated to combat the situation. Even today drug resistance continues to be a 
problem despite the preliminary success achieved in selected cases. The battle of 
human interact and parasite survival in host, therefore, continues to fascinate 
Biochemists. 
Leishmaniasis is a major global public health problem, ranging in severity 
from cutaneous (CL), post kala-azar dermal (PKDL), and diffuse cutaneous (DCL) 
to mucocutaneous (MCL) and visceral (VL) infections that are endemic in 88 
tropical and subtropical countries around the world, accounting for 75,000 deaths 
per year. Different forms of leishmaniases are generally cuased by different distinct 
species of Leishmania having a digenetic life cycle alternating between an 
aflagellated amastigote form replicative within the macrophages of the iiost and a 
flagellated promastigote form that multiplies within the gut of sandfly. Many times 
the dnigs active on one strain, have variable or no effect on other strains. Thus, 
identification of a Leishmania isolate is important to detennine prognosis and 
correct chemotherapeutic regimes and also for epidemiological and basic biological 
studies. Survival of parasite within the host is dependent on its successftil entry into 
macrophages and transformation into amastigote form. Given the role of 
macrophages in the eradication of invading microbes, coupled with their ability to 
kill Leishmania if provided with the correct stimulus, the parasite must have evolved 
under strong selective pressure strategies to ensiu e^ survival. One of the critical 
antileislimanial actions of phagocytic cells is the generation of toxic oxidative 
metabolites. Phagocytosis perturbs the plasma membrane of the macrophage leading 
to a rapid increase in the rate of oxygen consumption. This process, termed as 
respiratory burst, results in the production of reactive oxygen metabolites such as 
superoxide anion and hydrogen peroxide (H2O2). Thus, the oxygen generating 
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system of the host macrophages and antioxidant system of parasite plays an 
important role in survival of parasite and establishment of infection. 
The pentavalent antimonials (Sb^), sodium stibogluconate and N-
methylglucamine antimonate are the preferred drugs for the treatment of most forms 
of leishmaniasis, while amphotericin B and pentamidine are secondary 
chemotherapeutic agents. Treatment with these agents is not consistently effective 
(particularly for the most virulent Leishmania disease forms), are expensive and all 
have serious toxic side effects, including cardiac and/or renal failure. Many of these 
dnigs also cause hepatic damage and are immunosuppressants. The parasite also 
survives in macrophages by causing immunosuppression. Suppression of the 
symptoms of the disease with the parasite reappearing in immunosuppressed 
subjects is often achieved in most chemotherapy of leishmaniasis. In Indian 
traditional system of medicine, there is a long list of plants having immunostimulant 
and hepatoprotective activity. A standardized or crude fraction of such plant may be 
used in the form of a combination therapy alongwith known antileishmanial drugs. 
Although there are several compounds under various stages of development, 
no drug has yet been discovered which is definitively effective in achieving a 
complete (or radical) cure of the infections. Several clinical reports have noted the 
persistence of the parasite after treatment, and clinical cure has been demonstrated 
in both experimental anaimals and humans. Experimental drugs such as the 
pyrazolopyrimidines, allopurinol ribonucleotide, the 8-aminoquinoline WR6026, and 
the steroid synthetase inliibitor intraconazole, show promise and are currently being 
evaluated for the treatment of various forms of leishmaniasis. Still, there is a 
constant need of evaluation of newer prototypes and analogues of active compounds 
which may be orally active, non-toxic and may give complete erradication of 
parasite. Further, the development of a new drug for the treatment of leishmaniasis 
has been impeded by the lack of a simple, rapid in vitro dnig screening system 
through which a large number of compounds may be evaluated for their 
antileishmanial activity. Current approaches for design and development of 
antileishmanial agents involve identification and characterization of potential 
biochemical and molecular targets. 
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1 Analysis of Restriction Fragment Length Polymorphism in the 
Kinetoplast DNA of Leishmania donovani 
In the present study we have attempted to identify RFLP in Indian strains of 
L donovani. Kinetoplast DNA (kDNA) was isolated from 4 different strains viz: 
UR6, Dd8, RMRI and AG83 of L donovani prevalent in India. Strain UR6 is a 
nonpathogenic strain while Dd8, RMRI68 and AG83 are highly virulent and 
responsible for much of the havoc in the eastern region of India. 
Samples of kDNA from each strain were isolated and digested with EcoRI, 
which produced only a single fragment (a linearised minicircle of 875 bp) in all the 
strains. Hind III (6 bp recognition sequence) cleaved Dd8 kDNA at a single site of 
0.89 kb while in AG83, a band of 0.98 kb was obtained. AG83 kDNA digested witli 
Mspl (4 bp recognition sequence) showed 4 bands in the region of 0.83 kb-0.12 kb, 
whereas in case of Dd8, a linearised minicircle fragment of 0.83 kb was observed. 
Taq I (4 bp recognition sequence) released most of the kDNA minicircle from its 
highly concatenated form and produced 5 bands in the region of 0.98 kb-0.12 kb in 
Dd8 kDNA. TaqI produced 2 bands (0.83 kb and 0.12 kb) in UR6 kDNA. Hae III 
produced 2 bands (between 0.56-0.12 kb) in Dd8 and 4 bands migrating between 
mol. wt. region of 0.83 kb-0.12 kb in RMRI kDNA. Hind III produced a single 
linearised minicircle band of 0.89 kb in Dd8 kDNA while 2 bands between 0.83-
0.58 kb region in UR6 kDNA. 
In Southern blot analysis, ^^ P kDNA of UR6 was used as probe. It hybridised 
strongly with UR6 kDNA digested by EcoRI, Hae III and Hind III. In case of 
RMRI, kDNA digested with EcoRI and Hind III showed 2 bands (0.98-0.83 kb) and 
in case of Hae III, 5 bands below 0.83 kb were observed. AG83 kDNA and Dd8 
kDNA, when digested with EcoRI, Hind III and Mspl respectively, on hybridisation 
with nick translated "^ P^ kDNA of UR6 showed almost similar pattern. 
Confining our measure of homology to minicircle component only of 
mitochondrial kDNA, we found that three highly virulent strains viz: RMRI, Dd8 
and AG83 have homology to each other and have certain kDNA sequences common 
with UR6. DNA sequences which diverge at different rates among virulent strains, 
represent potentially valuable tools in diagnostics, epidemiological and ecological 
studies oi Leishmania. 
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No maxicircle derived bands could be seen in any of the restriction digests of 
kDNAs. This could be due, either, to low content of maxicircle in the purified 
network or the removal of the maxicircles during isolation procedure. 
II In vitro and In vivo Screening of Newly Synthesized and known 
Antileishmanial Drugs/Compounds Against Leishmania donovani 
Total 136 compounds belonging to different chemical structures were 
synthesized in Medicinal Chemistry Division of C.D.R.I. and screened for in vitro 
and in vivo antileishmanial activity. These included diamidines, fused pyrimidines, 
nitroalkanes, phenyl aceto nitriles, malonitriles, aplysinopsin, imidazoles, indoles, 
chalcones, quinolines, bisquinolines, isoquinolines and polyamines. The effect of 
standard antileishmanials viz: sodium stibogluconate (SSG), pentamidine 
isethionate, allopurinol and nystatin on superoxide dismutase (SOD), catalase 
(CAT), glutathione reductase (OR), glutathione peroxidase (GPx), xanthine oxidase 
(XO) and NADPH oxidase was observed. XO and NADPH oxidase could not be 
detected in parasite. Stibanate and pentamidine inhibited all the four antioxidant 
enzymes namely SOD, CAT, GR and GPx to a significant extent while allopurinol 
and nystatin inhibited only SOD and had no inhibitory effect on other three 
enzymes. Since, standard antileishmanials showed consistency with parasite SOD 
inhibition hence this was selected as a model for developing enzyme based in vitro 
screen. 
An integrated approach is being followed for screening of novel molecules 
designed and synthesized for leishmanicidal activity. The molecules are first tested 
for their effect on growth and proliferafion of L donovani promastigotes using in 
vitro culture system as evaluated by incorporation of [^H]-thymidine. It is a non-
specific general screening system depending on the parasite survival and 
multiplication. Inhibition of parasite SOD enzyme has been established by us as an 
enzyme based in vitro screen system. The enzyme plays a predominant role in 
establishment of Leishmania parasite within the hostile environment of macrophages 
. by constant detoxification of reactive oxygen intermediates. Advantage has been 
taken of the fact that the major SOD of host is Cu/Zn and/or Mn dependent whereas 
the parasite SOD has Fe as prosthetic group. Some of these compounds were also 
tested in ex-vivo screen system of amastigote-macrophage and also in vivo against 
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L. donovani infection in golden hamsters, the use of the two in vilro screens helped 
in screening a large number of compounds and reducing the labour of using ex-vivo 
amastigote-macrophage system which is tedious and time consuming and also 
weading out the compounds for in vivo testing in animals, thereby, reducing the use 
of a large number of animals for testing. 
In principle, a compound causing specific inhibition of leishmanial SOD with 
no significant effect on the host enzyme may be a potential leishmanicidal agent. All 
the standard antileishmanial drugs showed good correlation with parasite SOD 
inhibition together with boosting up host SOD. The results of the present 
dissertation show a positive correlation between parasite SOD inhibitory activity 
with the in vivo antileishmanial activity as far as compounds of diamidines, 
polyamines, nitroalkanes, malonitriles, imidazoles, indoles, polyamines, quinolines, 
bisquinolines, and isoquinoline series are concerned. In series pyrazolopyrimidines 
and phenyl aceto nitriles, there were some false negative results (stimulation of 
parasite SOD) when compared with leishmanicidal activity against L. donovani in 
golden hamsters (reduction in amastigote number in infected spleen). In these two 
series the ['H]-thymidine uptake test could be very well used for quick screening. 
Through these tests we have found few active compounds of certain series (viz: 
nitroalkane, pyrazolopyrimidine, diamidine and imidazole) showing 75% to 85% 
activity which can be further evaluated for their efficacy. 
Ill Status of Oxidative Stress and Antioxidant Defence System During L. 
donovani Infection and the Effect of Sodium Stibogluconate Treatment 
in Mesocricetus attrattts 
Leishmanial infection is a pathological disturbance which affects the host 
biosystem. The principal organs which undergo deleterious changes are the liver, 
spleen, thymus, lymphnodes and bone-marrow. Survival of L. donovani amastigotes 
in these tissues and the defence mechanism(s) evolved by the host to cope up with 
the infection are poorly understood. During L donovani infection there was 
formation of activated oxygen species such as superoxide anion, which in turn 
increased the levels of lipid peroxides in infected tissues. The activity of xanthine 
oxidase which is said to be an index of superoxide formation increased significantly. 
It was observed that the significant changes of varying degrees took place in 
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reactive oxygen species (ROS) generating and scavenging system in lymphoid 
tissues, the overall impact of these changes was the maintenance of lower 
concentraion of ROS in situ, that could be scavenged by the parasite antioxidant 
defence system and hence provided a favourable atmosphere to the parasite to 
survive. 
In infected spleen although superoxide anions were produced at a rate greater 
to that produced in normal spleen due to stimulated xanthine oxidase, these were 
quickly removed by elevated glutathione (GSH) levels. It is known that glutathione 
is a potent scavenger of ROS. Increased GSH levels are associated with decreased 
glutathione-S-transferase (GST) activity. Increased levels of lipid peroxides (LPO) 
in infected thymus indicated increased production of ROS which may be taken care 
by increased activity of catalase, while the GSH levels were decreased due to 
increased GST activity. Interestingly in lymphnodes, peritoneal exduate cells and 
bone marrow cells, no elevated levels of lipid peroxides were observed. However, 
increased levels of GSH were present in all the three tissues. 
Sodium stibogluconate (SSG; 10 mg/kg/day x 5, ip) caused reduction in 
parasite burden by 88.3% in liver and 84.4% in spleen. SSG appears to disrupt the 
balance between ROS generating and scavenging system, which is evident from 
significantly increased LPO levels in all the lymphoid tissues after its treatment. This 
is accompanied by normalization/lowering of increased antioxidant parameters 
resulting in increased ROS concentration in situ. The altered conditions appear to be 
injurious to parasite and as a result parasite does not survive. The inliibition of 
antioxidant enzymes of both host and parasites by sodium stibogluconate may 
represent one of its mode of action for the chemotherapeutic activity and also its 
toxicity. This is probably the reason that inspite of clearance of parasite by 
stibanate, the survival period of infected animals was comparatively larger than that 
of infected animals treated with stibanate. 
IV Protective Effect of Picroliv from Picrorhiza kurroa Against Leishmania 
donovani Infection in Mesocricettis auratus 
In L. donovani infection, liver is the primary site of infection with marked 
biochemical alterations in it. SSG remains the first line drug for treatment of VL. At 
10 mg/kg/day x 5, ip on 7th day post treatment (FT) it caused significant increase in 
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the levels of hepatospecific enzymes viz: glutamate oxaloacetate transaminase 
(GOT), glutamate pyruvate transaminase (GPT), y-glutamyl transpeptidase (y-GT), 
succinate dehydrogenase (SDH), glucose-6-phosphatase (G-6-P04ase), acid 
phosphatase (AP04ase), acid ribonuclease (ARNase), lipid peroxides (LPO) and 
bilirubin. However, on 21 day FT the magnitude of change in all the above 
described parameters was less marked v^th GOT and SDH reverting back to their 
normal values. 
L donovani infection caused severe liver damage which showed an 
increasing trend as the infection progressed in spleen. SSG administered to L 
donovani infected golden hamsters could not restore the altered parameters to 
nonnal levels but fiulher aggravated the magnitude of percent change by 10% to 
20% in various parameters. However, on 21st day FT the magnitude or change in 
the aforementioned parameters was less as compared to 7th day FT. 
Ficroliv, a standardized mixture of iridoid glycosides prepared from the 
alcoholic extract of root and rhizome of Picrorhiza kurroa has shown strong 
hepatoprotective activity against several models of hepatotoxicity. Therefore, the 
present study was undertaken with an objective to study its hepatoprotective effect 
(12.5 mg/kg/day x 7, oral) alone and in combination with SSG on parasitemia, lipid 
peroxidation and hepatic marker enzymes of golden hamsters during L. donovani 
infection. The results indicated an increase in leishmanicidal activity of SSG along 
with a marked hepatoprotective effect by Ficroliv in terms of biochemical markers. 
The survival of the animals infected with L donovani, normal animals treated with 
SSG, and infected animals treated with SSG also increased substantially by 
treatment with Ficroliv. Thus it can be said that Ficroliv can be used as an adjunct to 
chemotherapy of leishmaniasis with SSG by enhancing its efficacy, decrease in 
toxicity, reduction in parasitemia and restoration of immune status of host. 
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